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Abstract 
lntravitreal (IVT) injection of anti-angiogenic proteins has become common in treating 
blinding neovascular intraocular diseases, but this suffers from rapid exit of active agents 
from the eye. Rapid drug loss is even more problematic for smaller agents to treat glaucoma 
or inflammation. Thus, many researchers have sought devices, usually microparticles (MP), 
to prolong IVT residence. These have not been approved, except with steroids, owing to 
foreign body reactions, especially in primates. The vitreous contains poly-anionic 
carbohydrates which could anchor smaller cationic nanoparticles (NP) but polycations are 
usually cytotoxic. Several reports now indicate greatly improved safety if the cations are 
derived from L-arginine (R; Arg). Our main goal has been to design and characterize R 
peptide NP conjugates (NPC), relating their R content and surface charge to increased 
duration of IVT residence; and relating these to increased IVT duration. 
A novel nanoparticle-based system for sustained intravitreal drug delivery 
6 
In this thesis, we have studied the relation between the amount of positive charges of 
peptides loaded to the nanoparticles, how they affect the zeta potential on the NP surface 
and its residence time in the vitreous. For the in vivo study we used rabbit eyes, an animal 
model closely modeling human pharmacokinetics. Our results show a half-life of <3 days 
for simple NP residence in vitreous, increasing in NPC from 7 to 17 days, depending on 
peptide R content, without any pathology or inflammation in rabbit ocular tissue at doses 
up to 360 µg per eye. 
To enable prodrug delivery in this system, we have synthesized different types of amino-
alkoxy esters with varied ester hydrolysis rates. From our first screening, we selected four 
amino-alkoxy ester candidates, which we then attached to a chromophoric hexanoic acid, 
and then we conjugated these to the NP to study the relevant ester hydrolysis. This 
identified two bridging esters, with respective hydrolysis t1/2 near to 40 and 80 days, 
sufficient to enable sustained IVT protein delivery. 
We also discovered and optimized di-carboxy half-amides of small R-containing peptides, 
which are active in vivo in a mouse model of age-related macular degeneration (AMD). 
Finally, we synthesized an ester-peptide prodrug of one such peptide, as an NPC, for slow 
release and efficacy studies, it displayed in vitro release t1/2 of 28 days. Preliminary efficacy 
studies in the AMD model showed significant efficacy favoring the NPC over vehicle when 
these were each injected 14 days before laser-induced lesion. Free peptide injected 
simultaneously also gave a favorable trend (not statistically significant) compared to 
vehicle, but the conjugate was not clearly more efficacious than free peptide alone (not 
statistically significant). This is now being repeated with earlier injection (-28 days), where 
no free peptide effect is expected. 
Resumen 
La administración intravitrea de proteínas antiangiogénicas se ha convertido en el 
tratamiento más popular para las enfermedades neovasculares oculares, pero estos 
fármacos padecen de una excreción rápida del ojo. La rápida reducción de la concentración 
de fármaco en el ojo es incluso más acentuada para las pequeñas moléculas utilizadas en el 
tratamiento del glaucoma o la inflamación. Debido a esto, distintos grupos de 
investigadores han desarrollado formulaciones, normalmente micropartículas, para 
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incrementar la residencia intravitrea. Estos compuestos solo han sido aprobados para el uso 
con esteroides, debido a las reacciones de cuerpo extraño.  
El humor vítreo contiene carbohidratos polianiónicos que se podrían fijar a nanopartículas 
catiónicas (NP) pero los policationes por lo general son citotóxicos. Estudios recientes 
muestran la seguridad en el uso de cationes provenientes del aminoácido L-arginina (R; 
Arg). Nuestro objetivo ha sido diseñar y caracterizar péptidos con R conjugadas a NP, 
relacionando su contenido de R y la carga en la superficie con el incremento de la residencia 
intravitrea. 
En esta tesis doctoral, hemos estudiado cómo la relación entre la cantidad de cargas 
positivas de los péptidos conjugados a las NP afectan al potencial zeta en la superficie de 
las mismas y a su residencia en el humor vítreo. Para el estudio in vivo utilizamos ojos de 
conejo, el sistema experimental que más se aproxima al modelo farmacocinético de ojo 
humano. Nuestros resultados muestran una vida media de <3 días de residencia intravitrea 
para las NP sin péptido, aumentando en las NP conjugadas de 7 a 17 días, dependiendo de 
la cantidad de R que tenga el péptido conjugado a la NP, y sin ninguna evidencia de 
patología o inflamación en el tejido ocular de los conejos a una dosis de hasta 360 µg por 
ojo. 
Para posibilitar la liberación de los péptidos a partir de profármacos conjugados a las NP, 
hemos utilizado diferentes tipos de amino-alcoholes sintetizando una gran variedad de 
ésteres con diferentes velocidades de hidrólisis. De nuestro primer cribado, hemos 
seleccionado cuatro candidatos a los que les unimos a un compuesto cromóforo con ácido 
hexanoico y los hemos conjugado a las NP para estudiar la hidrólisis desde éstas. Hemos 
identificado dos compuestos amino-éster con las velocidades medias de hidrolisis de 40 y 
80 días, suficiente para conseguir una liberación intravitrea sostenida de proteínas. 
También descubrimos y optimizamos hemiamidas dicarboxilicas de pequeños péptidos que 
contienen R que son activos in vivo en un modelo de degeneración macular asociada a la 
edad en ratón. Finalmente, se sintetizó un profármaco éster-peptídico de uno de tales 
péptidos en forma de NP conjugada, para estudios de liberación lenta y eficacia que mostró 
una liberación in vitro con una t1/2 de 28 días. Los estudios preliminares in vivo mostraron 
eficacia significativa de la NP conjugada comparada con el vehículo cuando fueron 
inyectados 14 días antes de la inducción de la lesión. El péptido libre también dio una 
tendencia favorable (no estadísticamente significativa) en comparación con el vehículo, 
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pero la NP conjugada no fue claramente más eficaz que el péptido libre solo. Este estudio 
se está repitiendo ahora con una inyección anterior (28 días), donde no se espera un efecto 
del péptido libre. 
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10 peptide (335) COOH-adp-Sar-YNLYRVP-ethylamide 
11 peptide (336) COOH-adp-Sar-YNLYRVRS-amide 
67LR 67 kDa non-integrin laminin receptor 
ACN acetonitrile 
adp Adipic acid 
AdPEDF.11 adenovirus encoded PEDF  
AGEs advanced-glycation end products  
AMD age-related macular degeneration 
APase alkaline phosphatase 
BCA bicinchonic acid 
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BrMb Bruch's membrane 
CC choriocapillaris complex 
CDEX condensed dextran 
CDI N,N’-carbonyldiimidazole 
CK2 casein kinase  
cmpd compound 
CNTF ciliary neurotrophic factor  
CNV choroidal neovascularization  
ColCh column chromatography 
CP capillary plexus 
CS chondroitin sulfate  
Cy7  cyanine 7 amine 
d day 
DCM dichloromethane 
DDS drug delivery system 
DIPEA N,N-diisopropylethylamine  
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DNP dinitrophenyl-ε-amino-n-caproic acid 
EC endothelial cells 
ECM extracellular matrix 
EDI enhanced depth imaging  
EL elastic layer 
EMA European medicine agency 
eNOS endothelial nitric oxide synthase  
EPA US environmental protection agency  
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EtOAc ethyl acetate 
EVA ethylene vinyl acetate  
Fab fragment antigen-binding 
FasL Fas ligand 
FDA US food and drug administration 
GA geography atrophy 
GAG glycosaminoglycan 
GCV ganciclovir 
glt glutaric acid 
h hour 
HA hyaluronic acid 
HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate) 
HBTU N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HIF-1 hypoxia inducible factor  
HPLC high performance liquid chromatography 
HSC hepatic stellate cells  
HSPG heparin sulfate proteoglycans  
ICAM-1 intracellular adhesion molecule-1 
ICL inner collagenous layer  
IGF-I insulin-like growth factor-I  
IL-8 Interleukin-8 
IM intramuscular 
IVIS in vivo imaging system  
IVT intravitreal 
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LEDGF lens epithelium-derived growth factor  
LR laminin receptor 
MAC membrane attack complex  
MBHA rink amide 4-methylbenzhydrylamine  
MeOH methanol 
min minute 
MMp's metalloproteinases 
MP microparticle 
MW molecular weight 
MWCO molecular weight cut off 
NHP non-human primates  
nNOS neuronal nitric oxide synthase  
NOS nitric oxide synthase 
NP nanoparticle 
NPC conjuated nanoparticle 
OCL outer collagenous layer  
OCT optical coherence tomography 
OIR oxygen-induced ischemic retinopathy 
p/s photons/second 
P18 Peptide 18 
PAD peptidyl arginine deiminases  
PAMAM polyamidoamine  
PBS phosphate-buffered saline  
PDGF platelet-derived growth factor  
PEDF pigment epithelium-derived factor  
PEG polyethylene glycol  
PGA polyglycolic acid  
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PKA protein kinase  
PLA poly(lactic acid)  
PLGA copolymer poly(lactic-co-glycolic acid)  
PLGF placental growth factor  
p-nP p-nitrophenyl 
p-nPCOCl p-nitrophenyl chloroformate 
PPARϒ peroxisome proliferator-activated receptor ϒ  
PPI poly-propylene imine  
PR photoreceptor 
PVA polyvinyl alcohol  
Rh rhodamine b 
ROP retinopathy of prematurity  
RPE retinal pigment epithelium 
RT room temperature 
s second 
SDF-1α stromal cell-derived factor 1-alpha  
TEA tryethylamine 
TFA tryfluoroacetic acid 
TLC thin layer chromatography 
TM trabecular meshwork  
TSP-1 thrombospondin-1  
UV-vis ultraviolet-visible 
VEGF vascular endothelial growth factor 
VIP vasointestinal polypeptide 
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The primary objective of the research described in this thesis project is the improved 
treatment of unmet medical needs in intraocular disease. This involves the use of a novel 
intravitreal drug delivery approach in which ionic interactions between drug carriers and 
vitreal components sustain residence in the eye, contrasting with more common size-based 
methods to prolong drug release. The hypothesis is that an optimized ionic formulation will 
provide advantages in safety and efficacy.  
2.1 Wet age-related macular degeneration 
2.1.1 The posterior eye delivery problem 
Retinopathies and posterior eye diseases affect millions of patients and are major causes of 
blindness worldwide [1-3]. The effective treatments largely rely on a safe and efficient 
mode of therapeutic drug delivery. The unique anatomical and physiological barriers of the 
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eye block outside drug molecules from entering the posterior segment, thus, leaving the 
delivery efficiencies of conventional topical or systemic/oral drug administrations to be 
less than 5% [4, 5]. Currently, intravitreal (IVT) injection is the most efficient method for 
posterior eye drug delivery [6]. This directly delivers active agents near the lesions, 
increasing local drug concentration with low systemic exposure. IVT injection is the 
primary method to treat endophthalmitis, submacular/vitreous hemorrhage, retinal vascular 
occlusion, advanced age-related macular degeneration (AMD) and diabetic retinopathy [7]. 
In recent years, the acceptance of IVT injections has grown rapidly because of the injection 
of vascular endothelial growth factor (VEGF) inhibitors, which slows down the progress 
of neovascular retinal diseases, such as exudative AMD and diabetic retinopathy [6, 8]. In 
2012, more than 2.3 million injections were reported, and the number was estimated to 
reach 6 million in 2016. 
Despite advantages, with increasingly common use of IVT injection of proteins to treat 
retinopathies, IVT approaches to both large and small agent delivery are more acceptable 
but clearance varies with disease state [9], and is often impractical owing to rapid clearance, 
via retinal vasculature and intraocular drainage systems [3]. Consequently, repeated 
injections are needed to maintain a therapeutically effective concentration in the posterior 
eye. For example, the half-life of ranibizumab (a VEGF-neutralizing Fab fragment for 
treatment of exudative AMD) in human vitreous is approximately 8 days, requiring one 
administration per 4-6 weeks [10]. Frequent IVT injections raise the patients’ discomfort, 
and cumulatively increases the risk of potential complications, such as vitreous 
hemorrhage, cataract and infection [11]. Additionally, frequent outpatient visits are a 
burden for vision-impaired patients and significantly increase total treatment cost [12]. 
2.1.2 Age-related macular degeneration 
AMD is a progressive and degenerative chronic disease of the central retina, the macula, 
causing in advanced stages, a loss of central vision, which occurs at increasing frequency 
with age. The late stage of AMD is the third cause of blindness worldwide (8.7% in 2010) 
after glaucoma and cataracts and the main cause of legal blindness (10%-13%) among 
people, over 60 years old, and is their most common source of visual loss in developed 
countries. In fact, 30% of those at age 75 have lost vision to AMD [13]. This disease in the 
United States affects 15 million people. Moreover, AMD is a major medical and 
socioeconomic challenge worldwide also; the prevalence shows an expansion of this 
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disease due to the exponential increase in life expectancy and environmental risks like 
tobacco, genetic tendencies, the degree of pigmentation (with light colored eyes being at 
higher risk), arterial hypertension, ultraviolet rays, and consumption of a non-balanced diet. 
With these factors AMD incidence is predicted to increase by six-fold from 2010 to 2050 
[14]. Nowadays, there are several treatments from the field of antiangiogenic therapies, 
these drugs are effective and they can prevent blindness and sometimes restore vision. 
However, while new biologics offer improvement these treatments are expensive, 
especially in countries where there is not a public healthcare system or on those that these 
treatments are not available yet, their delivery by repeated IVT injection is burdensome and 
carries risk of morbidity. AMD is the consequence of one of two processes that cause 
photoreceptor (PR) dysfunction: geographic atrophy (GA, dry or non-exudative AMD) or 
the more rapidly progressing choroidal neovascularization (CNV, wet or exudative AMD), 
only the latter responds to antiangiogenic agents. More than 50% of legal blindness related 
to AMD is from vision loss due to CNV. This is typically diagnosed by the phenotypes in 
fundus photographs of the macula: Retinal pigment epithelium (RPE) and/or retinal 
detachment, exudates (lipid degradation products left behind from a previous edema), 
fibrovascular scars, and hemorrhage in a small subset of patients [15]. Using imaging 
techniques such as fluorescein angiography and optical coherence tomography (OCT), the 
lesions are classified in subtypes: type 1 (sub-RPE), type 2 (sub-retinal), type 3 (intra-
retinal), and mixed neovascularization [16]. These subtypes are gathered in three 
subclasses: classic, occult, and minimally classic lesions according to the filling patterns of 
fluorescein: well-defined lesions that leak fluorescein rapidly before the complete filling of 
retinal vessels are termed classic lesions, whereas occult lesions leak more slowly with 
poorly defined margins [17, 18]. 
In CNV, abnormal blood vessels sprout and grow from the choroid underneath the macula. 
These vessels leak blood into the retina, causing distortion of vision that makes straight 
lines look wavy, blind spots and loss of the central vision [19] (Figure 1 and 2). 
 
A novel nanoparticle-based system for sustained intravitreal drug delivery 
28 
 
Figure 1. Scheme of a healthy macula and a macula with wet AMD where appears an accumulation of 
blood in the Bruch’s membrane. Source: https://www.gene.com/patients/disease-education/age-related-
macular-degeneration[20]. 
 
Figure 2. Left: fluorescein angiography (FA) shows a fibrovascular pigment epithelial detachment. Right: 
spectral domain-optical coherence tomography (SD-OCT) shows and a retinal detachment in a patient 
with age-related macular degeneration affected by a type 1 choroidal neovascularization. Both techniques are 
necessary for the diagnosis of this disease. FA reports information about posterior vitreous detachment and 
OCT gives more details about the details in the macula but only coverages a field of 1 mm. Source: Schmidt-
Erfurth et al, 2014)[21]. 
2.2 Anatomy and physiology of the posterior eye 
The retina is a light-sensitive layer located in the posterior area of the eye. There are two 
main layers: one comprising the neuroretina, formed by photoreceptors cells and glia cells, 
the second layer is formed by the RPE separated from the retina by a virtual subretinal 
space. This area contains the central vision and the 15-20° of the visual field. This tissue 
contains more than one layer of neurons called retinal ganglion cells [22]. The macula is a 
circular area 5 to 6 mm in diameter with the fovea at its center (0.8 mm) and surrounded 
by the para-fovea [23]. The pathogenesis of wet-AMD is associated with angiogenesis, the 
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growth of new blood vessels, predominantly from the choroid, where new capillaries break 
through Bruch’s membrane growing aberrantly into the subretinal space. These vessels leak 
and bleed, causing exudative or hemorrhagic retinal detachments, ensuing scar formation 
leads to death of the RPE. A balance between positive and negative factors establishes the 
normal regulation of angiogenesis; the consequence of an alteration of this balance 
produces the growth of new vessels. The increased production of the proangiogenic VEGF 
has been identified as a strong driving factor of progression of the disease, thus anti-VEGFs 
are a mainstay of treatment. 
According to Bhutto et al. [19], a relationship exists between the components of the 
photoreceptor, RPE, Bruch’s membrane (BrMb), and the choriocapillaris (CC) complex. 
This is affected in AMD. CNV occurs when endothelial cells (EC) from this capillary 
plexus (CP) migrate and organize into sprouting neo-vessels perpendicular to their normal 
direction, and invade towards the retina. To accomplish this, the EC must first breach the 
BrMb. CC and BrMb structure are detailed below. 
2.2.1 Choriocapillaris 
This is the capillary component of the choroidal vasculature, sits adjacent and posterior to 
BrMb. CC is a single layer restricted to the inner portion of the choroid with the capillary 
plexus formed by arterioles and draining venules from below at right angles in the posterior 
pole. In the equatorial and peripheral choroid, arterioles and veins are located in the plane 
of CC. Inner choroidal vessels are sandwiched between two pigmented cells, apical RPE 
and outer choroidal melanocytes. The endothelial cells present in the CC are involved in 
secretion and /or filtration. The receptor expression of VEGFR-1 and VEGFR-2 have 
shown their expression on the vasculature side of the retina [24]. CC is the only capillary 
system in which the EC express intracellular adhesion molecule-1 (ICAM-1) [25]. ICAM-
1 is responsible for firm adherence to endothelial cells by leukocytes (macrophages and 
neutrophils), with CD11b/CD18 on their surface. 
The RPE/BrMb/CC system permits CC to provide the metabolic needs from serum for 
photoreceptors (PR) including 90% of the oxygen consumed by the PR in darkness [26]. 
The choroid lacks autoregulation [27]. Therefore, decreases in choroidal PO2 can be caused 
by systemic hypoxia or elevated intraocular pressure. Choroidal nonperfusion is 
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unfavorable for PR function and its viability and retinal detachment from choroid 
addressing in PR death [26]. 
There is an intrinsic network of ganglion cells [NADPH-diaphorase] and nitric oxide 
synthase (NOS) positive] in the human choroidal stroma, whose neurons are connected to 
each other and to the perivascular network [19]. Ganglion cells are located in the temporal 
and central regions of the choroid, close to the walls of large arteries. They are solitary, 
polygonal cells with a diameter of 10-40 µm close to the walls of arteries [28]. 
Nitric oxide (NO) is a mediator of endothelium-derived factor relaxation that causes 
vasodilatation. NO is localized in the choroid with vasointestinal polypeptide (VIP), which 
has a vasodilation action. Endothelial nitric oxide synthase (eNOS) is associated with blood 
vessels in choroid while neuronal nitric oxide synthase (nNOS) was, in scattered cells 
throughout the choroid and the retinal pigment epithelium (RPE). nNOS is expressed in the 
choroid as a vasodilator, adjusting blood flow in response to a reduction of arteria blood 
pressure or protecting the retina from thermal damage associate with light exposure [19] 
(Figure 3). 
2.2.2 Bruch’s membrane 
BrMb is a critical barrier separating the choroid capillary plexus from the retina, it is a 
connective tissue of 2-4 µm located between the RPE and the CC. This tissue is an elastin 
and collagen extracellular matrix (ECM), which function like molecular sieves. It has a 
penta-laminar structure formed by the basement membrane of the RPE (0.14-0.15 µm) most 
anterior; the inner collagenous layer (ICL); a porous elastic layer (EL); the outer 
collagenous layer (OCL; 0.7 µm of diameter); and the basement membrane of the 
endothelium of the choriocapillaris most posterior [29]. The main components of the 
structure are: collagen (type I, III, IV, V and VI) [30], fibronectin [31], laminin [32], 
heparin sulfate proteoglycans (HSPG) and chondroitin/dermatan sulfate [33]. 
BrMb is a stratified ECM complex that works as a biochemical barrier for normal 
physiological processes and to resist pathological ones like CNV. The functions of BrMb 
are: 
-Regulating the reciprocal diffusion of bio-molecules, minerals and antioxidants 
components, trace elements and serum constituents between the choroid and RPE. 
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-Providing physical support for RPE cell adhesion [34, 35] and a surface for migration and 
perhaps differentiation of RPE [36]. 
-Wound healing [37]. 
-Acting as a barrier that restricts retinal and choroidal cellular migration, hallmarks of 
CNV. 
Solute transport through BrMb is by passive diffusion due to its acellular nature. This 
depends on its molecular composition affected by age and location in the retina, the 
hydrostatic pressure on both sides and the concentration of the molecules and ions [19]. 
 
Figure 3. A cross section of the fovea from a Macaque monkey showing the layers of retina and the 
morphological relationship of photoreceptor/RPE/BrMb/choroid complex. On the sides of the foveal pit, the 
center of macula. The layers are formed by the ganglion cells (GCL). The inner plexiform layer (IPL). The 
inner nuclear layer of neurons (INL). The outer plexiform layer (OPL). The outer nuclear layer (ONL). The 
photoreceptor inner segments (IS). The outer segments (OS). The retinal pigment epithelium (RPE). The 
Bruch’s membrane (not discernible at this magnification). The choriocapillaris (CC). The melanocytes of 
choroid are the structures below the CC. Source: Bhutto I, Lutty G (2012) [19]. 
2.2.3 Retinal pigment epithelium 
The RPE is a single layer of hexagonal cells that are densely packed with pigment granules 
(melanosomes). Its location is posterior to the photoreceptors, these layers are polarized 
epithelial cells at the base of the retina. They are attached to their underlying basement 
membrane, which is the inner layer of BrMb. RPE continues as a membrane passing over 
the ciliary body and continuing as the posterior surface of the iris. At the surface, the RPE 
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faces BrMb, which separates RPE from the endothelium of the CC. The RPE function is to 
provide nutrients, like omega 3 fatty acids and glucose, to maintain the visual function by 
light-sensitive outer segments of the photoreceptors [38]. In addition, it transports ions, 
water and metabolic end-products from the subretinal space to the choroid. A second role 
of this tissue is the formation of the outer blood-retinal barrier to prevent nonspecific 
diffusion and transport material from the choroid. Melanosomes absorb the excess of light 
to protect the area from damage. Another function for RPE is serving as part of the waste 
disposal system. A RPE cell services between 20 and 30 photoreceptors, the RPE digests, 
and degrades 300 million rod membranes through a 70-year life span [39]. 
RPE produces and secretes several growth factors, angio-regulatory proteins, which 
maintain ocular angiogenesis in check: fibroblast growth factors (FGF-1, FGF-2, FGF-5) 
and transforming growth factor-β, insulin-like growth factor-I (IGF-I), ciliary neurotrophic 
factor (CNTF), platelet-derived growth factor (PDGF), VEGF, lens epithelium-derived 
growth factor (LEDGF), members of the interleukin family and pigment epithelium-
derived factor (PEDF) to build and sustain the choroid and photoreceptors [14, 19]. 
2.2.4 Photoreceptors 
PR are a type of neuron in the posterior retina which function in phototransduction, 
converting light into signals by triggering a change in the cell membrane potential after 
absorbing a photon. They are rich in mitochondria, supporting their highly metabolically 
active cells. These neurons consume more oxygen per gram of tissue weight than any cell 
in the body, also have a tissue oxygen level close to zero in the dark [26]. There are two 
types of photoreceptors cells that convert signals in vision: cones and rods. The chemical 
process in phototransduction is similar. Cones are wider than rods and less sensitive, so 
they require more brightness to produce a signal. The three cone cells that are present in 
humans are red, blue and green, they are responsible for response to different wavelengths 
of light. The average of rod loss is two rods /mm2 of retina per year [23, 40]. One of the 
characteristics in the aging retina is the accumulation of mitochondrial DNA deletions and 
cytochrome c oxidase-deficient cones. These continuous changes might affect the macular 
function observed in aging and age related maculopathy [41].  
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2.3 Physiopathology of the posterior eye 
2.3.1 Changes in PR/ RPE/ BrMb/ CC complex in exudative “wet” AMD 
PR might be affected by the presence of scar formation, but this could be less severe if RPE 
is present on the scar. In addition, the thickness of the scar is related to the degree of the 
receptor degeneration. The thicker the scar, the greater the distance of the photoreceptors 
from surviving choriocapillaris [42, 43]. 
Another factor that could affect by this disease is a change in the ECM, with consequences 
relating to RPE function such as adhesion, proliferation, differentiation and migration. The 
effect of ECM is mainly through BrMb. Accumulation of advanced-glycation end products 
(AGEs) in RPE and BrMb produce oxidative stress and induction of CNV [44-46]. 
There are several theories about the choroid in AMD. Using enhanced depth imaging (EDI) 
a 16 µm per decade per life decrease in choroidal thickness per decade of life has been 
observed [47, 48]. According to another study, the decrease in choroidal thickness is more 
extreme, 54 µm per decade per life [49]. Other groups have not seen differences in the 
choroidal thickness between the AMD group and control [50, 51], but Wood et al has 
observed a retinal thickness, which may be related to the loss of PR [51]. 
The Friedman study hypothesized that vascular insufficiency resulted in loss of PR and 
RPE [52]. The loss in CC resulted in accumulation of waste at and on BrMb. Furthermore, 
AMD could be a consequence of a hemodynamic sequela of atherosclerotic changes 
affecting the postcapillary resistance of the choroidal vasculature [53]. 
Alkaline phosphatase activity (APase) is an indicator of endotherilal cell viability which is 
found in all viable choroidal blood vessels [54]. Large areas that lacked APase+, in CNV, 
CC were covered with RPE. These areas with attenuation of CC around active CNV and 
scars were areas with associated with viable RPE cells. Areas with active CNV have RPE 
associated with them. These scars contain active CNV that appears stabilized. The vessels 
might be stabilized by the components of the scar. The scars are rich in two endogenous 
inhibitors of angiogenesis, PEDF and thrombospondin-1 (TSP-1) [19]. 
CNV is the endpoint in a variety of chorioretinal diseases. It is expressed as the growth of 
new blood vessels from the choroid into the subretinal space or sub-RPE [19]. There are 
three stages in CNV: 
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1 Initiation stage: endothelial cells from the choriocapillaris migrate towards the retina 
through the BrMb. Macrophages and cytokines are important on this stage. 
2 Active stage: when CNV expands. It depends on the presence of inflammatory cells 
responding to cytokines in the area or producing cytokines releasing them in the autocrine 
and/ or paracrine way [55, 56]. 
3 Involution stage: CNV becomes fibrotic and forms disciform scar [19]. 
A balance between factors that simulate or inhibit vessel growth controls angiogenesis. In 
healthy tissues, inhibitory factors push the balance to control the vessel growth. In AMD, 
neovascularization happens due to the decreased production of inhibitory factors or 
increase of stimulators [57]. Also related with this process are matrix metalloproteins 
(MMP’s) and other enzymes, which disrupt the ECM, permitting EC migration from 
vessels to tissue. 
CNV is stimulated by growth factors such as VEGF, among others (insulin-like and 
fibroblast growth factors, interleukins and angiopoietins) [19]. 
VEGF is secreted by RPE, the higher basal secretion occurs towards BrMb [24]. VEGF 
acts as a specific EC mitogen and promoter of vascular permeability. Importantly, levels of 
VEGF in the vitreous are elevated in patients with wet-AMD [58]. 
Hypoxia inducible factor (HIF-1) in the submacular tissue is a signal of overproduction of 
VEGF [59]. In addition to angiogenesis, vasculogenesis and incorporation of EC 
precursors, are implicated in CNV development. VEGF is a chemoattractant for endothelial 
cells (EC) precursors, inducing their mobilization and differentiation [60]. The chemokine 
stromal cell-derived factor 1-alpha (SDF-1α) and its receptor CXCR4 are HIF inducible 
and involved in the recruitment of EC precursors into CNV [61{Sengupta, 2010 #44, 62]. 
VEGF is also a chemotactic signal for macrophages [63, 64]. 
In the initiation stage, macrophages and their cytokines are important in the growth of 
CNV. Vascular endothelium and macrophages produce MMP’s, these enzymes degrade 
ECM allowing EC invasion through BrMb the infiltration of CNV [65]. MMP’s are a 
family of ECM degrading enzymes associated with neovascularization. MMP-2 and MMP-
9 types are closely involved in the progressive growth of choroidal neovascular membranes 
in AMD due to their location to the areas of new vessel formation and to the enveloping 
Bruch’s membrane [66]. 
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The physiological stability of the ocular vascular system is a balance between angiogenic 
and anti-angiogenic factors. Pathologic conditions shift the balance towards angiogenic 
factors that are released by the damaged cells [67, 68]. 
The endogenous angiogenesis inhibitors that are present in the eye are PEDF, endostatin 
and thrombospondin-1. They are extracellular proteins that are part of the matrix or bind to 
the matrix and frequently need proteolytic processing for their activation [69]. 
A study has shown that the three endogenous angiogenesis inhibitors are significantly 
reduced or absent in AMD in the BrMb/ CC complex due the presence of angiogenic 
inhibitors [70]. 
2.3.2 Inflammation in AMD 
Inflammation is a cellular defense mechanism, in which foreign or damaged material 
becomes sensed by various pattern-recognition receptors [71]. The ligand recognition 
process triggers the activation of intracellular signaling pathways giving the production of 
pro-inflammatory mediators [72]. The activated endothelium in the blood vessels promotes 
and attracts effector cells and there is an accumulation of soluble proteins within inflamed 
tissue [73, 74]. The etiology of the inflammation is not the classical process. Evidence 
suggest it is a response to immunological effect [75]. There are several complement factors 
involved in this process: C3 complement fragments, C5 and the membrane attack complex 
(MAC) C5b-9 are present in ocular drusen and the capillary pillars of the choroid and in 
the vitreous of the human eye [76-78]. 
The complement system is a biochemical cascade that supports to antibodies to destroy 
pathogens. It promotes inflammation, eliminates pathogens and increases the immune 
response. The complement system is formed by more than 20 proteins from the liver that 
circulate s as inactive precursors (pro-proteins). When one of several triggers stimulates the 
pro-proteins, proteases in the complement system can cleave specific proteins, as 
consequence of this, cytokines are released starting the cascade. The result of the cell-
killing MAC, which creates perforations in membrane [19]. 
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2.4 Ocular proteins resisting angiogenesis 
2.4.1 Thrombospondin-1 
TSP-1 is a homotrimeric matricellular glycoprotein (420 kDa) that was first discovered in 
activated platelets [79]. TSP-1 is the most studied glycoprotein of the thrombospondin 
family (TSP-1, TSP-2, TSP-3, TSP-4 and TSP-5). TSP-1 is expressed on the cell surface 
in normal physiological processes. It is secreted by EC, fibroblasts, adipocytes, smooth 
muscle cells, monocytes, macrophages and transformed cells (malignant glioma cells) [80, 
81]. TSP-1 is stored in the ECM, bound to proteins, like fibronectin, changing the 
conformation. The specific domain of this molecule binds to proteoglycans, membrane 
proteins like integrins among others [82, 83]. 
The structure of TSP-1 is formed by an N-terminal globular domain which binds heparin 
types I, II and III, and a terminal globular domain. The NH2-terminal interacts with low-
density lipoprotein receptor-related protein (LRP1). LRP1 releases any MMPs modulating 
the protease activity. This domain also binds heparin sulfate proteoglycans and several 
integrins related with angiogenesis, chemotaxis adhesion and cell motility [84, 85](Figure 
4). 
TSP-1 in humans is present at high levels in the vitreous and aqueous humor, and is an 
important component in BrMb [86, 87]. This protein plays a main role in the elimination 
of excess blood vessels during the late stages of retinal vascularization [14]. This effect is 
reduced in ischemic conditions when VEGF levels are high. The early and premature 
expression of TSP-1 in animal models, results in defective postnatal retinal vascular 
development and attenuation of retinal neovascularization during oxygen-induced ischemic 
retinopathy (OIR). A study with knockout mice for the gene Thbs1, compared to wild types, 
after a larger neovascular lesion, the CNV per area was 8 times greater in the knockout 
mice [88, 89]. There also exists a relationship between the area of CNV and the recruitment 
of macrophages after the lesion [14]. 
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Figure 4. Structure representation of TSP-1 schematically and its receptor sites. The monomers have 
interchain disulfide bond, procollagen homology domain. RFK and RGDA are binding sites for TGFβ and 
integrins respectively. CSVTCG is the receptor site for CD36. The C-terminal domain of TSP-1 binds CD47. 
TSP-1 mimetic peptides have been designed from the heptapeptide GVITRIR, part of the monomer Type I. 
Source: Lopez-Dee et al, 2011 [90].  
2.4.2 Pigment epithelium-derived factor 
PEDF is a non-inhibitory serpin proteinase, [91, 92], and is a multifunctional protein 
committed in several physiological and pathophysiological mechanisms related with 
angiogenesis, neuroprotection, fibrogenesis, and inflammatory responses [93]. PEDF was 
identified for the first time as a secreted protein in a conditioned medium from fetal RPE 
cells that stimulated neuronal differentiation of Y79 retinoblastoma cells [94]. PEDF has a 
potent activity in the inhibition of the proliferation and migration of EC [95]. PEDF has an 
inhibitory activity on angiogenesis, is present at high levels in the eye, and might block the 
activity of pro-angiogenic factors. PEDF may be a key to modulate the neovascular 
homeostasis and prevent angiogenesis in healthy ocular tissue [96]. Retinopathy of 
prematurity (ROP) is a serious neovascular AMD-like disease of low birth weight 
premature infants, induced when they are moved, during neonatal support, from high 
oxygen to normal air. The vitreous of low birthweight infants lacks detectable PEDF, 
normally seen a full term [96]. PEDF only first appears in third trimester placenta [97]. OIR 
is an animal model system for ROP, in which newborn mice/rats are maintained at >50% 
O2 for 5 days, then moved to room air, neovascularization appears 7-12 days later. 
PEDF modulates blood vessel growth that drives angiogenesis when the oxygen 
concentration is low (same behavior as retinopathies and tumors) and an inhibitory 
environment when oxygen concentrations are normal or high [98]. According to Huang et 
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al, [99], they studied the relationship of PEDF in normal postnatal vascularization of the 
retina and retinal neovascularization (NV) during OIR. 
OIR models produce robust pre-retinal neovascularization, mimicking the NV occurring in 
human ROP. ROP has become the leading cause of childhood blindness worldwide [100]. 
Even though many cases of ROP are not severe enough to require surgery ROP, with 
thousands of new cases worldwide every year frequently leads to lifelong vision problems 
([101]). The abnormal angiogenesis in ROP is driven by pro-angiogenic growth factors, 
such as VEGF, the same as AMD. The current treatment with IVT injection of an anti-
VEGF therapy (bevacizumab) has been reported as a supportive measure in aggressive 
posterior ROP [102-106]. Unfortunately, in newborns, the treatment is associated with 
concern about negative long-term outcomes in several organs due to its long half-life and 
the low blood volume in neonates [105, 107, 108]. PEDF has been identified as an “anti-
angiogenic guardian of ocular function” [96], was reported to suppress ocular angiogenesis 
in animal models of ROP [95, 109, 110], and some peptide fragments of PEDF retain its 
antiangiogenic function, and are active in vitro, and in vivo in ROP models [110-112]. This 
is discussed in detail below. 
An alternative OIR model in rats consists in the reduction of oxygen alternating 24-hour 
periods of 50% and 10% oxygen for 14 days of newborn rat pups. This regimen produces 
severe, reproducible, predictable, and measurable retinal NV similar to ROP and AMD 
[113-115]. Using PEDF-deficient knockout Serpinf1 mice, high oxygen exposure during 
OIR results in down regulation of pro-angiogenic factors and vessel obliteration and halts 
retinal vascular development. When animals were in presence of air, the ischemic retina 
produced a high level of angiogenic factors driving to the production of new abnormal 
blood vessels [99]. PEDF deficiency is associated with hyperoxia-mediated vessel 
obliteration during OIR with a crucial effect on retinal neovascularization [99]. 
PEDF acts as a protective factor for retinal EC tight junctions [116]. IVT administration of 
PEDF reduce retinal vascular permeability in rats with OIR and diabetes. Moreover, when 
there is a suppression of retinal neovascularization during OIR, overexpression of PEDF 
occurs with anti-angiogenic activity [117]. 
PEDF is also related with neuroprotection [118-120] and it promotes the survival of rod 
photoreceptor cells under degenerative conditions [118, 121, 122]. There is a link between 
the loss of PEDF and degeneration of photoreceptor cells in AMD [40, 123]. 
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Administration of PEDF decreases motor neuron death and protects the survival of neurons 
from atrophy in neonatal mice exposed to the sciatic nerve section [124]. The lack of PEDF 
slightly affect the degeneration of retinal ganglion cells in an optic nerve crush model [14]. 
PEDF inhibits EC migration towards different pro-angiogenic factor such as VEGF, PDGF, 
Interleukin-8 (IL-8), acidic FGF and lysophosphatidic acid [98], so PEDF stimulates Fas 
ligand (FasL) expression and activates the FAS/ FASL transduction cascade leading to EC 
death [125]. 
PEDF affects the function of various cell types. In addition, it participates in RPE 
differentiation and maturation and when PEDF is made deficient as in KO animals. It 
affects RPE cell proliferation, migration, adhesion, oxidative state and phagocytic activity 
with minimal effect on their basal rate of apoptosis. This uncommon situation in RPE cells 
contributes to the pathogenesis of AMD [14, 126, 127]. The phagocytic function of RPE 
cells has a main role in the elimination of toxic metabolic waste and RPE cell survival 
([128]; [129, 130]).  
There is a specific epitope of PEDF, which contains the antiangiogenic activity, 34-mer 
(residues 24–57) which reproduces the PEDF angioinhibitory signals linking on c-jun-NH2-
kinase-dependent (JNK) nuclear factor of activated T cell deactivation causing apoptosis. 
The 34-mer has an antiangiogenic effect though the induction of endothelial cell apoptosis. 
34-mer activates JNK increasing the inactive NFATc2 and reduces NFAT binding to the 
endogenous c-FLIP promoter, thus blocking proangiogenic survival signal [111]. One 
directly-binding high affinity receptor for the anti-angiogenic 34-mer within PEDF is the 
laminin receptor (LR), a 67 kDa protein localized on EC. It is involved in the inhibition of 
angiogenesis [131-133]. 
Also, 34-mer inhibits angiogenesis by selectively inducing tip cells apoptosis leaving 
unaltered the nonstimulated quiescent cells. 34-mer inhibits the angiogenesis through the 
Fas death pathway using peroxisome proliferator-activated receptor ϒ (PPARϒ), 
increasing surface FasL via up-regulating PPARϒ and activation of caspase-8 [134]. 
Wnt signaling-mediated PPARϒ suppression/ β-catenin [135], was studied a shorter 
sequence within the 34-mer this found that a sequence of 18 amino acids (P18) from the C-
terminus of the 34-mer, modulates the signaling transduction between VEGF/VEGFR2 and 
suppresses activation of the PI3K/ Akt cascades, increasing the mitochondrial-mediated 
apoptosis anti-antiangiogenic activity [136] (Figure 5). 
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Several studies have shown that the 34-mer binds to the 67kDa non-integrin laminin 
receptor (67LR) and binds to the EC membranes suggesting that LR might be the true PEDF 
receptor for the process of angiogenesis inhibition [133]. Matsui et al, [137], has study the 
mechanism of 67LR in myeloma cells showing that binding 67LR with an antagonist blocks 
the binding of PEDF suppressing the PEDF effects. Moreover, LR agonists mimics the 
PEDF action. The trigger of the presence of LR is GnRH-II in ovarian cancer, it induces 
the 67LR precursor increasing the levels of LR. LR interacts with laminin in the ECM 
inducing the production of MMP-2 increasing the ovarian cancer cell invasion [138]. The 
34-mer has a strong affinity and several interactions with 67LR. It acts as a proapoptotic 
epitope and, the 34-mer, uses the same mechanism to induce apoptosis in cancer, where 
67LR is a very poor prognostic marker in epithelial ovarian cancer [139] as well as of 
activated EC [140] [141] (Figure 6). The activity of the 34 mer and its smaller P18 and also 
more N-terminal 25 mer (P46) is believed to rely on its alpha helical structure in PEDF, 
which must be maintained even in the isolated peptides. 
 
Figure 5. PEDF peptide structure. Left: Linear diagram of PEDF NH2 terminus with the secondary 
structural elements indicated above. Peptides are marked in brackets below the primary structure. Right: The 
α-carbon diagram of PEDF backbone is sown with peptide location highlighted in green (arrow, TGA/34-
mer overlap). Source: Filleur et al, 2005 (adapted)[111]. 
 
Figure 6. 34-mer epitope binds to LR to phosphorylate JNK MAPK, which activates PPARϒ through 
PPARϒ-ligand binding and nuclear translocation. PPARϒ activates FasL gene inducing the protein 
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expression. FasL. Paracrine FasL binds to FasL on the membrane binding to Fas activating the caspase-8 
cascade. Source: Gong et al, 2014 [142]. 
2.5 The vitreous gel 
2.5.1 Collagens in the vitreous 
The human vitreous gel is a transparent extracellular matrix of 4.5 ml, formed by >98% of 
water without the presence of cells. The structure of the vitreous is formed by collagen 
fibrils with the types II, V/XI and IX [143]. The majority of the collagen corresponds to 
type II (60-70%). Type IX represents 20-25% of vitreous collagen, type IX is a heterotrimer 
and cannot form fibrils but it can interact with other collagen fibrils, moreover, alterations 
on this collagen might have a relationship with the most important age-related vitreous 
changes. Type V/XI collagen is the 10-15% of the total collagen in the vitreous. Types II 
and V/XI collagens combine to form a heterotypic fibril. Type IX collagen attaches to the 
COL2 domain of type II collagen keeping the space between fibrils. [144-148]. 
The average concentration of collagen in vitreous in humans is approximately 300 μg/mL 
[149]. The number of collagen fibrils to form the gel state of the vitreous comprises 10-20 
µm in size, creating a random non-cross-linked network. The collagen is not uniformly 
distributed in vitreous; the highest concentration is located in the main site of synthesis, in 
the vitreous base. The concentration decreases towards the central and posterior parts of 
the vitreous, but then, increases in the posterior vitreous cortex adjacent to the retina [143] 
(Figure 7). 
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Figure 7. Anatomy of the vitreous and surrounding structures. The anatomical regions include the central 
vitreous, the basal vitreous, the vitreous cortex, the vitreoretinal interface and zonule. Source: Bishop et al, 
2000 [143]. 
The central vitreous comprises the main bulk of the vitreous body. With age, the width of 
the retinal part of the vitreous base, might enlarge on its posterior border and become 
irregular [150]. The basal vitreous is formed by a dense bundle of collagen fibrils, which 
are very tightly adhered to the retina and to the non-pigmented ciliary epithelium of the 
pars plana [143] (Figure 7). 
The vitreous cortex is a thin layer of 100-300 µm of vitreous gel that surrounds the central 
gel. The concentration of the collagen fibrils is higher than the concentration in the central 
vitreous. The vitreous cortex has two parts. 
The anterior vitreous cortex goes from the pars plana covering the central part of the 
posterior surface of the lens. The vitreous cortex, which places between the pars plana and 
the lens and close to the zonules, is in contact with the aqueous humor (Figure 8). 
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Figure 8. Schematic diagram of the eye. Source: Riordan-Eva and Whitcher. Vaughan and Asbury’s 
General Ophthalmology, 17th Edition: http:www.accessmedicine.com (adapted) [151]. 
The physiological function of the vitreous gel is providing a conduit for metabolic 
requirements of the lens and excluding cells and large molecules from the vitreous to keep 
transparency [152]. Moreover, it is important its function coordinating eye growth 
protecting the eye from mechanical traumas and inhibition of angiogenesis [153] [154] 
[155]. 
The average in protein concentration in human vitreous is between 0.5 and 1 mg/mL. There 
are identified about 1,000 proteins [156]. The majority of the proteins funded in the 
vitreous, are derived from the plasma, so immunoglobulins and albumin are the 80% of the 
total protein [157]. The presence of these proteins in the vitreous might be due to the low-
level leakage across the blood-retinal barrier, which when compromised increase the pass. 
These proteins are derived from fenestrated capillaries in the ciliary body stroma [158]. 
Between the collagen fibers, there is a large amount of hyaluronan (hyaluronic acid, HA). 
The vitreous doubles in volume during the development of a human. The concentration of 
HA in the eye during the development increases more than double, from 0.07 mg/mL to 
1.8 mg/mL [159]. 
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2.5.2 Poly-anionic components of vitreous 
a) Hyaluronan of the vitreous 
HA is a naturally occurring linear polysaccharide composed of glucuronic acid and N-
acetylglucosamine repeats via a β-1,4 linkage. (Figure 9). It is found throughout the mucosa 
and many ECM of mammalian bodies, the highest concentration being in the vitreous body. 
HA comprises the vast majority of the uronic acid containing molecules (85–90%). HA is 
a polydisperse molecule with a high average molecular weight in the vitreous, where the 
major proportion, about 45 to 77% have a MW >1,000 kDa [160], It forms a spheroidal 
system with a diameter of 200-300 nm, ten times higher than the collagen fibrils. The HA 
molecular network consist of polysaccharide chains of 1-2 nm long space between chains 
is filled with water.  
The poly-anionic nature of this molecule has the property to repel and can bind to water 
molecules giving a viscosity similar to gelatin [161]. The charges are affected by the pH 
and ionic strength of the environment and by the shape of the chains and the interaction 
with surrounding molecules. The amount of HA in the human vitreous is in the range of 
100–400 µg/mL [162]; [161]. This solution creates a viscoelastic fluid system due to the 
molecular weight and the concentration and the structure, with the random distribution of 
thin molecular networks is responsible for vitreous transparency. HA distribution is not 
homogenous; the highest amount is located in the posterior cortical gel where the hyalocites 
are located, cells that continuously produce the HA. From the posterior chamber, it is 
washed by the aqueous to the anterior chamber and leaves the eye through the trabecular 
meshwork. The turnover time of HA in monkeys was several months due to the slow 
diffusion [163]. 
The main role of the HA is to provide a link between the collagen gel network of the 
vitreous and HA without covalent binding [160]. 
The rheological properties of the HA have shown that increasing the temperature and the 
presence of electrolytes in an aqueous solution with HA decreases the viscosity magnitude. 
[164]. 
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Figure 9. Chemical structure of HA. Source: Nagashima et al, 2011[165]. 
b) Proteoglycans of the vitreous 
Proteoglycans are the third component of the vitreous with collagen and HA. They are in 
the liquid vitreous and they are not attached to the other two components of the vitreous. 
The most common proteoglycan in mammalian vitreous is called versican, which has a 
mass of 37 kDa and contains several sulfated disaccharides [166] [167] [168]. The other 
subtype of proteoglycan presence in the vitreous is type IX collagen. Similar to versican 
but, contains uronic acid and chondroitin sulfate (CS) [166, 169, 170]. There is a direct 
interaction of proteoglycans with HA but is very weak. This complex shows structural and 
immunological characteristics as versican [160] (Figure 10). 
 
 
Figure 10. CS structure. Source: https://pubs.acs.org/cen/news/84/i33/8433sulfation.html [171]. 
The sulfation of the glycosaminoglycan (GAG) chains of the CS, gives the molecule the 
property to bind cationic molecules due to the high density of sulfate and carboxylic groups 
in its GAG moieties. The amount of versican in the human vitreous is 60 µg/mL [168] 
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2.5.3 Aging changes in the vitreous body 
There are two different processes that occur at the same time, gel liquefaction and 
vitreoretinal interface weakening. At the end, the last step of the aging process is the 
posterior vitreous detachment. 
Even when the presence of liquid vitreous has been observed at all ages, the first appearance 
is in the childhood [172]. The vitreous continues to develop after birth increasing the 
volume in parallel to the production of HA filling the vitreous body and giving support and 
stabilization for the collagen fibrillar network. The production of collagen fibers stops after 
birth and the space between fibrils increases as the gel becomes less dense (Figure 11). 
There is not liquid vitreous present in human eyes below the age of 4 years [173]. During 
the years, the amount of liquid increases reaching a 20% of the total vitreous volume to the 
age of 20. Sometimes might increases to 50% in people of 60 years old. In animals the 
liquid vitreous does not form, the exceptions are humans and rhesus monkeys [174]. During 
adulthood, the concentration of HA does not change in either of the two vitreous types 
[175] [176]. At age of 70, there is a slight increase of the HA concentration with the same 
molecular weight, but in that case in the liquid vitreous. This process starts with the 
appearance of narrow channels that evolve to pockets and pools of liquid vitreous that they 
gather each other at the age of 40-45 years. With time, this central liquid pocket occupies 
more than half the volume of the vitreous (Figure 12). 
 
Figure 11. Representation of the average of volume of gel and liquid vitreous during the human 
development. The gel is stable during the first 40 years. Source: Tozer et al, 2014[177]. 
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Figure 12. Concentration of HA in human gel vitreous throughout the life. The concentration increases 
until the age of 25. Source: Denlinger and Balazs [178]. 
Another process related to aging is the posterior vitreous detachment. This change is only 
documented in humans. This is a change that affects many people but it does not usually 
provoke an impairment of vision. The structural changes related on this process are a 
thickening of the basal lamina of the retina and an increase in the volume of liquid vitreous 
with a collapse of the gel and aggregation of the collagen fibrils. Posterior vitreous 
detachment can affect at any age as a result of chronic intraocular inflammation, traumas 
in the eye of highly myopic individuals. There are changes in the vitreous collagen like the 
nonenzymatic glycation and enzymatic cross-linking [179] [180, 181]. 
One of the procedures to substitute the vitreous is by vitrectomy surgery. In these cases, 
one uses a viscoelastic preparation made with Sodium Hyaluronate (Healon®). The 
properties of this compound are its high viscosity (varied MW & viscosities available) at 
low shear and at the same time low viscosity and high elasticity at high shear. This 
elastoviscous solution serves as a shock-absorbing body and protects delicate tissues and 
cell layers, such as, retina, iris, corneal endothelium [182]. 
2.6 Current treatments: Anti-VEGF’s 
VEGF is upregulated by hypoxia during the angiogenesis. VEGF activates quiescent 
endothelial cells and stimulate cell proliferation, migration and vascular permeability [183]. 
The intravitreal administration of recombinant human VEGF165 produces non-
inflammatory iris neovascularization, ectropion uvea and neovascular glaucoma [184]. An 
alternative strategy was designed to inhibit the VEGF receptor tyrosine kinase (VEGFR-
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2): sunitinib and sorafenib. These drugs were approved for the treatment of renal cell 
carcinoma and gastrointestinal stromal tumor respectively [185]. Avastin (bevacizumab) is 
a full-length humanized rhuMAb HER2 antibody (148 kD) and Lucentis (ranibizumab) is 
the humanized rhuMAb vascular endothelial growth factor Fab antibody (48.3 kD) isolated 
from bevacizumab [186]. But the inhibition of VEGFR-2 is proportionally related with the 
risk of blood pressure elevation [187] there is also a regulated increase in vascular 
permeability to both solutes and water [188] [189]. And VEGF regulates the apoptosis of 
EC, contributes to the maturation of vascular granulation tissue into avascular scar tissue 
and, to the pruning of retinal vessels during development [190]. 
The target of treatment has thus far been direct inhibition of VEGF in the eye with VEGF-
A antagonists. There are four anti-VEGF drugs on the market for wet AMD. 
2.6.1 Pegaptanib 
Pegaptanib (Macugen, Pfizer) is a specific 28-base ribonucleic acid aptamer of 50 kDa 
aprox, covalently linked PEG [191, 192] with a high selectivity and inhibitor of VEGF-
A165 isoform [192, 193], which has been implicated in blood-retinal barrier breakdown and 
pathological intraocular neovascularization [21]. Pegaptanib was found as the weaker drug 
to treat this disease [194]. The IVT half-life is 10 days; given at 0.3 mg every six weeks. In 
vitro and in vivo studies have shown that precursors of this drug inhibit the enhancement 
of EC proliferation and vascular permeability [195, 196]. Macugen was approved by the 
FDA in 2004 and by the EMA in 2006. Therapeutic benefit was very favorable in 
comparison with photodynamic therapy. However, was overturned in efficacy terms 
displaced by the next anti-VEGF drug, ranibizumab, since pegaptanib does not inhibit other 
bioactive isoforms of VEGF fragment in vivo. Pegaptanib is no longer recommended for 
the treatment of AMD [197]. 
2.6.2 Ranibizumab 
Ranibizumab (Lucentis, Genentech), is a 48 kDa recombinant, monoclonal, humanized 
antibody Fab fragment which inhibits VEGF-A isoforms [192, 198, 199]. The binding site 
is located at amino acid sites 88-89 [200]. It is designed from the full-length monoclonal 
antibody bevacizumab (developed for cancer angiogenesis) by removing the Fc fragment 
from the parent molecule [201, 202]. Ranibizumab binds with high affinity a site present 
in all isoforms and their bioactive proteolytic fragments, including the soluble VEGF 
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isoforms 110, 121 and 165 and the tissue-bound isoforms 189 and 206 [203-205]. The half-
life of ranibizumab is 2.9 days, in rabbits at a concentration of >0.1 µg/mL, the compound 
was maintained in vitreous humor for 29 days [206]. The relative molar binding activity to 
VEGF is 1, so excess drug has a rapid systemic clearance thus systemic safety of this drug 
is very high [207] [208]. The recommended dose is 0.5 mg/monthly injection and the initial 
loading dose is of three monthly injections. After this visual acuity is reached and patients 
have to be monitored monthly for visual acuity to continue the treatment, 1 injection every 
month if there is a loss of visual acuity. Lucentis was approved by the FDA in July 2006 
and by the EMA in January 2007 [21]. 
2.6.3 Bevacizumab 
Bevacizumab (Avastin, Genentech), is a full-length humanized anti-VEGF monoclonal 
IgG1 anti-VEGF-A antibody that inhibited the action of all isoforms of VEGF [192, 193, 
198]. It binds to both VEGF165a and VEGF165b with equal affinity [209]. The target is the 
same as ranibizumab, the MW is 149 kDa and the half-life is longer than ranibizumab [199, 
210]. Human IVT half-life is estimated at 4.32 days and its relative molar binding activity 
is 0.05-0.2, showing it has lower binding affinity than current treatments [211]. With a 
concentration of >10 µg/mL, bevacizumab was maintained in the vitreous humor for 30 
days [212]. Bevacizumab was approved by the FDA and EMA for the treatment of different 
types of solid tumors (colorectal, non-epithelial lung, breast, ovarian and renal) and 
glioblastomas [213]. In ophthalmology it is used off-label. The recommended dose for 
intraocular treatment is 1.25 mg/month [214]. This is usually given as a 50 μL injection of 
25 mg/mL protein. 
2.6.4 Aflibercept 
Aflibercept (Eylea, Regeneron), is a 115-kDa recombinant fusion protein which, in addition 
to inhibiting VEGF-A, also inhibits VEGF-B binding domains of human VEGFR-1 and 
VEGFR-2 fused to the Fc domain of human immunoglobulin G1. Aflibercept and 
ranibizumab have the same effect blocking endothelial cell proliferation and both are 10-
fold more potent than bevacizumab and aflibercept is non-inferior to ranibizumab in 
treating wet AMD [192, 215]. Aflibercept binds to placental growth factor (PLGF), a 
proangiogenic protein present on EC and leukocytes [208]. It acts as a soluble decoy 
receptor recognizing and neutralizing all VEGF-A isoforms, with the establishment of a 
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tighter binding than the native receptors. It binds also PLGF-1 and PLGF-2 with a high 
affinity, greater than bevacizumab or ranibizumab. Therefore, the predicted binding affinity 
of aflibercept to its ligand is higher than ranibizumab (aflibercept: kDa = 0.49 pmol/L; 
ranibizumab: kDa = 0.46 pmol/L; ranibizumab: kDa = 0.58 pmol/L) [191]; [193]; [194]. 
The intravitreal half-life of aflibercept is 7.1 days and the relative molar binding is 140 
thus, the activity in the eye of Eylea is 2.5 months [216] [217]. The FDA approval was 
granted in 2012. The recommended intravitreal dose is 2.0 mg/month for three consecutive 
treatments, followed by one injection every two months [218]. 
VEGF-A antagonists utility is limited by several factors. It has been reported that 
approximately 15-33% of patients with wet AMD are “nonresponders” despite undergoing 
treatment with anti-VEGF agents and a further 30-40% of patients will experience no 
improvement in vision and no change in lesion size [10, 219]. These treatments slow 
disease progression more often than they improve vision due to adaptive resistance of the 
system. The choroidal microenvironment responds to VEGF antagonists by increasing 
VEGF expression, and neovascularization can resurge between treatment cycles [220]. In 
addition, VEGF is not the only proangiogenic factor contributing to retinal 
neovascularization and its blockade can cause overproduction of other factors (IL-8, bFGF) 
as was shown for cancer angiogenesis [220]. In addition, the cons of these treatments, 
especially in the long-term period, are: the high frequently administration, IVT injection 
every 1-2 months, the price Eylea and Lucentis ranges from 800-1,900 USD (re-formulated 
Avastin is 50-100 USD) and most of them have potential side effects related to the eye and 
the circulatory system like, vitreous hemorrhage, retinal detachment, hypertension, etc 
[221, 222]. So novel compounds could decrease AMD progression with minimal local and 
systemic effects, with significantly reduced frequency of administration is important to 
enhance the effective of the treatment. 
2.7 New possible alternative treatments 
2.7.1 Trombospondin-1-mimetics 
TSP1 is an endogenous inhibitor of angiogenesis with a promising effect in several diseases 
with a neovascular implication. Up-regulation of endogenous TSPs, synthetic TSP1 
peptides or peptides derived from TSP were used to evaluate its therapeutic effects [223-
225]. The expression of TSP1 is necessary for keeping the homeostasis and for reducing 
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and re-building the retinal vasculature during the development and maintenance of the 
inactive state of vasculature [14]. 
The mimic peptides derived of TSP1 have been used in several in vitro and in vivo tumor 
models [226-229]. Several studies have demonstrated that TSP1 suppress the cancer cell 
proliferation [226]. 
ABT-510 was developed to improve the pharmacodynamics and pharmacokinetic activity 
of TSP1 type 1 repeat peptide [227]. This peptide contains anti-angiogenic TSP-1 sequence 
with a single D-amino-acid substitution giving 1,000-fold greater anti-angiogenic activity. 
ABT-510 affects angiogenesis mechanisms; it competes with TSP-1 for binding EC, 
induction of FasL expression in EC, and inhibition of VEGF activity [227]. 
ABT-898 is a later generation of TSP1 mimic peptide, which given systemically, decreases 
the tumor size in mice with uveal melanoma. Systemic administration of this peptide has 
shown a 10-fold reduction in the mice tumor volume in comparison of mice control group 
[226]. It is also active by IVT injection in the laser induced mouse model of CNV [230].  
TSP-1 blocks angiogenesis through specific apoptosis mechanisms that do not duplicate 
that of VEGF antagonists. Thus, TSP-1 mimetic peptides have the potential to act 
synergistically and to enhance activity of VEGF antagonists to mitigate CNV [14], (Figure 
4). 
2.7.2 Pigment epithelium-derived factor and peptides derived from PEDF 
PEDF is recognized as a potent endogenous inhibitor of neovascularization. It is a 50 kDa 
glycoprotein, member of the serpin superfamily without serine protease inhibitor activity 
[92]. PEDF is a multifunctional protein with a broad spectrum of activities [96, 98, 112]. 
The inhibitory effect of PEDF was demonstrated by the inhibition of VEGF and FGF 
activity, only on newly forming blood vessels without affecting pre-existing blood vessels. 
The administration of exogenous PEDF to a neovascularized area results in the inhibition 
of both EC migration and proliferation through the induction of apoptosis of recruited EC 
[231] [232]). The re-expression of PEDF in an area where this compound is not secreted 
like the human esophageal squamous cell carcinoma significantly inhibits their migration 
and proliferation and stop their growth by suppressing neovascularization [233]. 
Overexpression of PEDF decreased the size of ocular tumor metastasis associated with 
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reduced microvascular density in pre-clinical models [234]. PEDF overexpression 
decreased migration and capillary morphogenesis of melanoma cells in vitro [234] so; 
administration of PEDF is effective in attenuating angiogenesis and tumor growth. 
PEDF was used in different studies for the in vivo treatment of ocular neovascularization 
with the purified protein and the recombinant PEDF, even with low doses without affecting 
the pre-existing blood vessels and the morphology [98, 235]. The administration of an 
adenovirus encoded PEDF (AdPEDF.11), inhibited CNV that corresponded with induced 
apoptosis of EC within the neovascularized area [236]. 
The active anti-angiogenic PEDF region is located in the 34-mer epitope, an anti-
angiogenic 34-amino acid N-terminal peptide has been further shortened to 18 residues 
[111, 135], which was recently truncated to a smaller, more practical 9-amino acid fragment 
(P3-11), that retains anti-angiogenic activity. (Figures 5, 71, 72) [237]. A potently CNV-
active 2nd generation 9-mer, peptide 11, is our CNV drug candidate, to be delivered here in 
prodrug form, as described in Materials and Methods and Results. The details of its 
discovery and bioactivity are described under the discussion section. 
2.8 Prodrugs 
A prodrug is a precursor of an active compound without or less activity that requires a 
chemical or enzymatic reaction after its administration to be active. The aim of these 
compounds is to improve and optimize the physicochemical, biopharmaceutical or 
pharmacokinetic properties of the active substances (absorption, distribution, metabolism 
and excretion) [238, 239], (Figure 13). Prodrugs are also known as reversible or 
bioreversible derivatives, latentiated drugs or biolabile drug-carrier conjugates [240-242]. 
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Figure 13. Illustration of the prodrug concept. The drug–promoiety is the prodrug that is generally 
pharmacologically inactive. The drug and promoiety are covalently linked via bioreversible groups that are 
chemically or enzymatically labile. Source: Huttunen et al, 2011 [239]. 
Inside the prodrug, there are several sub categories such as: 
-Co-drugs, two pharmacologically active drugs that are coupled together in a single 
molecule so that each drug acts as a promoiety for the other [243, 244]. 
-Bioprecursor prodrug, a prodrug that does not contain a carrier or promoiety, but it needs 
a molecular modification to be the precursor that will be transformed to be 
pharmacologically active. 
-Soft drugs, active drugs that are designed to undergo a predictable and controllable 
deactivation or metabolism in vivo after achieving their therapeutic effect [245, 246]. 
Currently, 10% of the drugs approved worldwide are classified as prodrugs, and 
approximately one third of all new drugs approved in 2008 were prodrugs [247]. 
2.8.1 Functional groups related to prodrugs 
The selection of a prodrug might alter the characteristics of the drugs in terms of toxicity 
and distribution during the development of the drug. There are several factors that they 
have to study such as: 
-Functional groups that might be candidates to react with a promoiety and generate the 
prodrug. 
-Promoiety should be safe and without pharmacological activity and according to dose, 
duration of the therapy and state of the disease. 
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-Prodrug and drug need to study their ADME (absorption, distribution, metabolism, 
excretion) properties. 
-Degradation by-products could affect to the drug stability. 
The functional groups more used to design prodrugs are carboxylic, hydroxyl, amine, 
phosphate/phosphonate and carbonyl groups. The modification of these groups leads to 
ester, carbonates, carbamates, amides, phosphates and oximes. Other functional groups that 
have investigated for synthesize prodrugs. Thiols react as alcohols given new chemical 
bonds as thioethers and thioesters. Amines derivatize imines and Mannich bases [248-252] 
(Figure 14). 
 
Figure 14. Common functional groups on parent drugs that are amenable to prodrug design (shown in green). 
Most prodrug approaches require a ‘synthetic handle’ on the drug, which are typically heteroatomic groups. 
Source: Rautio et al, 2008 [238]. 
2.8.2 Esters as prodrugs of carboxyl and hydroxyl functionalities 
Ester is the chemical bond most used in prodrugs. The 49% of all marketed prodrugs have 
ester bonds whereby the drugs are released by enzymatic hydrolysis [253]. Spontaneous 
hydrolysis might be preferred when very long action is desired in a location where esterases 
are scarce. The most common purpose of ester prodrugs is to enhance the lipophilicity of 
water-soluble drugs by masking charged groups such as carboxylic acids and phosphates, 
to promote the passive membrane permeability [254]. 
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In the body, the ester bond is readily hydrolyzed by esterase enzymes in the blood, liver 
and other organs and tissues, including carboxylesterases, acetylcholinesterases, 
butyrylcholinesterases, paraoxonases and arylesterases [255]. 
Nevertheless, one problem for the ester prodrugs is the prediction and extrapolation of the 
preclinical pharmacokinetic to humans, specifically on the difference of carboxylesterase 
activities among species [238]. 
A review published by Beamunt in 2003 [254], shows examples of several ester prodrugs 
designed to enhance the oral absorption of poorly permeable and polar drugs. There some 
cases which the slow and incomplete bioconversion of esters in human blood affects to the 
bioavailability. As an example, the oral bioavailability of the drug enalaprilate in humans 
is 36-44%, despite the 53-74% of the administrated drug that has been absorbed [254]. 
There are cases that the bioactivation has been boosted by the use of a double prodrug. This 
compounds needs to be modified by an enzymatic breakdown followed by an activation 
due to a chemical reaction and releasing the active compound. This approaching has been 
used for the administration of oral acyloxyalkyl ester prodrugs of β‑lactam antibiotics [256, 
257] (Figure 17). 
2.8.3 Carbamates 
These chemical bonds, also known as urethanes, differs of the ester bond due the presence 
of an oxygen and an amine on both sides of the carbonyl carbon. Carbamates are carboxylic 
acids and amine derivatives. These bonds are enzymatically more stable than esters but are 
more sensitive to hydrolysis than amides. The bioconversion of these bonds requires 
esterases for the release of the drug [258], (Figure 15). 
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Figure 15. Example of commercial prodrugs formed by esters and carbamates and their properties. 
Source: Rautio et al, 2008 (adapted) [238]. 
2.8.4 Prodrugs for the protection from rapid metabolism and excretion 
Rapid metabolic degradation of drugs could be protected by prodrugs. With the 
bronchodilator and β2-agonist terbutaline, converting its phenolic groups, which is the 
trigger to start the metabolic breakdown, into bis-dimethylcarbamates (bambuterol, 
AstraZeneca) (Figure 16). This is slowly bioactivated to terbutaline mainly by a nonspecific 
butyrylcholinesterase enzyme outside the lungs. As a consequence of the slow release and 
prolonged action of the drug, it is possible the administration of bambuterol once per day 
for the treatment of asthma reducing the adverse effects in comparison with terbutaline 
which needs to be administrated three times per day [259]. 
 
Figure 16. Bioactivation of terbutaline from bambuterol through the enzyme butyrylcholinesterase. 
The carbamate bond is highlighted. Source: Huttunen et al, 2011 (adapted) [239]. 
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2.9 Drug delivery systems for intraocular administration 
Release of drugs in the posterior segment of the eye to treat diseases, is a challenge from 
the point of the physiologic-anatomical of the eye and from the physicochemical properties 
of drugs. On the first challenge, there are several limitations and barriers such as the number 
of layers of tissue (corneal epithelium, corneal endothelium, conjunctiva and sclera), static 
barriers (sclera, Bruch’s membrane-choroid and RPE), dynamic barriers (blood flow, 
lymphatic drainage, transport proteins of RPE, drug efflux pumps, organic ion transporters 
and bulk fluid flow from intraocular drainage systems). Metabolic barriers such as enzymes 
(esterase, peptidase, MMp’s, Trypsins). On the second challenge, there are several 
variables to take care of (solubility, molecular dimensions, molecular weight, charges and 
functional groups) [260-264]. 
2.9.1 Eye drops 
Eye drops is one of the vehicles used for the administration for anterior segment disorders 
(inflammation, glaucoma, infections), the disadvantage of this via is the low bioavailability 
through the cornea. The permeability of the drugs through the cornea is 1-7% but small 
hydrophilic drugs, peptides and proteins is zero [265]. On the other hand, molecules with 
the lower molecular weight have more permeability to cross to the posterior chamber [266]. 
Prodrugs were firstly used to improve the absorption of adrenaline through the cornea with 
its prodrug dipivalyl adrenaline (dipivefrin) [267, 268]. Dipivefrin is a dipivalic acid diester 
of adrenaline which penetrates the human cornea 17-times faster than adrenaline, due to 
the increase of 600 times of the adrenaline lipophilicity at pH 7.2 [269, 270]. Moreover, 
the efficacy of dipivefrin is almost 20 times more potent than adrenaline reducing the 
intraocular pressure and the systemic side effects are reduced [271, 272] (Figure 17). Fluid 
drainage from the anterior aqueous humor via the trabecular meshwork is relatively rapid, 
while vitreous is relatively stagnant, thus drugs entering from eye drops rarely reach the 
posterior eye. This makes topical delivery of agents against posterior disease nearly 
impossible. Figure 18.  
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Figure 17. Prodrugs for improve ophthalmic absorption and delivery using ester bonds. Source: Rautio 
et al, 2008 (adapted) [238]. 
 
 
Figure 18. Different routes of drug administration for retinal drug delivery. Source: del Amo et al, 2017 
[5]. 
2.9.2 New drug delivery systems 
Nowadays, the development of new drug delivery systems (DDS) to release drugs in the 
posterior segment of the eye is of increasing interest. The carriers are designed to release 
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drugs to a specific space in a particular time. To design these DDSs, three techniques are 
considered: 
1. Absorption promotion: Promotion of the passage of a drug through the tissue, which 
functions as a barrier. 
2. Controlled release: efficient time-controlled sustained release of a locally 
administered drug. 
3. Drug targeting: to allow it to act efficiently and exclusively on the target tissue 
[273]. 
The ophthalmic nanocarriers that have been more studied are liposomes and micro/ 
nanospheres and others that are taken more attention are emulsions and dendrimers. 
With intravitreal injection it is possible to deliver solutions, suspensions and implants 
[274]. The advantages of implants are the long-term release, the zero-order kinetic release, 
and the possibility of remove the implant in case there are toxicological levels of the drug. 
There is a case where ganciclovir is formulated in a nonbiodegradable implant and 
administrated inside the eye. The release of the drug is during 6-8 months [3, 275]. The 
implant with fluocinolone acetonide (Retisert®) releases the drug is up to 30 months [276]. 
The disadvantage of these formulations is that the only way to remove it is by surgery. The 
half-life of most drugs in the vitreous is limited from 1-10 hours to 9 days as ranibizumab, 
a VEGF inhibitor used on the treatment of Age-related macular degeneration [10, 277-279]. 
There are several formulations to administer drugs, Sun and collaborators [280] have 
developed a thermosensitive drug delivery system to treat glaucoma, which releases 
brimonidine (anti-glaucoma) in rabbit eye in 7 days. Li and collaborators [281] have 
increased significantly the residency of Bevacizumab (Avastin®), treatment for AMD, to 
90 days encapsulating the drug in nanoparticles of copolymer poly(lactic-co-glycolic acid) 
(PLGA). One of the problems of these formulations is the complexity of movement inside 
the eye, might be unpredictable and lead to toxicity and the observation of foreign body 
inflammatory responses to IVT-injected, spherical PLGA microspheres in rabbits, with 
more intense and prolonged such reactions recently seen in non-human primates (NHP) [5, 
282, 283]. Another issue to solve is the diffusion of the particles in the vitreous, according 
to Xu and colleagues [12], PLGA nanoparticles with a size below 500 nm and neutral or 
negative charges diffuse in the bovine vitreous with low barrier. However, liposomes with 
an average of 116-139 nm and positive charges showed 103 times slower diffusion than 
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anionic liposomes (138-170 nm) in the porcine vitreous. If the treatment needs frequent 
injections, might be a risk of vitreous hemorrhage, cataracts and endophthalmitis [11]. 
a) Liposomes 
Liposomes are small closed lipid vesicles (small lipid vesicles) formed by a phospholipid 
bilayer and where water-soluble drugs can be loaded in the aqueous phase and lipid-soluble 
drugs can be loaded into their lipid phase [284]. 
The advantages of liposomes are: 
1. There are not covalent aggregates and their lipid composition, size and electric 
charge can be controlled [285]. 
2. To improve the targeting, it is possible to modify their surface with polymers, 
carbohydrates and antibodies [286]. 
3. Their toxicity and antigenicity are negligible [287]. 
4. Liposomes can be biodegradable and metabolized in vivo [287]. 
5. Membrane permeability can be controlled to some extent [288]. 
6. It is possible to use different solutes with different properties and molecular weights 
(fat-soluble molecules, water-soluble molecules and amphiphilic molecules) [288]. 
The disadvantages of this DDS are: 
1. After the intravitreous injection, the vision is blurry. 
2. Limited storage conditions. 
Knowing these properties, several studies were developed on the intravitreal injection of 
drug loaded in liposomes. These studies have demonstrated that the release of the drug can 
be controlled, the half-life of the drug inside the vitreous body can be prolonged and the 
toxicity of the drug can be reduced [279]. 
A study conducted in rabbit eye, one group had received 1 mg of ganciclovir (GCV) 
encapsulated in a liposome. The other group had received free GCV in different 
concentrations (from 0.2 to 20 mg). After 72 hours, the rabbit eyes were they received free 
GCV, the one with the concentration higher that 5 mg showed therapeutic effect. In 
addition, GCV caused retinopathy at doses at 15 mg or higher. On the other hand, there 
was no indication of retinopathy in 1 mg of liposome-encapsulated GCV, in fact the 
concentration of the drug had demonstrated therapeutics levels up to 14 days after injection 
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ones, which had administered the free drug [289]. Moreover, fewer injections were required 
for liposomes loaded with GCV [290]. 
It is possible to improve the stability of the drug inside the vitreous by the addition of 
polyethylene glycol (PEG) to the surface of the liposomes, the function of PEG is to cover 
the liposome with a new aqueous layer [279]. 
There was a study where gentamicin was encapsulated in a liposome to check and compare 
with the free drug, the pharmacokinetics of the drug after injection in rabbit eyes [291]. 
This study has shown that the peak free drug concentration in the vitreous was significantly 
greater for the encapsulated drug than the free drug during 8 days. The areas under the drug 
concentration-time curve for the total drug and for the free drug in the case of the liposome 
encapsulated gentamicin were two fold and 1.5-fold higher, respectively [291]. 
In the case of bevacizumab encapsulated in liposomes, the concentration of the free drug 
and the encapsulated one was one fold and five fold higher at days 28 and 42, respectively, 
than the free drug [292] (Figure 21). 
 
Figure 19. Formulation for injectable particles. (A) Liposomes. (B) Micro/ nanocapsules. (C) Micro/ 
nanocapsules. (D) Microemulsion. (E) Dendrimer. Source: Honda et al, 2013. [293] 
b) Microspheres and nanospheres 
Microspheres are spherical particles with a diameter from 1 µm to several hundred 
micrometers. If these particles have a diameter below 1 µm, they are considered 
nanospheres [294]. The particles could be made by synthetic and/or natural polymers and 
the architecture of the micro/nanospheres are made by multinuclear micro/ nanocapsules. 
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Drugs are encapsulated inside the spheres permitting sustained local release and tissue 
targeting of the drug [293]. 
The most used polymers are poly(lactic acid) (PLA), polyglycolic acid (PGA), and PLGA. 
These compounds are nonenzymatically hydrolyzed and degraded in vivo. Intravitreally 
injected PLA and PLGA had not shown electrophysiological or histological toxicity in the 
retina [282, 295], but a recent study have shown that the size, shape, and/or surface area of 
PLGA microspheres induce ocular inflammation in both rabbits and mokeys.[283] (Figure 
19). 
The first FDA-approved sustained-released formulation was an intraocular implant of GCV 
(Bitrasert®; Bausch and Lomb, Rochester, USA) that is a non-degradable in vivo and is 
being used in the treatment of cytomegalovirus retinitis in AIDS patients. This system is 
made by the polymers ethylene vinyl acetate (EVA) and polyvinyl alcohol (PVA), is 
implanted and allows the sustained release of 450 mg of the drug in 6-8 months [275]. 
Sometimes when the retinitis is not cure, the implant has to be removed without any 
complication [296]. 
The implant Ozurdex®, releases dexamethasone in the vitreous, the purpose of this drug is 
the treating of macular edema and associated with retinal vein occlusion. After 180 days of 
treatment there was an improve of visual acuity and retinal thickness. In addition, its 
efficacy is remarkable for the treatment of uveitis and diabetic retinopathy [297]. 
Microsphere might be transported to retinal pigment epithelial cells [298, 299]. The 
distribution of the particles into the tissues depends on their diameter. When three different 
sizes of a fluorescent nanospheres were injected into the vitreous of the rabbits, the 2,000 
nm particles were found in the intravitreal cavity and the trabecula, whereas the 200 nm 
and 50 nm nanospheres were found inside the retina [300] (Figure 19). 
c) Microemulsions 
A microemulsion is a dispersion system made it by two immiscible substances (hydrophilic 
and hydrophobic) and a surfactant. The size of this system is as low as 100 nm or even less. 
Micelles are thermodynamically stable and can be formed easily without the need for strong 
agitation. The color is transparent or semitransparent due to the limited dispersion of visible 
light arising from their small size [301]. 
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These formulations have good tissue permeability due to the small size of micelle and the 
surfactant. Thanks to micelles it was possible to enhance the intraocular permeability of 
dexamethasone in rabbit eyes [302, 303]. 
Autoclave is not possible for microemulsion sterilization and it is only suitable for short-
term sustained drug release (Figure 19). 
d) Dendrimers 
Dendrimers are polymers formed by repetitive single molecules with a regularly branched 
structure, the central part is known as core meanwhile the external part is named dendrons. 
The regular shape is spherical and the molecular weight is homogeneous. All their physical 
properties, size and structures could be controlled at the molecular level [304, 305]. The 
disadvantages of this DDS are that the amount of drug that it is possible to conjugate is 
very limited and the in vivo safety is unclear. Most of the dendrimers are synthesized using 
polyamidoamine (PAMAM) and poly-propylene imine (PPI) [306]. There is not any 
approved dendrimer drug [293] (Figure 19). 
2.10 Novel charge-based nanoparticle strategy 
There have been many efforts to overcome the shortcomings of multiple IVT injections by 
extending the time of therapeutic release after delivery [4]. Slow-released colloidal drug 
carrier has become a preferred approach [4, 12, 307, 308]. These are normally nano/ micro-
spheres made of biodegradable materials, with drug molecules embedded in their body or 
coated on their surface. After injection, the carriers remain in the vitreous over a relatively 
long period of time and slowly release the therapeutic molecules during their breakdown to 
smaller fragments until total clearance [308]. Advantages include biocompatible material 
for the carrier, and minimally invasive administrations. One critical issue limiting the 
clinical uses of the colloidal carriers is their relatively large size. These generally rely on 
large particle size (>10 μm) to prolong the diffusion through the viscous vitreous. While it 
varies according to age and other factors, the normal mesh size of vitreous is estimated 
from 500-1,000 nm [309]. Thus, neutral or negatively charged particles <200 nm in 
diameter move freely, but a strong diffusional slowing is observed above 500 nm. Most 
attempts to achieve slow drug release rely on extending IVT residence of colloidal carriers 
larger than this mesh size. These range over liposomes and micelles, polymers and thermal 
gels, for prolonged delivery of agents, from small molecules to antibodies. Typical carriers 
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are microparticles (MP), diameters >2 µm, for slow vitreal diffusion. These generally 
biodegrade for eventual removal, but cannot be sterile-filtered or autoclaved, a problem for 
safe IVT delivery. Their breakdown produces a continuum of sizes, some of which may 
obstruct the trabecular meshwork (TM), or activate its phagocytes. Commonly used 
poly(lactic-co-glycolic) MP (PLGA), though well tolerated in non-ocular sites, elicited a 
foreign body response in rabbit eyes [282], such MP have recently led to rabbit eye 
inflammation, and more severe and prolonged reaction in primates with potential for 
damage to critical structures [283]. With risk of causing glaucoma or tissue damage, few 
size-based carriers are approved for non-steroid drugs, making long-acting, smaller NP 
(<100 nm diameter) desirable. 
One potential solution to reduce particle size while maintaining slow diffusion is to use 
cationic nanoparticle carriers. The vitreous has a very high content of poly-anionic 
polymers, especially the viscosity-enhancing, HA. Particles with poly-cationic 
compositions will anchor themselves to HA in vitreous through ionic binding, resulting in 
slow diffusion. In 2009, Kim et al. showed that albumin, freely diffusing in vitreous, was 
immobilized by converting its surface acidic residues to cationic amides with 
ethylenediamine (Zeta potential change from -33 to +11.7 mV) [310]. In 2013, Xu et al. 
reported that 200-nm polystyrene particles coated with cationic amine groups showed 
diffusion rates of 1000-fold slower than their neutral or anionic counterparts in bovine 
vitreous [12]. Using such cationic carriers, however, was not clinically practical since the 
particles are conjugated with multiple amino groups, which, along with most other cationic 
groups, are toxic, especially when multiple cations are on particles of a size that can be 
engulfed by cells [311]. 
Importantly, in 2011 Zern et al. [312] reported that when the positive charge is derived 
exclusively from L-arginine (L-Arg), small cationic particles were at least two orders of 
magnitude less toxic to cells. They compared cytotoxicity among cationic nanoparticles 
with varied sources of positive charges, including, L-Arg and D-Arg [312]. They found 
while all the particles are capable of forming complexes with polyanions, the L-Arg-based 
carriers were at least 200-fold less toxic than the non-arginine based cationic carriers and 
at least 10-fold less toxic than D-Arg carriers. Supporting evidence was then reported by 
Veiseh et al., who compared the safety of cationic magnetic nano-vectors coated with either 
PEI or L-Arg ([313]). L-Arg particles showed no toxicity when injected into mice, while 
the PEI-based carriers produced hemolysis, erythrocyte aggregation and acute organ 
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toxicity. Sarker et al. compared lipofectamine transfection with 100-nm-diameter 
liposomes based on inserted lipid L-Arg [314]. Those with Zeta potentials higher than 20 
mV gave far superior DNA delivery and displayed very low toxicity. The non-toxicity of 
L-Arg coating was further confirmed with dendrimers both in vitro and in vivo in delivery 
of Hsp27 siRNA to prostate tumor cells, this was efficacious against tumor growth in mice 
[315]. This range of observations suggested that L-Arg could be a practical and safe 
cationic group for anchoring nanoparticle carriers in vitreous humor. Based on these 
findings, our group designed and fabricated a novel L-Arg peptide-based cationic 
nanoparticle (NP), aiming to establish non-toxic, biocompatible therapeutic carriers for 
ocular drug delivery [316]. Their NP were less than 50 nm in diameter, with L-Arg 
containing peptides covalently linked to condensed dextran (CDEX) providing non-toxic 
positive charges for vitreous anchoring, thus extended IVT drug delivery. Small PEG 
peptides, having 1 to 4 L-Arg per peptide, were stably conjugated to carrier OH groups, 
with more Arg in a peptide increasing zeta potential [316], for which vitreal diffusion was 
monitored by rhodamine tag. Conjugates (approx. 100 kDa, 20-30 peptides/NP) with 4R 
peptides were highly immobilized. NP-conjugates (NPC) of 2R or 3R peptides gave slow 
diffusion in freshly isolated rat vitreous, and protamine competition, ex vivo, implied an 
ionic mechanism. These peptide conjugates gave prolonged intraocular residence in rats, 
histopathology showing no tissue damage. Our group experimentally confirmed ionic 
binding as the mechanism of slowed particle diffusion in a charge dependent manner, 
measured particle diffusion rate ex vivo and monitored the half-life in vivo in rat vitreous, 
and their relation to surface charge of the carriers (Zeta-potential). We found no adverse 
effects of NPC on ocular integrity by histological examination [316]. 
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The main goal of this project is to design a novel sustained drug delivery system of newly 
designed potent PEDF-mimetic peptides to improve life quality of patients suffering from 
wet age-related macular degeneration, and other posterior retinal diseases. To achieve it, 
we will use three different approaches. 
1) We will use a novel cationic charged-based NP for prolonged IVT residence. For 
this, we will conjugate anchoring peptides through stable carbamate bonds to NP 
(NPC). These cationic peptides with 2 or 3 L-arginines in their sequences have the 
property to be less toxic than any other source of positive charge. We will measure 
the residence time of NPC tagged with long wavelength fluorescent dye for in vivo 
clearance measurement in rabbit eyes. 
 
2) We will synthesize ester-bridges, linker between the peptide and NP, with different 
amino-alcohols to measure kinetics of the ester’s breakdown in physiological 
conditions. After a primary screening, we will measure their ester hydrolysis rates 
conjugated to the NP in an in vitro experiment in physiological conditions to select 
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the ester bonds with the same half-life hydrolysis rate as the residence time of the 
NPC with 2 R and 3 R peptides. These will define a platform for general ester 
prodrug delivery, where drugs are metastably attached to the long residence NPC 
described above. 
 
3) We will study the efficacy a PEDF-mimetic nonapeptide, with 2 L-arginine in the 
sequence, derived from the 34-mer epitope in an in vivo model of neovascular 
disease. For this, we will synthesize an ester-peptide prodrug with a slow hydrolysis 
rate, which will be conjugate to the NP and getting an extended release and 
residence of the peptide in the vitreous. 
 
By closely matching the half-life for residence time of the NPC and for the ester hydrolysis 
of the peptide prodrug we will accomplish an extended drug delivery system which will 
sustain the release of a maximum amount of the peptide in the vitreous. 
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3.1 Chemicals 
Cis-4-(Boc-amino)cyclohexanol and trans-4-(Boc-amino)cyclohexanol were from Alfa 
Aesar, Ward Hill, MA, USA. R,R-trans-3-N-Boc-aminocyclopentanol was from 
PharmaBlock, Hatfield, PA, USA. p-nitrophenyl chloroformate, glutaryl chloride and 
adipic chloride were from Santa Cruz biotechnology, Santa Cruz, CA, USA, Cyanine 7 
amine was from Lumiprobe, Hunt Valley, MD, USA. m-dPEG₄-amine was from Quanta 
Biodesign, Plain City, OH, US. All other chemical reagents were from Sigma Aldrich, St 
Louis, MO, USA. 
3.2 Synthesis of condensed dextran nanocarriers 
The nanoparticles, which were used on this project, were synthetized from condensed 
cholesteryl dextran (CDEX) from 70 kDa dextran, as described by Li et al, 2017[316]. 
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Dextran was first dried by twice repeated rotary evaporation from anhydrous pyridine, 
followed by exposure to high vacuum in a dessicator containing phosphorus pentoxide 
(P2O5). Then 4 mol% attachment of cholesteryl groups (based on 365 glycosyl monomers 
per 70 kDa, 4 g dextran = 21 mmol) was accomplished by linking cholesteryl chloroformate 
to polymer hydroxyl groups. Cholesterol chloroformate (0.4 g, 0.88 mmol) and one 
equivalent of triethylamine (TEA) in 10 mL of dichloromethane (DCM) was stirred into a 
solution of 4.0 g dry dextran in 50 mL of anhydrous dimethyl sulfoxide (DMSO). Sealed 
reaction continued 3 h at 40 °C, the mixture was quenched with 50 mL distilled water and 
exhaustively dialyzed (dialysis bag MWCO 12,400 Da, Spectra Por, Rancho Dominguez, 
CA, USA. Polymer solution was shell frozen freeze-dried (VirTis Benchtop lyophilizer, SP 
Scientific, Gardinier, NY, USA), the cake reconstituted with 50 mL of distilled water and 
sonicated (Branson 1800; Branson Ultrasonics, USA) for 2 h to maximize internalization 
of hydrophobic groups. Additionally, the cloudy CDEX solution was sequentially filtered 
through filter paper, then successively through syringe filters of 0.80 µm, 0.45 µm and 0.20 
µm pore size, the final filtrate then was frozen and re-lyophilized. Linked cholesterol units 
self-associate to form a core, thus contracting the carrier into a smaller, more spherical 
volume of condensed dextran (CDEX, 75 kDa), having a central hydrophobic domain. 
3.3 In vivo diffusion study of CDEX in rabbit vitreous 
To study the rate of diffusion, measured as rates of ocular NP loss, an in vivo experiment 
was designed to compare NP themselves with peptide-conjugated NP with two different 
types of anchoring peptides (2Arg or 3Arg), with similar loads of peptides attached to their 
surface. These peptides were designed to reduce the speed of diffusion of the nanocarrier 
in the vitreous due to the creation of multiple ionic interactions between the positive 
charges from peptide arginines and the negative charges of the hyaluronic acid present 
vitreous (Figure 20). The peptides were derived from short amino acid sequences of the 
alpha A proteins crystallin, Hsp20 and PEDF protein that were naturally found in the eye 
to minimize immunogenicity. They differ in that one of them had 2 positive charges 
(pyrrolidine-3-CO-PEG8-CO-YRVRS-amide; MW: 1,198 g/mol, 2R) and the other peptide 
contained 3 positive charges (pyrrolidine-3-PEG8-CO-RRYRL-amide; MW: 1,281 g/mol, 
3R). The function of positive charges was to interact with the molecules of hyaluronic acid, 
an anionic polymer very abundant in the vitreous humor. The sum of numerous weak ionic 
attractions was intended to reduce the rate of diffusion and therefore increases the residence 
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time of the particles in the eye. These peptides were anchored to CDEX through a short 
chain of PEG followed by a pyrrolidine molecule. The pyrrolidine nitrogen efficiently 
forms a stable carbamate bond with activated hydroxyl groups found in dextran. The 
pyrrolidine PEG peptide amides were synthesized via Fmoc-based solid-state peptide 
synthesis on rink amide 4-methylbenzhydrylamine (MBHA) resin using a CEM Liberty 
Blue microwave-assisted peptide synthesizer. Fmoc-N-amido-PEG8-carboxylic acid 
addition was carried out by manual coupling using N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) and excess N,N-
diisopropylethylamine (DIPEA). Following the Fmoc removal, N-Boc-pyrrolidine-3-
carboxylic acid was then coupled using HBTU and excess diisopropylethylamine. After 
cleavage from the resin and deprotection with trifluoroacetic acid (TFA), the final product 
peptides were purified by HPLC and lyophilized. Peptide purity before conjugation (>95%) 
was confirmed by analytical HPLC and mass spectrometry. In both cases, the positive 
charges were from the presence of the arginines in the sequences. 
 
Figure 20. Schematic view of CDEX NPC in vitreous. A hydrophobic cholesteryl domain forms the NP 
core. Conjugated PEG-peptides extend outwards (much lower than actual loading shown for un-crowded 
view). NP are labeled by Cy7 amine, to yield <1 Cy7/NP. Two types of positively charged peptides were 
linked at 61-64 peptides per NP. NPC are immobilized in vitreous by ionic binding between L-Arg 
guanidinium groups (blue circles) on their surface and HA polymer (red circles are HA carboxylate groups). 
3.3.1 Attachment of compounds to the nanogel CDEX 
a) Step 1: activation of CDEX 
The method used to attach the compounds to nanogels was based on the methods of 
Ramirez et al (1995) [317] and Vandoorne et al (1985) [318] with some modifications. 3 
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mg of the sterile-filtered lyophilized complex CDEX nanoparticles (75 kDa, 14 µmoles 
glycosyl units) were dissolved in 200 mL of a mixture of dry DMSO and dry pyridine 1:1 
volume ratio. Then, dimethylaminopyridine (DMAP) was added to the solution at a final 
concentration of 3 mM. 11 mg (54 µmoles, 3.9-fold excess) of solid p-
nitrophenylchloroformate (p-nPCOCl) was then added to the reaction mixture to activate 
CDEX, left at -20 °C in a sealed tube. By this reaction, p-nP was attached to the free 
hydroxyl groups of CDEX through carbonate bonds. After 17 h, to quantify p-nP covalently 
linked to CDEX, a 5 µL portion was mixed with 1 mL of ethyl acetate (EtOAc). Two 
methods [chromagenic and NMR, (NMR Bruker Avance III 500 MHz system, Bruker, 
USA)] confirmed that multiple glycosyl residues were activated by reaction of CDEX with 
p-NPCOCl. The solution was centrifuged, solvent decanted and centrifugation repeated, re-
suspending with a second 1 mL of EtOAc, and supernatant again decanted. The pellet, 
CDEX-(p-nP)n was then dissolved in 1.0 mL of 0.1 M NaOH, and UV-Vis spectrum 
scanned in a quartz cuvette (250-600 nm), after 10x further dilution by UV-Vis 
spectrophotometer 8453, Agilent, Santa Clara, CA, USA. 
b) Step 2 Stable anchor-peptide conjugation to CDEX 
The bulk reaction (0.038 µmol CDEX, 4.75 µmol p-nP groups) was quenched with 2 mL 
of EtOAc, the white suspension was centrifuge (14,000 g, 1 min, RT) (Labnet Spectrafuge 
24D Microcentrifuge, USA), solvent decanted, and pellet washed by re-centrifugation with 
2 additional mL EtOAc. Pellet was dissolved in 200 µL DMSO, transferred to a 4 mL vial 
and subjected to rotary evaporation under high vacuum. Then, 2.8 µmol of the pyrrolidine-
amido-PEG8-peptide (TFA salt) was dissolved in 200 µL DMSO with 10.0 µmol of dry 
TEA (1 µL, 3.6-fold molar excess) and 0.038 µmol of Cy7 amine (from 20 mM stock in 
DMSO). This was added to the DMSO solution of dry CDEX-(p-nP)125 and the reaction 
sealed and heated at 45 °C, with orbital shaking (Elmi, Latvia) over 6 days. Reaction was 
then quenched at RT, with 20 µmoles of methoxy-PEG4-amine at RT over 30 min. Then, 
the mixture was added dropwise to 2.5 mL of aqueous 0.2 M HCl solution. This was 
dialyzed against three 5 L changes of 0.1 mM HCl over 24 h, at RT, sterile filtered and 
lyophilized. 
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c) CDEX-peptide-conjugate characterization 
Two methods were used to quantify the amount of peptide per particle, one was the 
quantification of tyrosine by UV (ʎ = 275 nm; εTyr = 1,100 M-1 cm-1) and by bicinchonic 
acid (BCA) colorimetric assay procedure, where the standard curves were based on BCA 
reaction of the free peptides. Cy7 attached to CDEX was quantified by Vis spectrum (ʎ = 
750 nm; εCy7 = 199,000 M-1 cm-1). 
The particle size and the zeta potential (ζ) was measured by dynamic light scattering and 
electrophoretic mobility (n = 3) with a Zetasizer Nano ZSP, Malvern instruments, UK). 
3.3.2 In vivo diffusion experiment in rabbit vitreous 
a) Sample preparation 
For the experiment, samples were dissolved in buffer phosphate (Sigma Aldrich, USA) 10 
mM with NaCl 100 mM (Sigma Aldrich, USA) at pH of 7.2 ± 2. Final concentration 3 
mg/mL (CDEX70-0 and CDEX70-3R) and 3, 6 and 12 mg/mL for CDEX70-2R. Samples 
were sterile-filtered. 
b) Intravitreal injection 
This utilized small 9-week old rabbits (1.8 kg, White New Zealand, Charles River 
Laboratories) to insure prone fit within the IVIS apparatus. Rabbits were anesthetized by 
an intramuscular (IM) mixture of ketamine hydrochloride (20-35 mg/kg) and xylazine 
hydrochloride (3-5 mg/kg), further local anesthesia was provided by additional propacaine. 
Topical instillation of the antimuscarinic agent tropicamide (MydriaticumTM) was also 
administered to obtain the mydriasis (pupil dilation) effect. The last step before injections 
was to flush the eyes with povidone for prophylactic local antisepsis. 
To inject formulations, eyelids were retracted with a pediatric Barraquer wire speculum 
and the ocular bulbar conjunctivas were grasped at the lateral canthus via forceps to 
laterally rotate the globes towards the medial canthus. The needles tip, with their bevel 
directed backward were positioned on the lateral sclera 4 to 5 mm posterior to the limbus. 
Each eye was replaced to its natural position and a 31 gauge, 8 mm length needle (fixed to 
BD insulin syringe) was directed backward with an approximate angle of 45° and pushed 
through the sclera into the posterior ocular chambers towards the center of vitreous, until 
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the needle base just contacted the eye surface. Volumes of 30 µL were injected [CDEX-0, 
CDEX-3R and CDEX-2R 3 mg/mL (n = 3), CDEX-2R 6 mg/mL, CDEX-2R 12 mg/mL (n 
= 2)], n is the number of injected eyes. Needles were slowly withdrawn after the injections 
and the scleral conjunctiva were slightly compressed with the forceps tip to avoid any 
release of the injected material. The last step was to add on the eyes ointment at the end of 
the procedure. Intramuscular yohimbine (0.2-1 mg/kg) was used to reverse the effects of 
ketamine and xylazine (1 mL syringe, 25- or 27-gauge needle). 
c) Imaging 
Prior to imaging, rabbits were anesthetized by IM injection using ketamine/ xylazine. Eyes 
were kept open using a lid speculum for the duration of the imaging procedures. The 
imaging only took less than 1 min, with eyes only opened in the IVIS chamber <45 s. 
However, to avoid drying of cornea, ophthalmic solution eyewash (Akorn Animal Health, 
Lake, Forest, IL) was added to moisten the eyes before imaging. The fluorescence signal 
intensity in the rabbits were imaged on an in vivo imaging system (IVIS; Xenogen IVIS 
Spectrum; Caliper Life), over 52 days post-injection, first scan always at day 10 to allow 
IVT distribution. Animals were imaged for fluorescent emission intensity, the IVIS system 
being set to 745 nm excitation, and 800 nm for emission. 
3.4 Synthesis of prodrug bridges between peptides and 
nanocarrier Boc-N-R-O-spacer-aa-O-tbut 
There were several variables in the ester bridges used in this project. On the left hand side 
of the exemplary molecule shown below, different types of amino-alkoxy compounds were 
used (pyrrolidine-3-ol in this case), in order to explore the effects of different types of 
amino-alcohol (primary or secondary, cyclic, exocyclic) on the rate of spontaneous ester 
hydrolysis under physiological conditions, modeling release of peptides in the eye. The 
difference on the right hand side of molecules corresponds to the sequence of the active 
anti-angiogenic peptides that have been developed on this project. The spacers 
[dicarboxylic acid with chain of 5 (glutaric acid) or 6 (adipic acid) carbons] and the amino 
acids (sarcosine or glycine) are part of the active peptides sequences. Two different routes 
were used depending on whether an N-protected amino bromide compound or an N-
protected amino alcohol compound were used as starting material (Figure 21). 
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Figure 21. Example of a “Boc-N-R-O-spacer-aa-O-tbut” prodrug bridge; Boc-3-pyrrol-O-adp-Gly-O-
tbut. In this case, the Boc-amino-alkoxy compound (Boc-N-R-O-) corresponds to N-Boc-3-hydroxy-
pyrrolidine. The spacer is the adipic acid alkyl chain (-spacer-) and protected amino acid corresponds to 
glycine protected its carboxylic acid with tert-butyl (Gly-O-tbut). 
Synthesis reactions of the intermediates are described in the supplementary section. 
3.4.1 Synthesis of the ester compound through phase transfer reaction of 
cmpd (2) or (4). (5-7) 
For this case, we have used the method described by Sam and Simmons (1973) [319] where 
an alkyl bromide reacts with the potassium carboxylate salt to obtain an ester bond. 0.1 
mEq of the cmpd 2 or cmpd 4 and 10 µEq of 18-crown-6 (phase transfer catalyst) were 
dissolved in a mixture of dimethyl sulfoxide: toluene 2:8. The mixture was reacting under 
stirring at 40 °C. After 30 min, 0.11 mEq of the Boc amino bromide compound was added. 
After 18 h the reaction became cloudy from KBr precipitate, and was dried under vacuum. 
The crude product was washed in a separation funnel with water: chloroform. The organic 
phase was purified by column chromatography (ColCh) with a mixture of n-hexane: 
chloroform: methanol. The Boc-amino bromide compounds are shown in Table I (Figure 
22). 
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Table I. Boc-amino alkyl bromides 
Name Structure 
tert-butyl (4-bromobutyl)carbamate 
 
tert-butyl 3-bromopyrrolidine-1-
carboxylate 
 
tert-butyl 4-bromopiperidine-1-
carboxylate 
 
 
There were three compounds (below) for which we used the above alternative synthetic 
route to attach chromophoric carboxamides to aid in kinetic monitoring of ester hydrolysis, 
by HPLC. 
For example, cmpd 13 is a chromophoric glutaryl-sarcosine amide, which can be amide, 
bound to adipic or glutaric esters (left side) of N-blocked amino alcohols to enable facile 
observation of chromophore detachment following ester hydrolysis. 
3.4.2 Synthesis of Boc-amido-alkoxy esters through transesterification of 
cmpds (1), (3) or (13). (14-20) 
The method described by Hatano et al. (2013) [320] was used to synthesize these 
compounds. 0.1 mEq of cmpd 1 or cmpd 13 was dissolved in toluene. The reaction was 
stirred at azeotropic reflux, mixed with a 6% of trioctylphosphine dimethylcarbonate and a 
3% of lanthanum (III) nitrate and 0.15 mEq of the desired Boc amino alkoxy compound 
(see Table II). After 6 h the reaction was complete. The mixture was dried under vacuum 
and purified by ColCh with a mixture of n-hexane: chloroform: methanol. Boc-amino 
alkoxy compounds are shown in Table II (Figure 22). 
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Table II. Boc-amido alcohols attached to adipic Gly-t-But or to glutaric-Sar-t-But 
Name Structure 
tert-butyl [2-(2-hydroxyethoxy)ethyl] 
carbamate 
 
tert-butyl (trans-4-hydroxycyclohexyl) 
carbamate* 
 
tert-butyl [(1S,2S)-2-
hydroxycyclopentyl] carbamate 
 
tert-butyl [(1R,3R)-3-
hydroxycyclopentyl] carbamate 
 
tert-butyl (cis-4-hydroxycyclohexyl) 
carbamate 
 
tert-butyl {2-[(4-hydroxypentanoyl) 
amino]ethyl}carbamate (8) 
 
*With this compound two ester bridges were synthesized; one with the adp-Gly sequence and the other with 
the glt-Sar sequence. 
tert-butyl (cis-4-hydroxycyclohexyl) 
carbamate 
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Figure 22. Boc-amidoalkoxy esters via transesterification or phase transfer displacement of 
bromides. 
 
3.4.3 Ester hydrolysis testing 
Aminoalkoxy-ester compounds were dissolved in a solution of ethanol. These solutions 
were diluted with (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer 
0.1 M (pH: 7.5 ± 0.17) to a known concentration (0.1-1.0 mM). The solutions were 
incubated at 37 °C and time point samples evaluated by HPLC with a diode array detector 
(Agilent 1,100, Agilent, Santa Clara, CA, USA in different times. [Column: Zorbax SB-
C18 5 µm 150 x 4.6 mm, Agilent, Santa Clara, CA, USA. Mobile phase: Water (0.1% 
TFA):ACN 85:15 (0-5 min), Water (0.1% TFA):ACN 10:90 (15 min), Water (0.1% 
TFA):ACN 0:100 (17-20 min). Method time: 25 minutes. Volume of injection: 20 µL. 
Wavelength: 205 nm]. 
3.4.4 Comparison of the behavior of the ester degradation 
To compare the effect of the dicarboxylic chain on the ester hydrolysis rate on the right 
hand side of the molecules (adp-Gly vs glt-Sar) two model peptides were designed with a 
methyl ester bond, the shortest one, followed by the alkyl chain, adp or glt, preceding the 
same amino acid sequence (-Sar-GYNLYRVRS-amide) with the aim to improve the 
solubility and enhance with Tyr absorbance the sensitivity of the analytical method. The 
two peptides were dissolved in buffer HEPES 20 mM, 0.01% w/v azide, pH 7.4 and 
incubated at 37 °C. The solutions were checked by HPLC [Column: Zorbax SB-C18 5 µm 
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150x4.6 mm. Mobile phase: H2O (0.1% TFA):ACN 85:15 (0-5 min) to H2O (0.1% 
TFA):ACN 70:30 (55-60 min). Method time: 60 minutes. Volume of injection: 20 µL. ʎ = 
205 and 230 nm]. 
3.5 Boc-N-R-O-ahx-DNP. A simple model system to rapidly 
evaluate ester hydrolysis rates 
In order to evaluate amino-ester prodrug candidates, for spontaneous hydrolysis half-lives 
before being able to make the peptide versions, we utilized a simpler chromogenic model 
compound system, where hydrolysis products are readily quantified by HPLC. While 
environmental carboxylic esters have had aqueous breakdown rates compared in water 
[321], we are not aware of any published systematic comparison of ester hydrolysis as a 
function of alcohol structure. Since we found that direct ester linkage to polymeric 
carbohydrates or OH-dendrimers was low in yield and did not give very stable esters, our 
particular focus was on amino-bridged esters, thus the hydrolysis kinetics of esters of N-
blocked amino alcohols. The scant simple hydrolysis data suggested that esters of 
secondary alcohols, especially those exocyclic on 5 or 6 membered rings, were more slowly 
hydrolyzed than esters of primary alcohols [321]. 
We therefore began systematic comparison of the rate of hydrolysis under physiological 
conditions, of amino-alkoxy esters. We thereby hoped to find a range for tuning the rate of 
drug release from amino-bridged prodrugs. Below are the amino alcohol structures we 
examined after esterification to chromogenic hexanoic acid in the form of dinitrophenyl-ε-
amino-n-caproic acid (DNP). All give the same product, the starting DNP upon hydrolysis, 
simplifying HPLC measurement. 
3.5.1 Amino alcohol structures candidates 
After the first ester hydrolysis rate study with the Boc-N-R-O-spacer-aa-O-tbut 
compounds, we selected four amino–alkoxy compounds to synthesize these Boc-N-R-O-
ahx-DNP, one fast released compound, one medium released compound and two slow 
released compound (data in Results, Table V). 
0.1 mEq DNP was reacted in toluene at 80 °C under stirring with DMF (catalytic amount). 
When the temperature had reached 80 °C, 0.1 mEq of thionyl chloride and 50 µEq of 
pyridine were added to the reaction. The reaction was followed by thin layer 
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chromatography (TLC) (DCM: MeOH; 9:1). After 2 h the starting material was disappeared 
so 0.11 mEq of the desired aminoalcohol were added to the reaction. The selected 
compounds were tert-butyl (4-hydroxybutyl)carbamate; tert-butyl 3-hydroxypyrrolidine-
1-carboxylate; tert-butyl [(1R,3R)-3-hydroxycyclopentyl] carbamate and tert-butyl (trans-
4-hydroxycyclohexyl) carbamate. After 12 h the reactions were completed. The crudes 
products were purified by ColCh with a mixture of DCM:MeOH (Figure 23). 
 
Figure 23. Scheme of the synthesis pathway of the compounds Boc-aminoalkoxy-ester DNP. 
3.5.2 Ester hydrolysis kinetic testing 
DNP-ester compounds were pre-dissolved in DMSO and then, they were diluted in HEPES 
buffer 0.1 M at pH 7.4 at a known concentration (0.1-2 mM). The solutions were incubated 
at 37 °C and samples evaluated by HPLC at different times. [Column: Zorbax SB-C18 5 µm 
150 x 4.6 mm. Mobile phase: Water (0.1% TFA):ACN 70:30 (0-2 min); H2O (0.1% 
TFA):ACN 10:90 (10 min), H2O (0.1% TFA):ACN 0:100 (12-15 min). Volume of 
injection: 20 µL. Wavelength: 230 nm. The study was made by triplicate. 
3.5.3 Deprotection of the amines of Boc-amido-R-O-esters of ahx-DNP 
To attach the ester-DNP compound to a CDEX nanoparticle 0.1 mEq of Boc-N-X-O-ahx-
DNP was deblocked by dissolution in a mixture of TFA 20% v/v in DCM at RT. After 24 
h the reaction was complete. 20 volumes of toluene were added to the mixture and the 
sample was dried by rotary evaporation. The reaction was followed by TLC (DCM:MeOH; 
9:1). The crude product was extracted in a separation funnel (DCM/ water), and aqueous 
phase freeze-dried to give the free amine cmpd (TFA salt). Final product: NH-X-O-ahx-
DNP.  
3.5.4 Attachment of the DNP ester compounds to the nanogel CDEX. 
a) Step 1: activation of CDEX 
3 mg of the sterile-filtered lyophilized complex CDEX nanoparticles (75 kDa, 14 µmoles 
glycosyl units) were dissolved in 200 mL of a mixture of dry DMSO and dry pyridine 1:1 
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volume ratio. Then, DMAP was added to the solution at a final concentration of 3 mM. 11 
mg (54 µmoles, 3.9-fold excess) of solid p-nPCOCl was then added to the reaction mixture 
to activate CDEX, left at -20 °C in a sealed tube. By this reaction, p-nP was attached to the 
free hydroxyl groups of CDEX through carbonate bonds. After 17 h, to quantify p-nP 
covalently linked to CDEX, a 5 µL portion was mixed with 1 mL of EtOAc. The 
chromagenic method confirmed that multiple glycosyl residues were activated by reaction 
of CDEX with p-NPCOCl. The solution was centrifuged, solvent decanted and 
centrifugation repeated, re-suspending with a second 1 mL of EtOAc, and supernatant again 
decanted. The pellet, CDEX-(p-nP)n was then dissolved in 1.0 mL of 0.1 M NaOH, and 
UV-Vis spectrum scanned in a quartz cuvette (250-600 nm), after 10x further dilution by 
UV-Vis spectrophotometer. 
b) Step 2. CDEX conjugation of the DNP ester compounds 
Samples (mass: 4 mg) were quenched with 2 mL of EtOAc, the white suspension was 
centrifuged as above. As previously, solvent decanted, and pellet washed by re-
centrifugation with 2 additional ml EtOAc. Then, 11.5 µmol of the NH-R-O-ahx-DNP 
(TFA salt) was dissolved in 200 µL DMSO with 13.3 µmol of dry TEA (1 µL, 3.6-fold 
molar excess). This was added to the DMSO solution of dry CDEX-(p-nP)57-154 and the 
reaction sealed and heated at 45 °C, with orbital shaking over 3 days. Reaction was then 
quenched at RT, with 20 µmoles of ethanolamine at RT over 30 min. Then, the mixture 
was added dropwise to 2.5 mL of aqueous 0.2 M HCl solution. This was dialyzed against 
three 5 L changes of 0.1 mM HCl over 24 h, at RT, sterile filtered and lyophilized. 
3.5.5 Characterization of the nanocarriers 
The method used to quantify the amount of model-ester-DNP compound was by UV-Vis 
(ʎ = 360 nm, εDNP: 16,622 M-1 cm-1). 
The particle size was measured by dynamic light scattering (n = 3) with a Zetasizer Nano 
ZSP. 
3.5.6 In vitro release studies of DNP-ester compounds from CDEX 
CDEX70-N-R-O-ahx-DNP compounds were dissolved in buffer HEPES 20 mM [SDS 
0.1% (w/v) azide 0.02% (w/v)] pH 7.4 and storage in glass vials at 37 °C. To analyze them, 
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one aliquot was filtered through a centrifuge filter [MWCO: 3 kDa, (Amicon, EMD 
Millipore, Burlington, MA, USA) speed: 14,000 g, RT, 10 min]. Then the filtered was 
collected and checked by UV (ʎ = 360 nm). These measurements were made in triplicate. 
3.6 In vitro and in vivo release studies of prodrugs from CDEX 
The prodrug synthetic pathway was overcome with a new strategy whereby the protected 
amino-alcohol, N-Boc-pyrroliidin-3-ol is reacted to form its ester with a large excess of 
adipic di-acid chloride, all acid chlorides being subsequently quenched with aqueous 
bicarbonate. Careful acidification to pH 3-4 then preserves the Boc protecting group while 
enabling organic phase extraction of the ester, while adipic acid and its salts remain in the 
water phase (detailed below). The 3-Boc-pyrrolidinol adipic half ester is then used to cap 
the growing peptide linked to solid state resin. 
3.6.1 Synthesis of the peptide prodrug 
With the drug candidate (peptide 11: COOH-adp-Sar-YNLYRVRS-amide) and the amino-
alkoxy compound (tert-butyl 3-hydroxypyrrolidine-1-carboxylate) chosen, the ester was 
synthesized using a new route. 
Synthesis of 6-{[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]oxy}-6-oxohexanoic acid (21) 
3 mEq of adipic chloride were dissolved in 10 mL of DCM at RT under stirring. At the 
same time 1 mEq of the amino-alkoxy compound was dissolved in DCM with 1 mEq of 
TEA. This solution was added to the first one dropwise. After 30 min of reaction, the 
mixture was dried under vacuum and the crude product was dissolved in a solution of 
sodium bicarbonate 1 M. The solution was washed with EtOAc, and both phases were 
mixed in a separation funnel. After extraction and EtOAc removal, the aqueous phase pH 
was adjusted with HCl 1 M to pH 4. Then, the solution was mixed with ethyl ether and the 
organic phase was isolated. The organic phase was dried under vacuum. Final product: 
Boc-3-pyrrol-O-adp-COOH (Figure 24). 
 
Figure 24. Scheme of the synthesis pathway to get aminoalkoxy-ester bridge. 
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Synthesis of the ester prodrug 3-pyrrolidine-O-adipic-N-Sar-Tyr-Asn-Leu-Tyr-Arg-
Val-Arg-Ser-amide (22) 
To HN-Sar-YNLYRVRS on Rink MBHA resin in DMF was added 1.5 mEq of Comp 1, 
1.45 mEq (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate) (HATU), and 6 mEq of DIPEA. The reaction mixture was shaken on 
a mechanical shaker overnight (16 h) at RT. The resulting peptide was cleaved from the 
resin using a mixture of 95% TFA, 2.5% water, and 2.5% triisopropylsilane for 3 h. Crude 
peptide was precipitated from this solution using cold diethyl ether before purification by 
HPLC. Final product: 3-pyrrol-O-11 peptide (Figure 25). 
 
Figure 25. Scheme of the solid-state reaction and deblocking of 3-pyrrol-O-11 peptide. 
3.6.2 Conjugation of the prodrug peptide with CDEX 
Following the same procedure as the explained above for the CDEX70 activation with p-
nPCOCl, the sample (mass: 2.3 mg) was quenched with 2 mL of EtOAc, the white 
suspension was centrifuged as above, solvent decanted, and pellet washed by re-
centrifugation with 2 additional mL EtOAc. Pellet was dissolved in 200 µL DMSO, 
transferred to a 4 mL vial and subjected to rotary evaporation under high vacuum. Then, 
5.4 µmol of the pyrrolidine-ester-11 peptide prodrug (TFA salt) was dissolved in 200 µL 
DMSO with 16.9 µmol of dry TEA (2.36 µL, 3.6-fold molar excess). This was added to the 
DMSO solution of dry CDEX-(p-nP)108 and the reaction sealed and heated at 45 °C, with 
orbital shaking over 3 days. Reaction was then quenched at RT, with 20 µmoles of m-PEG4-
amine at RT over 30 min. Then, the mixture was added dropwise to 2.5 mL of aqueous 0.2 
M HCl solution. This was dialyzed against three 5 L changes of 0.1 mM HCl over 24 h, at 
RT, sterile filtered and lyophilized.  
3.6.3 Characterization of CDEX70-3-pyrrol-O-11 peptide 
The average amount of peptide conjugated to CDEX was quantified by UV because the 
presence of the amino acid tyrosine (ʎ = 275 nm; εTyr = 2,200 M-1 cm-1) and BCA. Samples 
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were dialyzed and weighted, and then they were dissolved in a known amount of water. 
The same procedure was followed to prepare the standard curves of the peptides. 
The size of the particles and the ζ of the compounds in water were analyzed in triplicate by 
dynamic light scattering and electrophoretic light scattering respectively (Zetasizer Nano 
ZSP). 
3.6.4 Stability test of the prodrug 3-pyrrol-O-11 peptide 
The aim of this experiment is to demonstrate the peptide prodrug does not suffer chemical 
alterations in the ester bond with the reagents during the conjugation reaction in the NP. 
The prodrug was tested by HPLC by itself, with the conjugation reaction conditions 
(nitrogen atmosphere, shake: 100 rpm, temperature: 45 °C, time: 3 d in presence of p-nP-
OH, DMSO and TEA. In addition, the prodrug peptide was mixed in the conditions of the 
quench step (DMSO, m-dPEG®₄-amine, temperature: RT, time: 1 h). The samples were 
checked by HPLC [Column: Zorbax SB-C18 5 µm 150x4.6 mm. H2O (0.1% TFA):ACN 
85:15 (0-5 min) to H2O (0.1% TFA):ACN 70:30 (55-60 min). Method time: 60 minutes. 
Volume of injection: 20 µL. ʎ = 230 nm. 
3.6.5 In vitro rate of adipic peptide release from CDEX70-3-pyrrol-O-11 
peptide 
1.43 mg of the nanocarrier was incubated in physiological conditions; 1 mL of phosphate 
buffer 10 mM and NaCl 100 mM pH 7.43. Temperature: 37 °C. 
Three aliquots were taken on different days and the released peptide (11 peptide) was 
separated by centrifugal filtration (MWCO: 10 kDa, 14,000 g, 10 min, RT). The filtered 
were checked by UV (ʎ = 275 nm) and by HPLC. The filtrate was compared with the 
peptide 336 as reference standard (concentration: 100 µg/mL in water). [Column: Zorbax 
SB-C18 5 µm 150x4.6 mm. H2O (0.1% TFA):ACN 85:15 (0-5 min) to H2O (0.1% 
TFA):ACN 70:30 (55-60 min). Method time: 60 min. Volume of injection: 20 µL. ʎ=230 
nm]. 
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3.6.6 In vivo CNV efficacy of the peptide 11 released from CDEX70-3-
pyrrol-O-11 peptide injected IVT in mice 
To study the efficacy of the formulation. The nanocarrier was dissolved in water and the 
pH was adjusted to 7.2 with NaOH 0.1 M. The sample was lyophilized. Then, the freeze-
dried was dissolved in a solution of NaCl 100 mM pH 7.2 ± 2 getting the peptide final 
concentration of 1 mg/mL. A sample of free peptide 336 was prepared at the same 
concentration, 1 mg/mL following the same steps as the nanocarrier sample. As negative 
control was used the vehicle, the solution of NaCl 100 mM pH 7.2. All the samples were 
filtered by 0.2 µm. 
The experimental system used on this study was the Laser-induced CNV according to the 
protocol described by Nourinia et al, 2015[322]. 20 C57BL/6J mice were used for this 
experiment. 2 µL of the samples were injected intravitreally 15 d before the induced 
damage of the Bruch’s membrane via laser. 15 d after the laser induction, 30 d after the 
injection, animals were euthanized and the eyes were enucleated and fixed in 4% 
paraformaldehyde at 4 °C for 2 h. To get the posterior sclerochoroidal eyecup, eyes were 
placed in phosphate-buffered saline (PBS) and sectioned at the equator by a stereoscopic 
zoom dissecting microscope (LABOMED, Luxeo 4Z number 444000; Nightingale Sales, 
Inc., Fort Myers, FL, USA). After 1 h of incubation in blocking buffer (20% fetal calf 
serum, 20% normal goat serum, and 0.01% Triton X-100 in PBS) at RT, the posterior 
eyecups were incubated with anti–intercellular adhesion molecule (ICAM)-2 (1:500 in 
blocking buffer, catalog N°. 553326; BD Biosciences, San Jose, CA, USA) overnight at 48 
°C. The samples were then washed three times with PBS and incubated with the Cy-3 anti-
rat secondary antibody (1:500 in blocking buffer; catalog N°. 712-165-153; Jackson 
ImmunoResearch, West Grove, PA, USA) for 2 h. Finally, the posterior eyecups were 
flattened by 5 to 6 relaxing radial incisions and mounted on a glass slide with VectaMount 
AQ (Vector Laboratories, Malvern, PA, USA). The CNV images were captured with an 
inverted microscope (Olympus TH4- 200; Olympus, Tokyo, Japan) fitted with appropriate 
excitation and emission filters (Olympus U-RSL-T) and equipped with a digital camera 
(Olympus U-TV0.63xc). ImageJ software (ImageJ 1.48, http://imagej.nih.gov/ij/; provided 
in the public domain by the National Institutes of Health, Bethesda, MD, USA) was used 
to quantify the total area of CNV associated with each laser burn. The statistical analysis 
was one-way ANOVA between CDEX70-3-pyrrol-O-11 vs vehicle; CDEX70-3-pyrrol-O-
A novel nanoparticle-based system for sustained intravitreal drug delivery 
90 
11 vs peptide 11 and peptide 11 vs vehicle. P value less than 0.05 was considered 
statistically significant. 
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4.1 In vivo diffusion experiment in rabbit vitreous 
4.1.1 CDEX activation and peptide conjugation 
The activation of CDEX with p-nPCOCl was checked by two different techniques 
(chromagenic and NMR). Assuming that there were 365 free hydroxyl groups on the 
surface of CDEX, the p-nitrophenolate spectrum was observed by more than of 1/3 of the 
OH groups have been activated. 1H-NMR, showed the presence of p-nP attached to CDEX 
through a carbonate bond. Two different compounds were compared by 1H-NMR, the 
conjugate CDEX-p-nP [1H NMR (500 MHz, DMSO-d6) δ 8.26-8.18 (m, 2H), 7.51-7.42 
(m, 5H), 6.45 (s, 1H), 5.52 (s, 1H), 5.46 (s, 1H), 5.31 (s, 1H), 5.21 (s, 1H), 5.02 (s, 3H), 
4.90 (s, 1H), 4.83 (s, 3H), 4.76 (s, 1H), 4.61 (s, 3H), 4.40 (s, 6H), 3.67 (s, 6H), 3.55 (s, 3H), 
3.28 (d, J = 6.1 Hz, 1H), 3.22 (s, 2H), 3.13 (s, 6H), 2.25 (s, 3H), -0.14 (s, 2H); and p-nP-
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OH itself [1H NMR (500 MHz, DMSO-d6) δ 8.18-8.09 (m, 2H), 6.97-6.90 (m, 2H)]. The 
aromatic signals of the p-nitrophenyl group did not appear in the same magnetic field as 
they did in p-nitrophenol. 
An UV-Vis absorbance spectrum of the 3R-NPC in water at 1.0 mg/mL is shown in Figure 
26. A peak at 275 nm, not present in unconjugated NP, is from a single tyrosine in each 
peptide. The minimum height of this peak, subtracting only the high background scattering 
at 300 nm, leads to calculation of at least 27-30 peptides/ NP, based on peptide molar 
extinction of 1,100 at 275 nm. However, this is a minimum estimate since light scattering 
goes up sharply and indeterminately at lower wavelength. Correction to the baseline of a 
spectrum of similarly activated but only PEG-amine quenched CDEX (CDEX-70-0), 
estimates approximately 60 peptides per NPC but is uncertain as particle size varies. Thus, 
UV spectrum is only a rough measure of peptide load. Tyr spectrum assay will be reliable 
only after trace large particles are removed through gel filtration. More accurate peptide 
load determination on weighed samples was accomplished by the same BCA colorimetric 
assay procedure described previously, where standard curves were based on BCA reaction 
of the free peptides. Cy7 attached to CDEX was quantified by Vis spectrum (ʎ = 750 nm; 
εCy7 = 199,000 M-1 cm-1) as seen in Figure 26. 
This showed the number of peptides linked per particle for the three nanocarriers 
(CDEX70-0, CDEX70-2R and CDEX70-3R) were 0, 64 and 61 respectively. Thus, the 
number of positive charges, derived exclusively from Arg residues per NP/NPC were 0, 
128 and 183. The measured ζ of the conjugates increased with the number of positive 
charges per particle (CDEX70-0: -0.61 ± 0.1 mV, CDEX70-2R: 3.9 ± 0.9 mV, CDEX70-
3R: 6.34 ± 1.3 mV) and particle size was CDEX70-0: 150 nm, CDEX70-2R: 85 nm, 
CDEX70-3R: 82 nm. Properties of the NP/ NPC are summarized on Table VI.  
NP/NPC diameter and ζ were measured by dynamic light scattering and electrophoretic 
mobility (n = 3) with a Zetasizer Nano ZSP. Percent CDEX mg recovered was based on 
the total mg of CDEX used, corrected to the theoretical added masses of peptide and PEG4-
amine. Lower yield in unconjugated CDEX (PEG4-amine only) may reflect multimeric 
aggregates lost on sterile-filtration, since NP without peptides are not cationic, thus not 
self-repelling. We attribute the smaller diameters of cationic conjugates to mutual charge 
repulsion preventing self-association, presuming CDEX without peptides to have trace 
contamination with multimeric NP/ MP. Based on the extinction coefficient of Cy7, the 
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amount of dye attached to the nanoparticles was less than 0.3 dye molecules/NP. This low 
level was sufficient to study the diffusion of tagged NP in vitreous while unlikely to perturb 
diffusion, the dye being uncharged and <0.5% of any NP/ NPC mass (100-160 kDa). Table 
VIII. 
 
Figure 26. UV-VIS spectrum of a 3Arg peptide and the Cy7 dye conjugated to the nanocarrier (Cy7-
CDEX70-3-pyrrolidine-CO-PEG8-RRYRL-NH2). ʎmax tyrosine of peptide = 275 nm, 67 peptides per 
particle of CDEX; ʎmax Cy7 = 750 nm, <1 dyes per particle of CDEX. 
Table VIII. Physicochemical characteristics of the NP and NPC 
NP or 
NPC Pept/CDEX 
Positive 
charges/CDEX ζ (mV) Cy7/CDEX 
Particle 
diam. (nm) 
% CDEX 
mass 
recovered 
Cy7-
CDEX 0 0 -0.6±0.1 0.16 150±2 50 
Cy7-
CDEX-
R2 
64 128 +3.9±0.9 0.24 85±15 80 
Cy7-
CDEX-
R3 
61 183 +6.3±1.3 0.28 82±7 90 
Characterization and measurement of the NP and NPC by dynamic light scattering and electrophoretic 
mobility (n = 3). Number of peptides per particle of CDEX; the quantification of peptide was determined by 
BCA. Number of molecules of Cy7; the quantification of cyanine 7 was determine also by absorbance (ECCy7 
= 199,000 M-1 cm-1). 
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4.1.2 In vivo clearance from rabbit vitreous is surface charge (ζ)-dependent 
For the in vivo diffusion-dependent loss study, the images of the photons per area of the 
posterior part of the rabbit eye have checked by fluorescence at excitation: 745 nm, 
emission: 800 nm in a defined circular area surrounding the rabbit eye facing upward. Each 
rabbit eye received 30 µL, by intravitreal injection, of one of the three samples [Cy7-
CDEX70-0, Cy7-CDEX70-2R, Cy7-CDEX70-3R; concentration = 3 mg/mL, (90 µg total 
polymer mass)]. All data were corrected against the autofluorescence background signal of 
the vitreous. After the injection, 10 days were waited to let the particles distribute around 
the whole vitreous. The day 10 was marked as time 0 for subsequent clearance. The loss of 
the Cy7-tagged NP particles was followed over 6 weeks beyond day 10 (taken as day 0 for 
clearance analysis). The change of fluorescence intensity for exemplary individual rabbit 
eyes is shown on Figure 27. This illustrates how individual eyes injected with equal 
amounts of Cy7-tagged NP can be repeatedly imaged over 1 to 3-week periods for 
estimation of emitted photon/s, a measure of ocular NP retention since dye is linked as a 
stable carbamate (urethane) bond. The rate of loss (diffusion) of the three conjugates was 
in the following order: CDEX70-0 >CDEX70-2R >CDEX70-3R. The half-life of 
CDEX70-0 (control) in the vitreous was less than 3 days. The half-life of CDEX70-2R was 
7 days over which time, the average remained of CDEX70-3R was 65%. While the half-
life of CDEX70-3R was 17 days (range between 14-21 days) (Figures 28 and 29). 
 
Figure 27. Rabbit eye imaging by IVIS of a single exemplary eye injected the sample Cy7-CDEX-3R 
followed over 5 weeks. Measurement of number of photons per area (excitation: 745 nm; emission: 800 nm). 
Line A: IVIS scan of the rabbit eye with Cy7-CDEX70-3R. The picture number 1 is the first scan after 10 
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days post injection. This measurement is marked as time 0. The Table shows the percentage of photons 
remained in the eye during the study after the correction substracting the autofluorescence background. The 
50% was achieved after 3 weeks. 
 
 
Figure 28. Rabbit eye imaging by IVIS. Measurement of number of photons per area (excitation: 745 nm; 
emission: 800 nm). Line A: IVIS scan of the rabbit eye with Cy7-CDEX70-3R. Line B: IVIS scan of the 
rabbit eye with Cy7-CDEX70-2R peptide. Line C: IVIS scan of the rabbit eye with Cy7-CDEX70-0 peptide. 
Row 1: IVIS scan after 10 days post injection. This measurement is marked as time 0. Row 2: IVIS scan after 
3 weeks experiment. Row 3: IVIS scan after 6 weeks experiment. 3R peptide conjugate is seen to be retained 
longer in the eye compared with 2R peptide conjugate at similar peptide loading. Spreading and loss of 
fluorescence was slowed in more highly charged NPC. 
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Figure 29. In vivo charge and ζ -dependent loss of NP from rabbit vitreous expressed as a percentage 
of the first measured photon flux at day 10 post-injection (taken as day 0). Volume of injection: 30 µL; 
nanocarrier concentration: 3 mg/mL. [Control: CDEX70-0: (n = 2). CDEX70-2R; 64 peptides per particle by 
BCA (n = 3) and CDEX70-3R; 61 peptides per particle by BCA (n = 3)]. Half-lives: CDEX-0: 4 days; CDEX-
2R: 7 days; CDEX70-3R: 13 days. 2R and 3R peptides linked as carbamates of 3-pyrrolidine-CO-amido-
PEG8-CO-peptide to Cy7-CDEX70. Cy7 amine was carbamate-linked at <1 mol/mol NP. 
4.1.3 In vivo loss from rabbit vitreous is concentration dependent 
Four different concentrations of the same nanocarrier were tested to compare the total 
retention capacity of the polymer dose. The results corresponded to the same nanocarrier 
(CDEX70-2R) in three different concentrations [Control: 0 mg/mL (n = 6), 3 mg/mL (n = 
3), 6 mg/mL (n = 2) and 12 mg/mL (n = 2)]. As in the previous experiment, we checked 
the fluorescence in the vitreous at a specific wavelength excitation: 745 nm, emission: 800 
nm. The results were corrected to the background fluorescence from 0 mg/mL (vehicle 
injection). The measurement started 10 days post injection, considering this time point as 
100% of remained nanocarriers in the vitreous. The measurements were 0 mg/mL 
(0.85x109 p/s), 3 mg/mL (7.20x109 p/s), 6 mg/mL (16.13x109 p/s) and 12 mg/mL (4.95x109 
p/s), the last being much lower than an expected value near 25-30 x109 p/s. The fluorescent 
intensity of the samples at 3 mg/mL and 6 mg/mL were proportional to total dose and both 
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samples kept the proportion during the entire study. The sample at 12 mg/mL (a dose of 
360 µg total) had lower intensity than 3 mg/mL (90 µg) at day 10. After 14 additional days, 
the percentage remained of CDEX in the vitreous was for the 3 mg/mL sample 2.25x109 
p/s; (22%), for the 6 mg/mL sample 5.75x109 p/s; (32%), both consistent with 7-day half-
life. For the 12 mg/mL sample, 2.84x109 p/s; (49%), but only 14% of the total flux expected 
in proportion to the two lower doses. All the samples were eliminated from the vitreous 
after 21 additional days of study (5 weeks), for the 3 mg/mL sample 1.79x109 p/s, for the 
6 mg/mL sample 1.79x109 p/s and for the 12 mg/mL sample 1.48x109 p/s (Figure 30). 
 
Figure 30. Initial dose dependence of in vivo loss of nanocarriers from rabbit vitreous expressed as 
fluorescent photon flux, compared to the first measurement at day 10 post-injection of 20 µL, (taken as 
day 0) of Cy7-CDEX70-2R (64 peptides per particle) at 4 different concentrations, [Control: 0 mg/mL (n = 
6), 3 mg/mL (n = 3), 6 mg/mL (n = 2) and 12 mg/mL (n = 2)]. This indicates consistent slowing of nanoparticle 
loss up to 300 µg injected 2R conjugates, but large initial loss, implying binding capacity is exceeded at 600 
µg in 2 mL rabbit eye. 
4.1.4 Safety evaluation 
Eye globes were enucleated, and immediately fixed in formalin and prepared for histology. 
Paraffin sections were stained with hematoxylin/eosin and examined for structural 
abnormalities and signs of inflammatory infiltrations in masked fashion. The study eyes 
were submitted for routine, masked histopathologic examination using standard preparation 
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techniques. No inflammation was observed in any of the ocular tissues in the sections 
examined. Some changes consistent with injection or mechanical trauma during or post-
enucleation were noted. Isolated instances of developmental abnormalities in the retina and 
ciliary body were also observed. 
4.2 Boc-N-R-O-spacer-aa-O-tbut compounds 
4.2.1 Characterization of Boc-N-R-O-spacer-aa-O-tbut compounds 
The characterization of the Boc-N-R-O-spacer-aa-O-tbut synthesized compounds were the 
following. The characterization of the intermediate compounds are described in the 
supplementary section. 
N-Boc-4-aminobutoxy-glutarylsarcosine-tert-butyl ester (5) 
Name of the structure: 4-(tert-Butoxycarbonylamino)butyl 5-[N-methyl(tert-
butoxycarbonylmethyl) amino]-5-oxovalerate. 
Appearance: orange oil. The molecular weight of the compound was 414.54 g/mol. The 
yield of the reaction was 52.2% (Figure 31). 
1H NMR (500 MHz, Chloroform-d) δ 5.34 (s, 1H), 4.18-4.12 (m, 2H), 3.24 (t, J = 7.5 Hz, 
1H), 3.09 (s, 2H), 2.90 (t, J = 5.4 Hz, 1H), 2.35 (t, J = 8.1 Hz, 1H), 1.96 (tt, J = 8.1, 5.3 Hz, 
1H), 1.82-1.72 (m, 1H), 1.68 (tt, J = 7.6, 5.5 Hz, 1H), 1.43 (d, J = 4.9 Hz, 9H). 
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Figure 31. Chemical structure of N-Boc-4-aminobutoxy-glutarylsarcosine-tert-butyl ester (Boc-N-but-
O-glt-Sar-O-tbut). 
N-Boc-pyrrolidine-3-ol-adipoyl glycine-tert-butyl ester (6) 
Name of the structure: 3-5-Oxo-5-[(tert-butoxycarbonylmethyl)amino]pentyl 1-tert-butyl 
1,3-pyrrolidine- dicarboxylate. 
Appearance: yellowish oil. The molecular weight of the compound was 428.52 g/mol. The 
yield of the reaction was 53% (Figure 32). 
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1H NMR (500 MHz, Chloroform-d) δ 6.73 (s, 1H), 4.96 (p, J = 7.1 Hz, 1H), 4.34 (d, J = 
12.4 Hz, 1H), 4.10 (dd, J = 9.5, 7.0 Hz, 1H), 3.99 (d, J = 12.5 Hz, 1H), 3.77 (dt, J = 9.5, 
7.1 Hz, 1H), 3.51 (dt, J = 9.5, 7.1 Hz, 1H), 3.38 (dd, J = 9.5, 7.0 Hz, 1H), 2.65 (dt, J = 12.4, 
3.1 Hz, 1H), 2.58-2.35 (m, 3H), 2.30-2.19 (m, 1H), 2.12-1.96 (m, 2H), 1.87 (qdd, J = 12.7, 
3.9, 2.5 Hz, 1H), 1.79-1.58 (m, 2H), 1.45 (d, J = 20.0 Hz, 18H). 
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Figure 32. Chemical structure of N-Boc-pyrrolidine-3-ol-adipoyl glycine-t-butyl ester (Boc-3-pyrrol-O-
adp-Gly-O-tbut). 
N-Boc-piperidine-4-ol-adipoyl glycine t-butyl ester (7) 
Name of the structure: 4-5-Oxo-5-[(tert-butoxycarbonylmethyl)amino]pentyl 1-tert-butyl 
1,4-piperidine- dicarboxylate. 
Appearance: yellowish oil. The molecular weight of the compound was 442.54 g/mol. The 
yield of the reaction was 48% (Figure 33). 
1H NMR (500 MHz, Chloroform-d) δ 6.73 (s, 1H), 4.19-4.08 (m, 2H), 3.22 (dt, J = 12.4, 
7.1 Hz, 1H), 2.52 (t, J = 5.4 Hz, 1H), 2.35 (t, J = 5.4 Hz, 1H), 2.08-1.97 (m, 1H), 1.91-1.80 
(m, 1H), 1.77-1.67 (m, 1H), 1.66-1.56 (m, 1H), 1.45 (d, J = 20.0 Hz, 9H). 
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Figure 33. Chemical structure of N-Boc-piperidine-4-ol-adipoyl glycine t-butyl ester (Boc-4-piper-O-
adp-Gly-O-tbut). 
N-Boc-4-aminoethoxyethyl-1-ol-glutaryl-Sarcosine-tert-butyl ester (14) 
Name of the structure: 2-[2-(tert-Butoxycarbonylamino)ethoxy]ethyl 5-[N-methyl(tert-
butoxycarbonyl-methyl) amino]-5-oxovalerate. 
Appearance: yellow oil. The molecular weight of the compound was 446.54 g/mol. The 
yield of the reaction was 70% (Figure 34). 
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1H NMR (500 MHz, Chloroform-d) δ 5.34 (s, 1H), δ 4.24-4.14 (m, 2H), 3.77-3.66 (m, 2H), 
3.16-3.07 (m, 3H), 2.90 (t, J = 5.4 Hz, 1H), 2.35 (t, J = 8.2 Hz, 1H), 1.96 (tt, J = 8.2, 5.4 
Hz, 1H), 1.43 (d, J = 4.9 Hz, 9H). 
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Figure 34. Chemical structure of N-Boc-4-aminocyclohexanol–adipoyl sarcosine-tert-butyl ester (Boc-
N-etOet-O-glt-Sar-O-tbut). 
(1S,4R) N-Boc-4-aminocyclohexanol-adipoyl-Glycine-tert-butyl ester (15) 
Name of the structure: 4-(tert-Butoxycarbonylamino)cyclohexyl 6-oxo-6-[(tert-butoxy- 
carbonylmethyl) amino] hexanoate. 
Appearance: yellow oil. The molecular weight of the compound was 456.57 g/mol. The 
yield of the reaction was 24% (Figure 35). 
1H NMR (500 MHz, Chloroform-d) δ 6.73 (s, 1H), 4.47 (s, 1H), 4.34 (p, J = 6.8 Hz, 1H), 
4.16 (s, 2H), 3.11 (s, 3H), 2.90 (t, J = 5.5 Hz, 2H), 2.35 (t, J = 5.3 Hz, 2H), 2.06-1.92 (m, 
6H), 1.68-1.56 (m, 2H), 1.58-1.46 (m, 2H), 1.43 (d, J = 4.9 Hz, 18H). 
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Figure 35. Chemical structure of (1S,4R) N-Boc-4-aminocyclohexanol-adipoyl-Glycine-tert-butyl ester 
(Boc-t,4-N-cyhex-O-adp-Gly-O-tbut). 
(1S,4R) N-Boc-4-aminocyclohexanol-glutaryl-Sarcosine-tert-butyl ester (16) 
Name of the structure: 4-(tert-Butoxycarbonylamino)cyclohexyl 5-[N-methyl(tert-
butoxycarbonyl- methyl)amino]-5-oxovalerate. 
Appearance: yellow oil. The molecular weight of the compound was 456.58 g/mol. The 
yield of the reaction was 22.28% (Figure 36). 
1H NMR (500 MHz, Chloroform-d) δ 4.47 (s, 1H), 4.41-4.36 (m, 1H), 4.16 (s, 2H), 3.73-
3.71 (m, 1H), 3.11 (s, 3H), 2.90 (t, J = 5.5 Hz, 2H), 2.35 (t, J = 5.3 Hz, 2H), 2.06-1.92 (m, 
6H), 1.68-1.56 (m, 2H), 1.58-1.46 (m, 2H), 1.43 (d, J = 4.9 Hz, 18H). 
 
Results 
103 
 
NHO
O N
O
O
OO
O
CH3
CH3
CH3
CH3
CH3
CH3
CH3
 
Figure 36: Chemical structure of (1S,4R) N-Boc-4-aminocyclohexanol-glutaryl-Sarcosine-tert-butyl 
ester (Boc-t,4-N-cyhex-O-glt-Sar-O-tbut). 
(1S,2S) N-Boc-2-aminocyclopentanol-glutaryl-Sarcosine-N-diethylamine-4-
nitrobenzamide ester (17) 
Name of the structure: (1S,2S)-2-(tert-Butoxycarbonylamino)cyclopentyl 5-(N-methyl{2-
[2-(p-nitrobenzoylamino) ethylamino]-2-oxoethyl}amino)-5-oxovalerate. 
Appearance: yellow oil. The molecular weight of the compound was 577.64 g/mol. The 
yield of the reaction was 7.99% (Figure 37). 
1H NMR (500 MHz, Chloroform-d) δ 8.33-8.27 (m, 2H), 7.99-7.93 (m, 2H), 7.37 (s, 1H), 
6.75 (s, 1H), 5.30 (q, J = 7.0 Hz, 1H), 5.07 (d, J = 12.5 Hz, 1H), 4.24-4.06 (m, 3H), 3.73 
(ddd, J = 12.3, 2.8, 1.4 Hz, 1H), 3.48 (td, J = 12.0, 2.7 Hz, 1H), 3.37 (td, J = 12.0, 2.7 Hz, 
1H), 3.08-2.99 (m, 2H), 3.01 (s, 3H), 2.59 (td, J = 12.3, 1.1 Hz, 1H), 2.56-2.42 (m, 1H), 
2.30-2.16 (m, 3H), 2.07-1.92 (m, 2H), 1.81-1.69 (m, 2H), 1.71-1.54 (m, 2H), 1.44 (s, 10H). 
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Figure 37. Chemical structure of (1S,2S) N-Boc-2-aminocyclopentanolol-glutaryl-Sarcosine-N-
diethylamine-4-nitrobenzamide (Boc-2-N-cypent-O-glt-Sar-NetN-CO-ph-NO2). 
(1S,3R) N-3-amino-Boc-cyclopentanol-glutaryl-Sarcosine-N-diethylamine-4-
nitrobenza (18) 
Name of the structure: (1S,3R)-3-(tert-Butoxycarbonylamino)cyclopentyl 5-(N-methyl{2-
[2-(p-nitrobenzoylamino)ethylamino]-2-oxoethyl}amino)-5-oxovalerate. 
Appearance: yellow oil. The molecular weight of the compound was 577.64 g/mol. The 
yield of the reaction was 9.33% (Figure 38). 
A novel nanoparticle-based system for sustained intravitreal drug delivery 
104 
1H NMR (500 MHz, Chloroform-d) δ 9.16 (s, 1H), 8.33-8.27 (m, 2H), 7.99-7.93 (m, 2H), 
6.75 (s, 1H), 5.20 (d, J = 12.4 Hz, 1H), 4.84 (p, J = 6.9 Hz, 1H), 4.47 (s, 1H), 4.08-3.99 (m, 
2H), 3.59 (td, J = 12.0, 4.2 Hz, 1H), 3.37 (td, J = 12.0, 2.7 Hz, 1H), 3.24 (td, J = 11.9, 4.2 
Hz, 1H), 3.01 (dtd, J = 25.4, 12.1, 2.6 Hz, 2H), 2.97 (s, 3H), 2.63 (td, J = 12.4, 1.3 Hz, 1H), 
2.45 (qdd, J = 12.6, 2.7, 1.6 Hz, 1H), 2.36-2.14 (m, 4H), 2.01-1.89 (m, 2H), 1.84 (dt, J = 
13.0, 7.0 Hz, 1H), 1.44 (s, 9H), 1.41-1.29 (m, 1H). 
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Figure 38. Chemical structure of (1S,3R) N-3-amino-Boc-cyclopentanol-glutaryl-Sarcosine-N-
diethylamine-4-nitrobenzamide (Boc-3-N-cypent-O-glt-Sar-NetN-CO-ph-NO2). 
(1S,4S) N-Boc-4-aminocyclohexanol-adipoyl-Glycine-tert-butyl ester (19) 
Name of the structure: 4-(tert-Butoxycarbonylamino)cyclohexyl 6-oxo-6-[(tert-
butoxycarbonylmethyl) amino] hexanoate. 
Appearance: yellow oil. The molecular weight of the compound was 456.58 g/mol. The 
yield of the reaction was 21.2% (Figure 39). 
1H NMR (500 MHz, Chloroform-d) δ 6.73 (s, 1H), 4.44 (s, 1H), 4.39 (p, J = 6.9 Hz, 1H), 
4.17 (s, 2H), 3.68 (p, J = 6.9 Hz, 1H), 2.52 (t, J = 5.2 Hz, 2H), 2.35 (t, J = 8.1 Hz, 2H), 
2.08-1.87 (m, 4H), 1.80-1.67 (m, 2H), 1.66-1.56 (m, 4H), 1.49 (ddd, J = 12.6, 7.6, 6.3 Hz, 
2H), 1.43 (d, J = 4.9 Hz, 18H). 
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Figure 39. Chemical structure of (1S,4S) N-Boc-4-aminocyclohexanol-adipoyl-Glycine-tert-butyl ester 
(Boc-c,4-N-cyhex-O-adp-Gly-O-tbut). 
N-Boc-N’-amidoethyleneamidovaleric-4-ol-glutaryl-Sarcosine-amidoethyleneamino-
4-nitrobenzamide (20) 
Name of the structure: 1-Methyl-4-oxo-4-[2-(tert-butoxycarbonylamino) ethylamino]butyl 
5-(N-methyl{2-[2-(p-nitrobenzoyl- amino)ethylamino]-2-oxoethyl} amino)-5-oxovalerate. 
Appearance: yellow oil. The molecular weight of the compound was 636.70 g/mol. The 
yield of the reaction was 2.86% (Figure 40). 
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1H NMR (500 MHz, Chloroform-d) δ 9.49 (s, 1H), 8.33-8.27 (m, 2H), 7.99-7.93 (m, 2H), 
6.75 (s, 1H), 6.19 (s, 1H), 5.24 (d, J = 12.5 Hz, 1H), 5.10 (s, 1H), 4.77 (ddddd, J = 9.3, 7.9, 
6.9, 4.5, 1.6 Hz, 1H), 4.05 (d, J = 12.4 Hz, 1H), 3.71-3.46 (m, 4H), 3.41-3.31 (m, 2H), 3.16 
(td, J = 11.9, 2.9 Hz, 1H), 3.04 (td, J = 12.0, 4.1 Hz, 1H), 2.97 (s, 3H), 2.87 (td, J = 12.5, 
2.6 Hz, 1H), 2.61 (td, J = 12.4, 1.4 Hz, 1H), 2.53-2.37 (m, 4H), 2.36-2.20 (m, 3H), 1.83-
1.69 (m, 1H), 1.44 (s, 9H), 1.06 (d, J = 6.8 Hz, 3H). 
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Figure 40. Chemical structure of N-Boc-N’-amidoethyleneamidovaleric-4-ol-glutaryl-Sarcosine-
amidoethyleneamino-4-nitrobenzamide (Boc-NetN-val-secO-glt-Sar-NetN-ph-NO2). 
4.2.2 Ester hydrolysis testing 
The study of the ester hydrolysis was made by HPLC, a mixture of a hydroalcoholic 
solution was used due to the precipitation of cmpd. The reason of using a wide range of pH 
in the buffer (from pH 7.5 ± 0.17) was to prevent the precipitation of the cmpd. Kinetic of 
ester degradations are shown in Figures 41 and 42 and half-lives are shown in Table III. 
 
Figure 41. Semi-log representation of the half-live of ester cmpd with less than 25 days. The compound 
with the ester most labile for hydrolysis was Boc-N-etOet-O-glt-Sar-O-tbut and the compound with the ester 
most stable for hydrolysis was Boc-c,4-N-cyhex-O-adp-Gly-O-tbut. 
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Figure 42. Semi-log representation of the half-live of ester cmpd with more than 25 days. The compound 
with the ester most labile for hydrolysis was Boc-t,4-N-cyhex-O-glt-Sar-O-tbut and the compound with the 
ester most stable for hydrolysis was Boc-t,4-N-cyhex-O-adp-Gly-O-tbut. This result suggests that the speed 
of hydrolysis rate is also affected by the composition in the right side of the molecule. 
Table III. Half-lives of the ester compounds 
Cmpd Structure Half-lives (days) 
5 Boc-N-but-O-glt-Sar-O-tbut 17 
6 Boc-3-pyrrol-O-adp-Gly-O-tbut 31 
7 Boc-4-piper-O-adp-Gly-O-tbut 20 
14 Boc-N-etOet-O-glt-Sar-O-tbut 12 
15 Boc-t,4-N-cyhex-O-adp-Gly-O-tbut 51 
16 Boc-t,4-N-cyhex-O-glt-Sar-O-tbut 24 
17 Boc-2-N-cypent-O-glt-Sar-NetN-ph-NO2 38 
18 Boc-3-N-cypent-O-glt-Sar-NetN-ph-NO2 45 
19 Boc-c,4-N-cyhex-O-adp-Gly-O-tbut 21 
20 Boc-NetN-val-secO-glt-Sar-NetN-ph-NO2 25 
 
The same cmpd with different conformation (15 and 19) has shown different hydrolysis 
rate suggesting that the equatorial conformation of the cyclohexyl structure (15) is more 
stable than the same structure with axial conformation (19). The results suggest five-
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member rings amino-ester compounds are more stable than six-member ring when the right 
side of the molecule is the same (6 vs 7), (17 vs 16) and (18 vs 16). 
Even, after using a wide range of pH (7.5 ± 0.17) and ethanol there were partial 
precipitations of the cmpd on the walls of the vials and the analytical method was not 
sensitive and selective. The cmpd with the shortest half-life was the number 14 (12 days) 
and the one with the longest half-life was the number 15 (51 days). 
4.2.3 Comparison of the behavior of the ester degradation 
Due to the results showed in the ester hydrolysis study where the same amino-alkoxy cmpd 
attached to different alkyl chains (15 and 16) got different half-lives (51 days and 24 days 
respectively). Two peptides were synthesized to compare how the length of the alkyl chain 
might affect to the speed of ester hydrolysis. The peptides were incubated in physiological 
conditions. The results have shown that the peptide with the shortest dicarboxylic acid alkyl 
chain (glutaric, 5 carbon chain) had a faster hydrolysis of the ester than the adipic (6 carbon 
chain) meaning that the right side of the molecule might affect the speed of hydrolysis rate, 
suggesting that could be affected by side reactions besides hydrolysis and thus, is a factor 
to consider (Figures 43 and 44, Table IV). 
 
Figure 43. Semi-logarithmic graph of the half-lives of the two peptides with different alkyl chains. 
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Table IV. Effect of alkyl chain in the half-lives 
Peptide Half-life (days) 
meO-glutaric-Sar-GYNLYRVRS 9 
meO-adipic-Sar-GYNLYRVRS 13 
 
 
 
Figure 44. Mechanism of cyclic side reactions. A: Chemical mechanism of the cyclic side reaction. B: 
Kinetic graph of the cyclic side reaction rate at physiological conditions. Source: Yano, 2000 (adapted)[323]. 
4.2.4 De-blocking of the amino acid carboxylic group of Boc-N-R-O-spacer-
aa-O-tbut 
All the ester compounds (see Table I), were reacted with TFA 10% (v/v) to deprotect the 
carboxylic group of the amino acid (Sar or Gly) to attach the rest of the sequence of the 
active peptide through the solid-state reaction. Unfortunately, the yield in all the reactions 
were 0 due to the more rapid de-blocking of the Boc-amine in the left side of the molecule. 
4.3 Boc-N-R-O-ahx-DNP compounds 
4.3.1 Characterization of Boc-N-R-O-ahx-DNP esters 
To study the ester degradation only affected by the difference of the amino-alkoxy 
compound and avoiding the effect of the presence of the length of the alkyl chain. 
According to the results in Table I, four compounds (tert-butyl (4-hydroxybutyl)carbamate; 
tert-butyl 3-hydroxypyrrolidine-1-carboxylate; tert-butyl [(1R,3R)-3-hydroxycyclopentyl] 
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carbamate and tert-butyl (trans-4-hydroxycyclohexyl) carbamate) were selected to 
synthesize the ester model compounds and compare their speed of degradation of the esters. 
While the peptide series may be complicated by cyclization reactions whereby the amide 
nitrogen mat may displace the ester, this is not possible in the model compound, which 
lacks any amides. Based on the ester hydrolysis rates of the Boc-N-R-O-spacer-aa-O-tbut 
compounds (Figures 41 and 42), one fast released compound (tert-butyl (4-hydroxybutyl) 
carbamate), one medium released compound (tert-butyl 3-hydroxypyrrolidine-1-
carboxylate) and two slow released compound (tert-butyl (trans-4-hydroxycyclohexyl) 
carbamate). 
4-(tert-Butoxycarbonylamino)butyl 6-(2,4-dinitrophenylamino)hexanoate (21) 
Appearance: yellow oil. The molecular weight of the compound was 468.50 g/mol. The 
yield of the reaction was 55.2% (Figure 45). 
1H NMR (500 MHz, Chloroform-d) δ 8.86 (d, J = 2.0 Hz, 1H), 8.24 (dd, J = 7.5, 2.0 Hz, 
1H), 7.68 (s, 1H), 7.22 (d, J = 7.5 Hz, 1H), 5.34 (s, 1H), 4.15 (t, J = 7.4 Hz, 2H), 3.48 (t, J 
= 5.3 Hz, 2H), 3.24 (t, J = 7.5 Hz, 2H), 2.35 (t, J = 5.4 Hz, 2H), 1.82-1.72 (m, 2H), 1.73-
1.63 (m, 4H), 1.60 (tt, J = 7.7, 5.4 Hz, 2H), 1.44 (s, 9H), 1.38 (tt, J = 7.8, 5.7 Hz, 2H). 
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Figure 45. Chemical structure of 4-(tert-Butoxycarbonylamino)butyl 6-(2,4-dinitrophenylamino) 
hexanoate (Boc-N-but-O-ahx-DNP). 
3-5-(2,4-Dinitrophenylamino)pentyl 1-tert-butyl 1,3-pyrrolidinedicarboxylate (22) 
Appearance: yellow oil. The molecular weight of the compound was 466.49 g/mol. The 
yield of the reaction was 64.75% (Figure 46). 
1H NMR (500 MHz, Chloroform-d) δ 8.86 (d, J = 2.0 Hz, 1H), 8.24 (dd, J = 7.5, 2.0 Hz, 
1H), 7.22 (d, J = 7.5 Hz, 1H), 4.96 (p, J = 7.1 Hz, 1H), 4.07 (td, J = 12.4, 2.5 Hz, 1H), 3.73 
(dt, J = 9.5, 7.1 Hz, 1H), 3.61 (dd, J = 9.4, 7.1 Hz, 1H), 3.54-3.45 (m, 2H), 3.14 (td, J = 
12.2, 3.5 Hz, 1H), 2.68 (ddd, J = 13.7, 12.6, 1.5 Hz, 1H), 2.61-2.49 (m, 2H), 2.35 (dq, J = 
14.0, 7.1 Hz, 1H), 2.19 (s, 1H), 1.99-1.88 (m, 1H), 1.65-1.47 (m, 3H), 1.47 (s, 9H), 1.41 
(dddd, J = 15.7, 12.3, 5.3, 3.5 Hz, 1H), 1.14-1.03 (m, 1H). 
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Figure 46. Chemical structure of 3-5-(2,4-Dinitrophenylamino)pentyl 1-tert-butyl 1,3-pyrrolidine 
dicarboxylate (Boc-3-pyrrol-O-ahx-DNP). 
(1R,3S)-3-(tert-Butoxycarbonylamino)cyclopentyl 6-(2,4-dinitrophenylamino) hexan- 
oate (23) 
Appearance: yellow oil. The molecular weight of the compound was 480.51 g/mol. The 
yield of the reaction was 65.8% (Figure 47). 
1H NMR (500 MHz, Chloroform-d) δ 9.99 (s, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.24 (dd, J = 7.5, 2.0 
Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 4.89-4.79 (m, 1H), 4.66 (s, 1H), 3.75-3.66 (m, 1H), 3.25 (pd, J = 
12.4, 3.4 Hz, 2H), 2.57 (ddt, J = 12.2, 6.1, 1.5 Hz, 1H), 2.57-2.47 (m, 1H), 2.16-2.01 (m, 2H), 1.91-
1.81 (m, 4H), 1.84-1.76 (m, 1H), 1.75-1.62 (m, 1H), 1.58 (dddt, J = 15.2, 8.2, 3.5, 1.3 Hz, 1H), 1.44 
(s, 9H), 1.48-1.35 (m, 1H), 1.34-1.21 (m, 1H). 
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Figure 47. Chemical structure of (1R,3S)-3-(tert-Butoxycarbonylamino)cyclopentyl 6-(2,4-
dinitrophenylamino)hexanoate (Boc-3-N-cypent-O-ahx-DNP). 
4-(tert-Butoxycarbonylamino)cyclohexyl 6-(2,4-dinitrophenylamino)hexanoate (24) 
Appearance: yellow oil. The molecular weight of the compound was 494.54 g/mol. The 
yield of the reaction was 77.6% (Figure 48). 
1H NMR (500 MHz, Chloroform-d) δ 8.86 (d, J = 2.0 Hz, 1H), 8.24 (dd, J = 7.5, 2.0 Hz, 
1H), 7.69 (s, 1H), 7.22 (d, J = 7.5 Hz, 1H), 4.47 (s, 1H), 4.40 (p, J = 6.9 Hz, 1H), 3.67 (p, 
J = 6.9 Hz, 1H), 3.48 (t, J = 7.6 Hz, 2H), 2.35 (t, J = 8.1 Hz, 2H), 2.07-1.92 (m, 4H), 1.72-
1.55 (m, 6H), 1.55-1.45 (m, 2H), 1.44 (s, 9H), 1.38 (t, J = 7.8 Hz, 2H). 
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Figure 48. Chemical structure of 4-(tert-Butoxycarbonylamino)cyclohexyl 6-(2,4-dinitrophenylamino) 
hexanoate (Boc-t,4-N-cyhex-O-ahx-DNP). 
4.3.3 Ester hydrolysis kinetics of Boc-N-R-O-ahx-DNP cmpd 
The study of the ester hydrolysis was made by HPLC, in a HEPES buffer solution at pH of 
7.4. Kinetics of ester degradations are shown in Figure 49. The half-lives are shown in 
Table III and are compared with the same esters of the previous study (Table V). 
 
Figure 49. Semi-log representation of the half-live of the model ester compounds Boc-N-but-O-ahx-
DNP, Boc-3-pyrrol-O-ahx-DNP, Boc-3-N-cypent-O-ahx-DNP and Boc-t,4-N-cyhex-O-ahx-DNP. 
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Table V. Half-lives of the model ester compounds 
Cmpd Structure Half-lives (days) Proportion half-lives increased* 
21 Boc-N-but-O-ahx-DNP 21 1:1.4 
22 Boc-3pyrrol-O-ahx-DNP 160 1:5.2 
23 Boc-3-N-cypent-O-ahx-DNP 120 1:2.7 
24 Boc-t,4-N-cyhex-O-ahx-DNP 290 1:5.7 
*Ester half-lives compared with the ester half-lives of the compounds 5, 6, 18 and 15 respectively (Table III). 
The results have shown, in all cases, a reduction of the speed of degradation of the esters 
in physiological conditions, especially the ester compounds made with a secondary alcohol, 
the speed of degradation was reduced between 5 and 6 times. Semi-log loss curves and 
half-lives showed that the speed of cleavage was Boc-N-but-O-ahx-DNP <Boc-3-N-
cypent-O-ahx-DNP <Boc-3-pyrrol-O-ahx-DNP <Boc-t,4-N-cyhex-O-ahx-DNP. The half-
life of the cmpd made with amino-cyclopentanol (23) is shorter than the cmpd 22 made 
with 3-pyrrolidine, when in the previous study was the opposite. 
The half-lives shown on Table III are probably representative of the relative hydrolysis 
rates of simple carboxyl ester prodrugs for these bridging carbamates since there is no 
opportunity for 5-, 6- or 7-membered cyclic intermediates with distal amide nitrogen atoms, 
as in the case of amides/peptides. 
However, the N-Boc group is very sterically crowded and electron donating thus may 
influence the ester hydrolysis. Therefore, we sought to compare kinetics of hydrolysis with 
the corresponding bridged carbamates on the relevant CDEX OH groups. 
4.3.4 Attachment of the N-R-O-ahx-DNP cmpd to the nanogel CDEX 
a) Deprotection of the amine 
Before the conjugation of the amino-ester compounds to the nanogel, the amine had to be 
de blocked via Boc removal. The final compounds were the following (Figure 50). 
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Figure 50. Schematic representation of a conjugate NP: NP-OCON-3-pyrrol-O-ahx-DNP. 
4-Aminobutyl 6-(2,4-dinitrophenylamino)hexanoate (25) 
Appearance: yellow oil. The molecular weight of the compound was 368.39 g/mol. The 
yield of the reaction was 100% (Figure 51). 
1H NMR (500 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.24 (dd, J = 7.5, 2.0 Hz, 1H), 7.22 (d, J = 
7.5 Hz, 1H), 4.12 (t, J = 4.8 Hz, 2H), 3.48 (t, J = 7.6 Hz, 2H), 2.66 (t, J = 5.1 Hz, 2H), 2.34 
(t, J = 8.0 Hz, 2H), 1.72-1.53 (m, 8H), 1.38 (p, J = 5.7 Hz, 2H), 1.05 (s, 2H). 
NH
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Figure 51. Chemical structure of 4-Aminobutyl 6-(2,4-dinitrophenylamino)hexanoate (NH2-but-O-ahx-
DNP). 
3-Pyrrolidinyl 6-(2,4-dinitrophenylamino)hexanoate (26) 
Appearance: yellow oil. The molecular weight of the compound was 366.37 g/mol. The 
yield of the reaction was 100% (Figure 52). 
1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.24 (dd, J = 7.5, 
2.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 4.95 (p, J = 7.1 Hz, 1H), 3.34-3.26 (m, 1H), 3.21-
3.12 (m, 2H), 3.06 (dt, J = 9.5, 7.1 Hz, 1H), 2.98 (dt, J = 9.5, 7.0 Hz, 1H), 2.75 (dd, J = 9.5, 
7.0 Hz, 1H), 2.48 (td, J = 12.8, 1.5 Hz, 1H), 2.25 (dq, J = 12.2, 1.9 Hz, 1H), 2.05-1.87 (m, 
2H), 1.76-1.64 (m, 2H), 1.55-1.44 (m, 1H), 1.48-1.34 (m, 2H), 1.31 (tt, J = 11.6, 3.1 Hz, 
1H), 1.09 (ddtd, J = 13.9, 12.3, 3.4, 1.8 Hz, 1H). 
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Figure 52. Chemical structure of 3-Pyrrolidinyl 6-(2,4-dinitrophenylamino)hexanoate (3-pyrrol-O-ahx-
DNP). 
(1R,3S)-3-Aminocyclopentyl 6-(2,4-dinitrophenylamino)hexanoate (27) 
Appearance: yellow oil. The molecular weight of the compound was 380.40 g/mol. The 
yield of the reaction was 100% (Figure 53). 
1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.24 (dd, J = 7.5, 
2.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 4.82 (p, J = 6.9 Hz, 1H), 3.58-3.50 (m, 1H), 3.00 (td, 
J = 12.3, 1.4 Hz, 1H), 2.72 (p, J = 6.9 Hz, 1H), 2.24-2.12 (m, 2H), 1.97 (dt, J = 13.0, 7.0 
Hz, 1H), 1.92-1.72 (m, 4H), 1.49 (s, 2H), 1.43-1.20 (m, 4H), 1.20-1.06 (m, 2H), 1.07-0.94 
(m, 1H). 
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Figure 53. Chemical structure of (1R,3S)-3-Aminocyclopentyl 6-(2,4-dinitrophenylamino)hexanoate 
(3-NH2-cypent-O-ahx-DNP). 
4-Aminocyclohexyl 6-(2,4-dinitrophenylamino)hexanoate (28) 
Appearance: yellow oil. The molecular weight of the compound was 394.43 g/mol. The 
yield of the reaction was 100% (Figure 54). 
1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.24 (dd, J = 7.5, 
2.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 4.24 (p, J = 6.9 Hz, 1H), 3.48 (t, J = 7.6 Hz, 2H), 
2.41 (p, J = 7.0 Hz, 1H), 2.32 (t, J = 8.2 Hz, 2H), 1.81-1.53 (m, 9H), 1.48-1.25 (m, 6H), 
1.30 (s, 3H). 
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Figure 54. Chemical structure of 4-Aminocyclohexyl 6-(2,4-dinitrophenylamino)hexanoate (t,4-NH2-
cyhex-O-ahx-DNP). 
b) CDEX activation and DNP cmpd conjugation 
The activation of CDEX with p-nPCOCl was checked by the chromogenic method. The p-
nitrophenolate by spectrum shown a range of 57-154 of the OH groups have been activated. 
All the compounds were analyzed by spectrophotometry UV-Vis to quantify the amount of 
ester-DNP cmpd/ NP. The sizes were analyzed, by dynamic light scattering in triplicate 
(Figure 55, Table VI). 
 
Figure 55. UV-vis spectrum of the 3-pyrrol-O-ahx-DNP conjugated with the nanocarrier (CDEX70-3-
pyrrol-O-ahx-DNP). ʎmax DNP = 360 nm. 
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Table VI. CDEX characterization 
Cmpd DNP/CDEX  Particle diameter (nm) % CDEX mass recovered 
25 17 102.6±6 61.54 
26 30 179±21 9.35 
27 2 187±19 70.1 
28 3 228±44 90 
 
The results have shown a low yield of conjugation of the DNP cmpd. However the 3-
pyrrolidinyl compound gave the highest coupling, making it favored for high yield 
conjugation. 
UV-Vis quantification of the compounds shows a height of the DNP peaks at 360 nm, 
subtracting only the high background scattering at 600 nm, leads to calculation of DNP/NP 
which appears in Table II, based on the molar extinction of (ʎ = 360 nm, εDNP: 16,622 M-1 
cm-1). Due to the minimum light scattering of the NP at this wavelength in comparison with 
the conjugate NP with ethanolamine, we could consider this measurement precise. 
Conjugation results suggest that the nature of the reactive amine is critical to achieve good 
conjugate results. According to the observed results, the order of reactive amines are: 3-
pyrrolidine- >NH2-but- >NH2-cyclohexyl = NH2-cyclopentyl. 
c) In vitro release studies of DNP-ester compounds from CDEX 
The four CDEX70 conjugates with the amino-ester-DNP compounds were incubated in 
HEPES buffer, pH 7.4 at 37 °C. At different day time-points filterable free DNP compounds 
(3 kDa MWCO centrifugal filter) were identified by UV-VIS spectroscopy, (ʎmax = 360 
nm). Semi-log loss curves and half-life have showed that the speed of cleavage was 
CDEX70-N-but-O-ahx-DNP <CDEX70-3-pyrrol-O-ahx-DNP <CDEX70-3-N-cypent-O-
ahx-DNP <CDEX70-4-N-cyhex-O-ahx-DNP (Figure 56 and Table VII). The behavior of 
the ester hydrolysis of three of these compounds was different with their predecessors [Boc-
N-R-O-ahx-DNP Figure 49 and Table V (cmpd 22, 23 and 24)]. But it was the same as the 
first ester hydrolysis study with the Boc-N-R-O-spacer-aa-O-tbut cmpd (Figures 41 and 42 
and Table III; cmpd 5, 6, 18 and 15), where the ester cmpd made with secondary alcohols 
have slower hydrolysis rate than the ester made with the primary alcohol. On this case, the 
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hydrolysis of the esters is only affected by the nature of amino-alkoxy compound of the left 
side of the molecule and not by the length of the alkyl chain of the right side of the molecule. 
 
Figure 56. Semi-log representation of the half-life of the hydrolysis of the DNP amino ester compound 
conjugates to NP affected by the nature of the amino-alcoxy cmpd. 
Table VII. Half-lives of the DNP-ester conjugates to NP 
Cmpd Structure Half-lives (days) 
28 CDEX70-N-but-O-ahx-DNP 9 
29 CDEX70-3-pyrrol-O-ahx-DNP 40 
30 CDEX70-3-N-cypent-O-ahx-DNP 74 
31 CDEX70-4-N-cyhex-O-ahx-DNP  81 
 
4.4 In vitro release studies of dicarboxypeptide prodrugs from 
CDEX 
4.4.1 Attempted alpha aminoacyl group t-butyl esters deprotection to yield 
peptide cap 
To attach an aminoalkoxy-ester bridged Gly or Sar to the distal resin-linked peptide to give 
aminoalkyl-prodrug, the t-butyl esters on the right hand sides of the molecules have to be 
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deprotected. 0.1 mEq of the compounds (5-7, 14-20) were dissolved, separately, in a 
solution of 10% (v/v) TFA in DCM. The reactions were carried out at RT over 24 h. 
Progress was checked by TLC (DCM: MeOH; 9:1). When complete, 20 volumes of toluene 
were added to the mixture and carboxylic products were dried under vacuum and extracted 
with a mixture of water:DCM, the isolated aqueous phase then lyophilized (Figure 57). The 
designed synthesis pathway to get the final ester prodrug peptide was to react the free 
carboxylic acid of the Boc-amidoalkoxy (adp or glt)-capped amino acid (Sar or Gly) with 
the extending peptide chain immobilized on a resin through a solid state reaction. After 
attaching the rest of the peptide sequence, the compound was treated with TFA to release 
the peptide from the resin and de-block the amine of the left side of the molecule (Figure 
58). 
 
Figure 57. Scheme of the deprotection of the sarcosine carboxylic group of aminoalkoxy-ester bridge. 
 
 
Figure 58. Scheme of the solid-state reaction and de blocking of the ester prodrug peptide. 
 
Unfortunately, we found that the acid deprotection reaction step removed the N-Boc group 
much more rapidly than it removed the t-butyl ester. This required our establishing another 
route to give the desired intermediate shown on the top left of Figure 25, needed for 
appending to the peptide during solid-state synthesis. Our successful new route is described 
in the synthesis of the cmpd 22. 
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4.4.1 Characterization of the peptide prodrug 
Due to the problems on the de-blocking step of the amino acid carboxylic group of the 
previous compounds, an alternative synthesis pathway was used to get the prodrug ester. 
6-{[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]oxy}-6-oxohexanoic acid (32) 
Appearance: yellow-orange oil. The molecular weight of the compound was 315.36 g/mol. 
The yield of the reaction was 46.6% (Figure 59). 
1H NMR (500 MHz, Chloroform-d) δ 4.96 (p, J = 7.1 Hz, 1H), 4.10 (dd, J = 9.5, 7.0 Hz, 
1H), 3.78 (dt, J = 9.5, 7.1 Hz, 1H), 3.52 (dt, J = 9.5, 7.1 Hz, 1H), 3.37 (dd, J = 9.4, 7.1 Hz, 
1H), 2.63 (td, J = 12.5, 1.5 Hz, 1H), 2.40-2.30 (m, 2H), 2.32-2.22 (m, 3H), 2.08-1.77 (m, 
3H), 1.66-1.55 (m, 1H), 1.47 (s, 9H). 
N
O
OH
O
O
OCH3
OCH3
CH3  
Figure 59. Chemical structure of 6-{[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]oxy}-6-oxohexanoic acid 
(Boc-3-pyrrol-O-adp-OH). 
Ester prodrug 3-pyrrolidine-O-adipic-N-Sar-Tyr-Asn-Leu-Tyr-Arg-Val-Arg-Ser-
amide (33) 
Appearance: white powder. The molecular weight of the compound was 1,337.55 g/mol. 
The yield of the reaction was 26% (Figure 60). 
To demonstrate the purity of the compound, it was checked by mass spectrometry (Figure 
61). 
 
Figure 60: Chemical structure of 3-pyrrolilidine-O-adipic-N-Sar-Tyr-Asn-Leu-Tyr-Arg-Val-Arg-Ser-
amide (3-pyrrol-O-11 peptide). Highlighted the region of the structure with positive charges. 
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Figure 61. Mass spectrometry of the compound 3-pyrrolidine-O-adipic-N-Sar-Tyr-Asn-Leu-Tyr-Arg-
Val-Arg-Ser-amide. 
4.4.2 Characterization of CDEX70-3-pyrrol-O-11 peptide 
The first quantification was the analysis of p-nP attached to CDEX70 UV-VIS (ʎ = 400 
nm; εpNP-OH = 18,100 M-1 cm-1). The amount of p-nitrophenyl groups per CDEX particle is 
108 (29% of the free hydroxyl groups of dextran). 
The analysis for the conjugation reaction were the yield of the reaction, the size by dynamic 
light scattering and the ζ by electrophoretic light scattering (n = 3). The amount of peptide 
was quantified by UV (ʎ = 275 nm; εTyr = 2,200 M-1 cm-1) and by BCA (Table IX). On this 
case we have to take as valid the result by UV (Tyr). BCA was inaccurate due to the length 
and the MW of the peptide are under the recommended specifications for this technique. 
Table IX. Characterization of CDEX70-3-pyrrol-O-11 peptide 
Amount p-nP/CDEX 108 
% CDEX mass recovered (%) 78 
Particle diam. (nm) 178±9.4 
ζ (mV) 2.3±0.4 
Peptide/CDEX by UV 57 
Peptide/CDEX by BCA 30* 
Positive charges/CDEX 114 
*The peptide quantification was taken to be that established by UV Tyr spectrum. UV (based on Tyr molar 
extinction of 2,200 at 275 nm). BCA is considered less accurate when peptide is appended to carrier, where 
free peptide is used as BCA reference standard. 
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4.4.3 Stability test of 3-pyrrol-O-11 peptide 
The peptide 3-pyrrol-O-11 was checked by HPLC in several reaction conditions, the 
peptide itself, the peptide in presence of p-nP-OH, TEA, DMSO at 45 °C in N2 atmosphere 
during 3 d and the quench step, mixed with m-dPEG®₄-amine (Figures 62-64). 
 
Figure 62. Chromatogram of 3-pyrrol-O-11 peptide (100 µg/mL in water), reference standard (Retention 
of time: 23.1 min). 
 
 
Figure 63. Chromatogram of 3-pyrrol-O-11 peptide in the reaction conditions. There is a new peak 
(Retention of time: 22.0 minutes) due to the degradation of the prodrug peptide in the reaction conditions. 
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Figure 64. Chromatogram of 3-pyrrol-O-11 peptide in the quench step (mixed with m-dPEG®₄-amine). 
There was a change on the shape of the peak, due to the degradation of the prodrug peptide. 
4.4.4 In vitro rate of the active peptide release from CDEX70-3-pyrrol-O-11 
peptide 
0.44 mg/mL of the CDEX70 conjugate containing 76 µM linked 11 peptide was incubated 
in HEPES buffer, pH 7.4 at 37 °C. At 0, 3 and 12 day time-points filterable peptide (10 
kDa MWCO centrifugal filter, speed: 14,000 g, time: 10 min, RT) was identified by UV 
spectrum of the filtrate, where 100 µM peptide has peak (ʎ = 275 nm; εTyr = 2,200 M-1 cm-
1). Filtrate was checked by the validated analytical method, by HPLC using the peptide 11 
as reference standard. A semi-log loss curve (n = 3) shows half-life of 28 days, releasing 
bioactive peptide at approximately 2% per day of the nanoparticle-bound amount (Figures 
65-69). In comparison of the release rate of the DNP-ester compound made with 3-
pyrrolidinol (cmpd 28) attached to the NP (t½ = 40 days) (Table VII). Suggests that there is 
some type of side reactions besides the hydrolysis reaction giving new side compounds 
which appear as new peaks in the chromatogram (Figure 68) but even this circumstance, 
the mayor compound recovered from the release study was the peptide 11. 
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Figure 65. UV spectrum of CDEX70-3-pyrrol-O-11 peptide (in black) and 11 peptide released from the 
nanocarrier (in red). ʎmax = 275 nm. 
 
 
Figure 66. Chromatogram of the phosphate buffer, vehicle where the sample was dissolved. 
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Figure 67. Chromatogram of 11 peptide (100 µg/mL in water), reference standard. Retention of time: 28.2 
min. 
 
 
Figure 68. Chromatogram of 11 peptide released from CDEX70-3-pyrrol-O-11 peptide. Retention of 
time: 27.5 min. Other peaks might be new compounds of side reactions. 
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Figure 69. Semi-log representation of the half-life of the conjugate CDEX70-3-pyrrol-O-11 peptide. 
4.5 In vivo efficacy experiment of CDEX70-3-pyrrol-O-11 
peptide study in mice eye 
All the mice were euthanized after 30 days post injection. The eyes were collected and the 
surface of vessels in the retina was calculated. Figure 70 shows a bar graph of the mean 
area of CNV in µm2 after two weeks after the laser treatment. There is a difference between 
the vehicle and the CDEX70-3-pyrrol-O-11 peptide, but according to the statistics there 
was not difference between vehicle vs free peptide and free peptide vs CDEX70-3-pyrrol-
O-11 peptide. As a preliminary experiment, the NPC shows a slightly improve in 
comparison with the free 11 peptide. This will require further experiments to achieve a 
solid result which shows a significance efficacy improve of CDEX70-3-pyrrol-O-11 
peptide vs free 11 peptide. 
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Figure 70. Bars representation of the mean area of CNV in the retina of mice eyes at 14 days after the 
laser treatment. The statistical analysis (one way ANOVA) has shown that there is a difference between 
vehicle vs CDEX70-3-pyrrol-O- adipic-11 peptide but not in the other two cases. (P value: 0.0012; P <0.05). 
(336 stands for 11 peptide). 
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Sustained intraocular drug delivery for posterior disease is an urgent need in ophthalmology 
[324]. Both increased lifespan and improved neonatology have increased devastating 
neovascular diseases in the very elderly and also the very youngest and smallest in 
humanity, as with exudative AMD and ROP [101, 325]. Diabetes, also with increasing 
incidence, leads to similar neovascular disease [58, 326], while glaucoma and posterior 
inflammation take an enormous toll, adding to the worldwide suffering from blindness 
[327]. Drug exposure to the relevant intraocular and choroidal tissues is a challenging 
problem as these are not readily accessed from the circulation or through eye drops. Both 
protein agents and especially small molecules, given via IVT injection, exit the eye rapidly, 
with each repeated injection taking a great toll on this fragile organ, in already very 
burdened patients [199, 207, 210, 211, 216]. Making a single IVT injection last for several 
months is thus a major goal in visual science[328]. Recent studies find that microparticles 
induce a strong and damaging foreign body reaction in primate eyes [283], and that 
A novel nanoparticle-based system for sustained intravitreal drug delivery 
130 
intraocular tissues are exceptionally sensitive to even low amounts of endotoxin [329]. 
These observations place additional hurdles in the developmental paths microparticles and 
liposome or micellar carriers, the latter being difficult to free of endotoxin and both difficult 
to sterilize [330]. 
Nanotechnology presents the new alternative for posterior delivery of drugs and genes, to 
reduce injection frequency, improve compliance and patient outcome, and includes a 
variety of devices and materials to enhance access [331]. MP and NP, comprising liposome 
or micellar structures, have also been utilized, including for gene therapy [332]. Several 
cases have described new prolonged drug delivery systems as a thermosensitive gel as drug 
delivery system using a polymer called poly(ethylene glycol)-poly(serinol hexamethylene 
urethane) (ESHU), which turns from sol to gel at 37 degrees and releasing bevacizumab in 
17 weeks [333]. In this formulation the particle size was impossible to control, driving it to 
the formation of aggregates and giving as a result large particles that could trigger 
inflammation. 
Here we defined a sterile-filterable, cationic NP system for sustained IVT residence, where 
diameter <100 nm makes foreign body response unlikely. No signs of inflammation were 
observed in the eyes of any of our test animals. 
Our strategy was the design of a conjugated dextran nanoparticle, CDEX (condensed 
dextran) formed from dextran polymer (Mw: 70,000 g/mol). It was chosen because of its 
extensive use in parenteral administrations as plasma expander and reducing blood 
viscosity and its use for ophthalmic drugs in the current medicine [334-337]and its property 
of excretion through the kidney. As condensing agent, it is possible to use fatty acids [338, 
339] or cholesterol. Using cholesterol chloroformate as condensing agent provides dextran 
the capacity of solubility in organic solvents, forcing the dextran polymer to form compact 
nanoparticles and enables the transport of hydrophilic drug molecules. CDEX takes on a 
conformation leaving inside the hydrophobic domain core with the property of loading 
small lipophilic drug on its core (without exceeding 10 –100 µg/mg), such as brimonidine, 
sirolimus, doxorubicin, or taxanes. Kinetic release studies are necessary to support this 
application. The outside surface of the nanoparticle facing the aqueous environment has 
365 glycosyl monomers sites to potentially carry hydrophilic drugs as peptides [316, 340]. 
Approximately half of 125 activated p-nP carbonates were pyrrolidine-PEG-peptide linked 
in our rabbit eye experiments, the remainder being discharged with amino-PEG. 
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Alternatively, in a similar case, it should have been possible to replace the 60-65 PEG-
amine groups with a pyrrolidin-3-ol ester of any carboxylated drug. More than 100 such 
prodrug molecules could be simultaneously appended with more intense charging. Other 
alternatives are anti-VEGF proteins. These can likely be attached at 1-3 moles per NPC 
through disulfide bonds with cysteine peptides where intraocular glutathione drives release, 
or via esters bridging protein-SH and NPC cysteines through bifunctional linkers, related 
to those discussed here. Another option is to link small-molecule carboxylated drugs as 
diclofenac, methotrexate and peptides directly or, preferably, using amine-ester bridges, 
such as those we have characterized. Adherence to IVT HA, without use of charge 
interactions, has also been recently employed, attempting to prolong the IVT residence of 
anti-VEGF proteins. Fusion of an anti-VEGF Fab fragment and 97-amino-acid LINK 
domain of a hyaladherin protein (TSG-6) gave 30-fold higher IVT Fab fusion protein at 30 
days, post-injection IVT in rabbits, compared with ranibizumab at 21 days [341]. Possible 
liabilities include a novel epitope at the fusion site, and the LINK region affecting CNS 
function of the same protein [342]. 
In our approach, NPC adherence relies only on multiple weak charge associations with HA, 
without resorting to novel recombinant protein fusions. The advantages of the NP are its 
solubility in aqueous solution, its size of 38-58 nm and the transparency. These features 
avoid the risk of their precipitation in the vitreous, the small size prevents the attack by 
macrophages and the transparency avoids opacity inside the eye. 
Manufacturing lipid NP is problematic because of their high affinity for endotoxin [330], 
inserted in their structure, and the finding that tissue-contacting vitreous is exceptionally 
sensitive to endotoxin [329]. Cationic particles, as described here, also attract anionic 
endotoxin micelles but, without surface lipid, the latter can be removed by immobilized 
poly-histidine [343], when needed. 
Our first specific aim was to prolong NP residence in the vitreous through poly-cationic 
interaction of carriers with poly-anionic vitreal components. Using L-Arg makes a safer 
cationic NP due the capacity of cells to detoxify L-Arg through the presence in the retina 
of type 2 enzyme of peptidyl arginine deiminases (PAD), which converts them into 
citrulline [344-346]. The slow diffusion of the particles increases the time of enzymatic 
detoxification [316]. We have synthesized two different (without bioactivity) anchor 
peptides with five amino acid sequences each and a small PEG chain of 8 units followed 
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by a pyrrolidine group. To reduce the immunogenicity in the in vivo experiment, the 
sequences were mimicked from three proteins which are naturally present in the vitreous. 
The PEDF protein (residues 66-70) [133] for the two arginine peptide and Hsp20 chaperone 
protein and the type A α-Crystallin protein (residues 121-125) [347] for the three arginine 
peptide, also in both peptides, there is tyrosine to identify and quantify the amount of 
peptide per particle. The success in the high controlled conjugation of peptides per NP 
through a carbamate bond lies on two factors:  
1) The p-nPCOCl activation which has a higher coupling yield than N,N-
Carbonyldiimidazole (CDI) [316] due to the high sensitivity of CDI to atmospheric 
moisture, been affected even in unopened containers [348]. With these new conditions, we 
have typically activated 150 hydroxyl groups of the NP, with certainly of quantification, 
and the ability to confirm complete discharge of all p-nP groups.  
2) Modification of the linker by secondary amines (pyrrolidine) that are more 
reactive to conjugate compounds than primary amines, reaching a difference of 50% of 
conjugates. This observation is corroborated with the conjugation of the DNP ester 
compounds (Table VI). 
Controlling the amount of base is crucial for the conjugation process: large amount of this 
reagent reacts with tyrosine changing its maximum absorbance, and thus to its structure a 
possibly to its safety and efficacy effects (data not shown). Thus, we conclude that the 
unexpected reactivity here arises from a favorable reaction of 3-substitued pyrrolidines 
(carboxyl or hydroxyl) with p-nP mixed carbonates. 
If it is desired to have an exceptionally stable ester prodrug such as was found here in the 
case of (trans) 4-aminocyclohexanol, (half-life near 80 days) its attachment would be 
hampered by the low direct yield it displayed in CDEX carbamate formation. It would 
probably be necessary to first cap the cyclohexylamine group with a pyrrolidyl group to 
affect simultaneously both a good yield and maximal prodrug stability. 
We have used two different techniques to quantify the amount of peptides per CDEX, BCA 
(a protein quantification assay based on colorimetry) and UV, which quantifies the amino-
acid tyrosine. Tyr is present in both peptides. With the two quantification methods, we have 
similar values of peptides per CDEX, more than 60. The observed difference could be due 
to the fact that the peptides are in the threshold to be quantified by BCA but the CDEX 
particle might affect the background when measured by UV. As an alternative 
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quantification method we propose to use in the future the nitration reaction of Tyr by 
tetranitromethane, as described by Bakhoj and Heegaard in 1999 [349]. This will move the 
Tyr absorbance to a longer wavelength (NO2-Tyr 360-400 nm), far from the confounding 
light scattering of the NPs. We have demonstrated that p-nPCOCl activation pathway 
increases the chances of conjugating more peptides than the CDI activation pathway [316]. 
Most importantly, the active intermediate can be isolated. Moreover, the p-nP charge levels 
can be evaluated in real time to keep the synthesis well controlled and reproducible. 
As in vivo model, we selected the rabbit eye due to the similarities with the human eye and 
because there are not significant differences in pharmacokinetics between the human and 
rabbit vitreous. [277, 350]. As a major improvement, we have used as cyanine7 (Cy7) dye 
instead of the rhodamine (Rh), as in the Li et al. publication. The advantages of using Cy7 
instead of Rh are that 1) Cy7 is 60 times more sensitive than Rh and 2) its maximum 
wavelength is in the long visible spectrum (745 nm) while the Rh maximum is 540 nm 
[351]. With this wavelength is highly improbable that a signal overlap occurs between the 
probe and the tyrosine (ʎ = 275 nm) during the experiment. With Rh, fluorescence detection 
must be accomplished through the pupil, requiring specialized equipment and eye 
immobilization. We succeed in measuring Cy7 fluorescence in a simple IVIS instrument 
designed for luminescence studies in rodents. This rapidly quantified 800 nm emission 
through the sclera and lid, in freely moving eyes of mildly anesthetized young rabbits. A 
recent study used Cy7 injected in the hearts of rabbits, which allowed to track the 
distribution of the dye ex vivo using a chamber very similar to the IVIS instrument. The 
same dye was also used to track bone-targeted NP in mice using the IVIS instrument. [352, 
353]. Regardless of the type of particle used for intraocular delivery, we have demonstrated 
that Cy7 labeling enables simplified time-residence measurement in eyes of small- to 
medium-sized animals, which should itself be a significant contribution to imaging in 
ophthalmology. 
We might preformulate the NPC with Healon [182] to increase their residence in the 
vitreous of patients who have a lack of HA due to their age or after being operated of 
vitrectomy. We should test the residence of this mixture in a rabbit vitrectomy model. 
Our second aim was the design of the amino ester bridge, as used in the peptide 11. To 
characterize a range of useful bridged esters, we selected the amino alcohol compounds for 
the left side of the molecule. We expanded on a report from the US Environment Protection 
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Agency (EPA) (2006)[321] where they studied the ester hydrolysis in unbuffered water of 
varied organic esters. They observed that the rate of hydrolysis is related to the nature of 
the hydroxyl group used to generate the ester bond (primary, secondary or tertiary). For the 
right side of the molecule, we selected glutaryl and adipoyl according to the description of 
how the length of the alkyl chains affect ester stability [354]. 
The synthesis of complex esters presented many challenges, since esters are energetically 
uphill from their component carboxylic acids and alcohols. They are also highly reactive 
dehydrating agents, which are not readily applicable to peptides or carbohydrate polymers. 
Phase transfer reaction was a successful reaction to get the amino ester prodrugs: we did 
not reach the same range of yields as other authors (up to 80%) [355], probably due to 
solvent replacement. Moreover, our potassium compounds precipitated in N,N-
dimethylformamide (DMF), possibly due the nature of the mixed solvent we used which 
requires an optimization of conditions. On the other hand, with the transesterification 
reaction, it was difficult to obtain good yields of ester product. It is critical for the product 
to eliminate the MeOH generated during the reaction. The presence of MeOH reacts with 
the ester product giving the starting material. Low yields were reached with secondary 
alcohols due to their low reactivity on this type of reaction [356-359]. 
Ester hydrolysis rate studies of the Boc-N-R-O-spacer-aa-O-tbut cmpd have shown that the 
nature of the hydroxyl groups affects the speed of ester hydrolysis, being the speed of 
degradation secondary alcohols >primary alcohols[321]. The molecule conformation 
affects the speed of hydrolysis, especially when bulky substituents such as Boc or 
polysaccharide are present. The axial conformation (19) reduces the steric influence of the 
electron density on the oxygen and thus, a reduction in the non-bonded repulsions which 
increases the probability of the nucleophiles attacking the ester, when compared to the same 
compound with the equatorial conformation (15) in which the ester is more protected [360]. 
The same reasoning can be applied when we compare a five-member rings to a six-member 
rings cmpd, (6 vs 7; 17 vs 16 and 18 vs 16). The proximity of the high electron density of 
the Boc group reduces the steric influence on the ester bond. As appears the EPA 
study[321]. 
The length of the alkyl chain affects the rate of hydrolysis due to the steric effect [354], but 
an ester breakdown could accelerate it, due to internal cyclization reactions where the 
amide or N-methyl-amide nitrogen of the amino acids (Gly or Sar) attack the carbonyl 
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group of the ester, displacing the amino-alcohol. Increasing the distance between the amine 
of the amino acid and the carbonyl group is critical to improve the probability to avoid side 
reactions [323]. The ester hydrolysis of the model compound corroborated all our findings, 
the proximity of high electron density of the Boc group and the elongation of the amine 
from the ester reduce the speed of ester hydrolysis. Moreover, the flat aromatic 
conformation of the pyrrolidine reduces the possibility of water reaching the ester bond and 
causing the cleavage [361]. In the future, to reduce the ester hydrolysis by external 
conditions, we will have to carefully select the conformation of the rings, the length of the 
alkyl chains and the use of methylate amines in the amino acids. We propose to study this 
with different alkyl chains to understand the relationship between the alkyl length chain 
and the speed of hydrolysis. The suberic (8 carbon) dicarboxylic acid may minimize cyclic 
side reactions as well. 
The conjugation of the free amine-DNP ester compounds has shown high of DNP/ NP when 
a secondary amine (pyrrolidine) reacts (data not shown). There is not literature about 
carbamoylation reactions with p-nP and the nature of the amines. Release studies from DNP 
have shown the real effect of amino-alcohols on the speed of hydrolysis without 
interference from cyclization side reactions [323] and the steric influence of the electron 
density [360]. 
Our third aim was to select a potent anti-angiogenic and anti-CNV peptide amenable to 
prodrug linkage, hoping to extend the duration of its IVT action. The active anti-angiogenic 
PEDF region is located in the 34-mer epitope, an anti-angiogenic 34-amino acid N-terminal 
peptide has been shortened to 18 residues[135], which it was truncated to 9 amino acids 
(P3-11), that retains anti-angiogenic activity (Figures 5, 71 and 72). 
 
 
A novel nanoparticle-based system for sustained intravitreal drug delivery 
136 
 
Figure 71. Novel modified peptides and new peptide sequences as exemplified by SEQ ID Nos: 1–13. 
The ED50 (50% effective dose), is the measure of anti-angiogenic potency obtained by quantitative assessment 
of apoptosis of activated human EC. Source: Henkin et al, 2017 [237]. 
 
Figure 72. ED50 in vitro experiment of the anti-angiogenic peptides. A. Selective killing of the ovarian 
cancer cells by SEQ ID N0:2. Ovarian cancer cells (ID-8, OVCAR-3 and SKOV-3 cell lines) normal ovarian 
epithelial cells (nOSE) and unstimulated mouse endothelial cells (mEC) were treated with increasing 
concentrations of SEQ ID N0:2 and survival was measured using a WST assay. B. Relative potency of 
peptides at inducing EC apoptosis. Human microvascular EC (HMVEC) were seeded on glass coverslips and 
grown in EGM, supplemented with defined growth factors and full serum (5%) to 80–90% confluence. The 
cells were trans-ferred overnight in the medium with 1% serum, w/o growth factors. VEGF (10 ng/mL) was 
added to induce pro-angiogenic function/survival. Peptides were added at indicated concentrations. After 48 
h the cells were fixed in 1% buffered paraformaldehyde and apoptosis detected by in situ TUNEL. Apoptotic 
cells were quantified in ≈10x fields per condition and apoptotic fraction (apoptotic/total cells) calculated for 
each condition. Apoptosis induced in EC by indicated peptides (SEQ ID N0:6, 8, 10, and 11) is compared to 
SEQ ID N0:4. Source: Henkin et al, 2017[237]. 
After the initial screening, Peptide Seq ID No: 1 was tested ex vivo in a choroidal sprouting 
assay. Results showed an antiangiogenic choroidal activity (Figure 73). In vivo experiment 
of the Laser-induced CNV in mice of the most potent peptides, adipic-SEQ No. 10 (10 
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peptide) and adipic-SEQ No. 11 (11 peptide), were showed a significant anti-angiogenic 
effect of choroidal vascularization (Figure 74). 
 
Figure 73. Inhibition of choroidal angiogenesis by conjugable P3-11. Choroidal explants from Actin-GFP 
mice are plated in Matrigel and maintained with or without VEGF for additional capillary spouting. Peptide 
Glt-Sar-P3-11 was added in the presence of VEGF. Fluorescence images were taken and sprouting area 
measured after 6 days using Elements software (Nikon). Statistical significance was determined by pairwise 
comparisons with two-tailed Student’s t-test. P<0.05 was set as significant. Source: Henkin lab. Northwestern 
University (manuscript in preparation). 
 
Figure 74. In vivo experiment of the Laser-induced CNV in mice of the 10 peptide (named 335) and 11 
peptide (named 336). The statistical analysis (one way ANOVA) shows a significant difference between 10 
peptide vs control and 11 peptide vs control. (P<0.001). Source: Henkin lab and Sheibani lab. University of 
Wisconsin-Madison (manuscript in preparation). 
Due to the potency and polarity of the 10 peptide, was administrated at 10 mM as eye drops 
in mice using the Laser-induced CNV model. Peptide was administered every 2 days, 18 
days before the laser-induced lesion, skipping the weekends. Results showed statistical 
difference with the control Figure 75. In rabbits, the amount of peptide which reached the 
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posterior area was not significant due to the difference of size of the eye and the thickness 
of tissues. This peptide might not be useful for the posterior area of the eye but could have 
applications in the front of the eye (manuscript in preparation). 
 
Figure 75. In vivo experiment of the Laser-induced CNV in mice of the 10 peptide (named 335). A: 
Administration of 335 10 mM by eye drops. The statistical analysis (one way ANOVA) shows a significant 
difference between 10 peptide vs control. (P<0.1). B: Administration of 335 2 mM by intravitreal injection. 
The statistical analysis (one way ANOVA) shows a significant difference between 10 peptide vs control. 
(P<0.1). Source: Henkin lab and Sheibani lab. University of Wisconsin-Madison (manuscript in preparation). 
 
11 peptide (also known as 336) is a potent antiangiogenic (ED50 = 3 nM) and containins 2 
Arg residues, that might allow it to simultaneously be an anchor and a prodrug. This peptide 
also contains N-terminal adipic half amide intended for ester prodrug formation, and a 
modified compensating internal sequence change, where an Asp-3 from PEDF is 
exchanged to asparagine. It was potent by IVT injection in blocking laser induced mouse 
CNV, when injected 2-4 days before laser induction. This requires a slow hydrolysis ester 
prodrug of 11 peptide attached to CDEX. 
Since the deprotection of the Boc-amine (cmpd 6, intended 11 peptide prodrug precursor) 
was faster than the tert-butyl-carboxyl ester in the de-blocking reaction (due to the second-
order dependence upon the acid concentration[362], we had to redesign the synthesis 
pathway achieving the desired compound in a one-step synthesis pathway. During the 
reaction we used and excess of the double diacyl chloride compound to reduce the 
probability of producing the bis-ester. For the future, we will adjust the number of 
equivalents to increase the yield. The conjugation of the peptide to CDEX following the 
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same procedure as the previous compounds yielded the targeted number of conjugates per 
NP (57 peptides per NPC). 
The half-life of hydrolysis of the ester of CDEX70-3-pyrrol-O-11 (28 days) matches the 
half-life of hydrolysis of Boc-3-pyrrol-O-adp-Gly-O-tbut. The proximity of the nanocarrier 
to the ester had the same function as the Boc but with different behavior. Meanwhile the 
Boc group repelled the proximity of the water to the ester bond due to its hydrophobicity. 
Due to its size, CDEX would only modestly protect the ester bond from attack by water. 
Another reason is that the peptide has the amino acid sarcosine instead the amino acid 
glycine as the previous study. Sarcosine is a methylated glycine on its N terminus, and it 
should be less internally reactive to cyclization releasing the 11 peptide sooner than 
expected, as described by Yano in 2000 [363]. 
Preliminary results have shown only a mild improvement in terms of efficacy when using 
the NPC vs the free peptide in an in vivo model of Laser-induced CNV (Figure 70). The 
release of the free peptide was longer than expected, due to the ionic bonds between the 
Arg and HA. This will require further experiments spacing the time between the IVT 
injection and the laser induction to clearly demonstrate the efficacy of NPC. These results 
are consistent with the prolonged protection by CDEX70-3-pyrrol-O-11 peptide given at 
day-14 before laser induction, against CNV, compared with no treatment the difference 
being statistically significant. The free peptide given at day-14 still shows a tendency to be 
protective, although it is not statistically significant. We are starting new experiments with 
injections at day-28, in which we expect that all the free peptide will be eliminated at the 
time of the laser induction but our NPC will still be pharmacologically active. 
Here we have described some key factors, which increase ester hydrolysis rates. Even, on 
these circumstances, we got two ester prodrugs with different prolonged hydrolysis rates. 
After we have shown the variables that, we have to control to get high yields of conjugation 
with the NP. The efficacy results were not conclusive due the space of time between the 
injection and the laser induction. 
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Conclusions 
1. 60 pyrrolidine-PEG-peptides with 2 L-arginines and 3 L-arginines per nanoparticle were 
loaded due to the high controlled conjugation factors: 1. the activation of the nanoparticles 
with p-nitrophenyl chloroformate and 2. using pyrrolidine as a reactive amine in the 
carbamoylation reaction. Preload of p-nitrophenyl suggests that 50-80 anchor peptides 
along with 2-50 ester prodrug aminoalkoxyesters is an attainable target. 
2. The presence of positive charges (L-arginines) and the increase of zeta potential decrease 
the rate of diffusion of the conjugate nanoparticles, and they reduce their rate of intravitreal 
elimination. The half-life of residence has been related to zeta potentials (range +3.9 to 
+6.3 mV), results that suggest that reproducible half-life of 1-3 weeks is attainable with 2 
and 3 L-arginines peptide conjugates at 60 peptides per nanoparticle load. 
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3. Two arginines peptides conjugated to nanoparticles at 12 mg/mL have not shown any 
type of inflammation response in rabbit eyes. The slow diffusion of the particles not 
exceeded the enzymatic detoxification capacity. 
4. Three amine ester compounds have been described conjugated to condensed dextran 
nanoparticles with a half-life between 40 and 81 days. The distance of the amine group to 
the ester bond has a critical effect on the prevention of side reactions cyclization. Suberic 
peptides may improve this (9 membered rings form slowly). 
5. A pyrrolidin-ester peptide prodrug conjugated to a nanoparticle has been designed with 
a half-life of 28 days. Efficacy studies in the laser-induced CNV model have shown 
promising preliminary results, although it has not found differences between the free 
peptide and the nanoparticle, due to the short space of time between the administration of 
the compounds and the laser-induced lesion. 
Conclusiones 
1. Se han conjugado 60 pirrolidin-PEG-péptidos con 2 L-argininas y 3 L-argininas por 
nanopartícula debido al control de los factores de la reacción de conjugación: 1. la 
activación de las nanopartículas con cloroformiato de p-nitrofenilo y 2. el uso de pirrolidina 
como amina reactiva en la reacción de carbamilación. La carga de p-nitrofenilo sugiere que 
50-80 péptidos de anclaje junto con 2-50 profármacos de amino-éster es un objetivo 
alcanzable. 
2. La presencia de cargas positivas (L-argininas) y el aumento del potencial zeta disminuyen 
la velocidad de difusión de las nanopartículas conjugadas, reduciendo a su vez la velocidad 
de eliminación intravítrea. Se ha relacionado la vida media de residencia con los potenciales 
zeta (rango +3.9 a +6.3 mV), resultados que sugieren que la vida media de 1 a 3 semanas 
es alcanzable con péptidos de 2 y 3 L-argininas conjugando 60 péptidos por nanopartícula. 
3. Los péptidos de dos argininas conjugados a nanopartículas a una concentración de 12 
mg/mL no han mostrado ningún tipo de respuesta inflamatoria en ojo de conejo, debido a 
que la lenta difusión de las partículas no excede la capacidad desintoxicación enzimática. 
4. Se han descrito tres compuestos amino-estér conjugados a nanopartículas de dextrano 
condensado que poseen una vida media entre 40 y 81 días. La distancia del grupo amina al 
enlace éster tiene un efecto crítico para la prevención de reacciones secundarias de 
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ciclación. Péptidos subéricos podrían mejorar esto (la velocidad de formación de anillos de 
9 miembros es muy lenta). 
5. Se ha diseñado un profármaco formado por un péptido de pirrolidín-éster conjugado a 
una nanopartícula con una vida media de 28 días. Los estudios preliminares de eficacia en 
el modelo CNV inducido por láser han mostrado unos resultados prometedores, aunque no 
han mostrado diferencia con el péptido libre debido al corto espacio de tiempo entre la 
administración de los compuestos y la inducción de la lesión ocular con el láser. 
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The IVT diffusion of the NP described here in rabbit eyes corroborates the results of Xu et 
al, 2013 [12] and Li et al, 2017 [316] in a different experimental system, and, importantly, 
without cell damage in a live animal, with intact circulation and eye drainage, rather than 
in isolated bovine eyes post slaughter. The presence of positive charges (arginines) and the 
increase of zeta potential, decrease the rate of diffusion of the NPC, reducing their rate of 
IVT elimination. We related the half-life of residence to zeta potentials (range +3.9 to +6.3 
mV), results suggesting that reproducible t1/2 of 1-3 weeks is attainable with 2R- and 3R-
peptides conjugates at 60 peptides/ NP load. This, combined with the previous results with 
Rh tagged NPC [316], suggests that the use of a 4R-peptide, available in 5-8 amino acid 
fragments of protamine 1, attached at similar loading, could yield a zeta potential in the 
range of +10 to +15 mV reaching a half-life of residence of 6-8 weeks. Pharmacokinetic, 
vitreous capacity and safety studies would be performance to assure the safety and efficacy 
of the 4R-NPC. 
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Here we concluded that doubling NPC zeta potential roughly increases ocular residence 
half-life by 2.5 to 3- fold in going from 2R to 3R conjugates. The original Rh-tagged NPC 
underwent doubling of zeta potential where the linked peptide went from 2-3 Arg, and 
doubled again when increasing from 3-4 Arg [316]. Thus, we extrapolate that a 4 Arg 
peptide, similarly loaded, would increase rabbit eye half-life to between 40-60 days. With 
an ester prodrug attached, intraocular cargo available at times after injection would decline 
both NPC lost from the eye and the ester lost by hydrolysis. Having largely succeeded in 
achieving our specific aims, we now wish to show the usefulness of their convergence in 
offering the promise of addressing an unmet medical need. Thus, we now extrapolate our 
results to a real world-situation concerning the current treatment of AMD, for which our 
finding may improve therapy. Lucentis (ranibizumab), approved and widely used for 
therapy of AMD, is a 50kDa Fab fragment which binds and neutralizes VEGF. Its typical 
IVT dose in affected elder eyes is 500 µg and it is typically injected at 4 to 6-week intervals. 
Given its half-life of 8 days the total available in the eye is expected to be 50 µg, 14 µg, 
and 2 µg at 4, 6 and 8 weeks post-injection, respectively. Not surprisingly, discussions with 
Genentech indicate they would be pleased to have a release system which maintains >4 µg 
at 90 days, or beyond. This would reduce the burden on patients significantly. 
We should vary some CDEX conditions to improve its capacity. 1. The cholesterol core 
percentage and the collesterollinkage to the sugar through carbamates instead carbonate 
bonds (eg: link N-Boc-amino-PEG3-amine to p-nP activated dextran, then add the 
cholesterol chloroformate to amine after Boc removal). 2. The dextran size (40 vs 70 kDa) 
to maximize the conjugation yield of peptides to CDEX. Moreover, we need to demonstrate 
carboxy drugs (eg: diclofenac) conjugation and release rates and show delivery as amino-
pyrrolidine ester on surface. Also, if half the surface Arg (say 90 Arg) are loaded to bind 
phosphate groups of nucleic acid, the genetic material should slowly be released when 
phosphates are replaced by HA carboxylates as the the NPC slowly spread out in vitreous. 
Arg deiminases will release even more as these reach the cells on the inner eye surface 
[313] [364] [345]. As another strategy, we propose to study lipophilic drugs imbibed in the 
core (eg: rapamycin, brimonidine, doxorubicin). 
We have defined small amino alcohol bridges where the amine links stably to polycationic 
CDEX NPC, the OH group is esterified to ordinary COOH groups. Two of these bridges 
are especially useful and we find they respectively give 40-day and 80-day spontaneous 
ester hydrolysis half-lives respectively under physiologic conditions. 
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Our experience suggests that each additional L-Arg residue (after 2 Arg) per small 
conjugated peptide, doubles the zeta potential at similar anchor-peptide loading. Also, we 
observed that doubling zeta potential increases IVT residence half-life by 2.5-3 fold. We 
thus believe that using a 4 Arg peptide at loads of 50-60 peptides per NPC, we will achieve 
rabbit IVT residence half-lives of 40-60 days. 
As we have two ester bridges with different slow hydrolysis rates (ester made with 
pyrrolidin-ol: t1/2 = 40 days and ester made with t,4-aminocyclohexanol t1/2 = 80 days) we 
can prepare NPC with varied loads of 4R anchor peptide aiming for two different zeta 
potentials, one in the range of +10- +12 mV and another of the range of +12- +15 mV). 
With these values, we anticipate approximately t1/2 residences of 40 days for the first one 
and 60 days for the second one. Assuming 600 µg of ranibizumab is injected in 1:1 mass 
ratio with NPC, the rate of release of the peptide is approximately 1 µg per day, after 90 
days. The dose will be 1 µg/eye but assuming the accumulation of drug from the previous 
days, the total IVT content will be on day 90, 8 µg/eye. Figure 76 shows the formulas that 
we have used to make these calculations. In Table XI, appears the calculation based on a 
first order decay of the release rate of ranibizumab esterified to our carriers, as a function 
of time post IVT injection. The calculations were made for two residence half-lives. 
 
Figure 76. This formula describes monoexponential decay in monocompartimental model. We 
calculated first order loss of Fab fragment by NPC IVT-exit diffusion or by ester hydrolysis. 
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Table XI Amount of Fab per day per eye released from the NPC 
 Particle 
residence 
t1/2 
40 days 40 days 60 days 60 days 
Ester 
hydrolysis 
t1/2 
40 days 80 days 40 days 80 days 
Daily loss 
factor, k 0.017 0.0087 0.017 0.0087 
Fraction 
remaining 
on 
Day 30 0.35 (210 µg) 0.45 (270 µg) 0.15 (90 µg) 0.19 (114 µg) 
Day 70   0.132 (79 µg) 0.238 (143 µg) 
Day 90   0.08 (47 µg) 0.166 (99 µg) 
Day 120 0.017 (10 µg) 0.047 (28 µg) 0.033 (20 µg) 0.09 (54 µg) 
µg/day/eye 
day 
Day 30 3.6 2.3 1.5 1.0 
Day 70 1.4 1.2 1.34 1.24 
Day 90   0.8 0.86 
Day 120 0.17 0.24 0.34 0.47 
Underlined: k value. 
Liquefaction of the vitreous is a regular process that increases with the age. After the 60’s 
the production of liquid vitreous reaches a 50% affecting the diffusion of the NP [177]. As 
in our study we used young rabbits, one might think that the residence of the NP cannot be 
extrapolated to elderly people. However, rabbit eye NPC capacity is expected to be at least 
several-fold lower than human eyes, which have been estimated to contain 6-8 times greater 
HA content per mL. The residence of the NP extrapolated to human vitreous could show a 
slower speed of diffusion. Also, according to Denlinger and Balazs[178], while the 
liquefaction of the vitreous, the amount of hyaluronic acid increases after the 70’s and this 
could partially substitute the lack of viscosity conjugating more peptides with arginines to 
create ionic bonds with these new poly-anion molecules. This can be best addressed by 
comparing NPC diffusion directly when added to freshly obtained rabbit vitreous, with 
human samples from enucleation surgery or cadavers. 
Our results on the 2R-NPC samples have shown a correlation between the fluorescence 
signal and concentration with 3 and 6 mg/mL samples. This proportionality was remained 
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during the entire study until the experiment reached after the third week, where the signal 
value of 3 and 6 mg/mL samples were the same as 0 mg/mL, background.  
By contrast, the sample of 12 mg/mL (200 µg of NPC) was rapidly lost, even the time 0 
measurement was lower than the measured value with 3 mg/mL. This suggests that the 
loaded positive charges on the surface of the NPC, exceeded the retention capacity of the 
hyaluronic acid that when the volume of the vitreous is 1.5-2 mL vitreous. Extrapolating to 
the human eye, which has a vitreous volume of 4 mL, the same dose of 2R-NPC should be 
effectively even we could increase the dose, the amount of 2R conjugate peptides or use 
3R and 4R peptides. With this particular behavior, the histological studies have not shown 
any damage in tissues even in the case of the overloaded eyes. Thus, we conclude that cell 
capacity for L-Arg detoxification is adequate even when diffusion is relatively fast. 
In achieving the specific aims of this project, we generated some important and promising 
contributions to science and medicine. We have identified novel PEDF peptides active vs. 
CNV, by a non-VEGF mechanism. These may well augment current anti-VEGF therapy, 
which is less than ideal and may be useful in treating ROP where current Avastin injections 
are of concern because of their lasting activity systemically in infants. We have developed 
a promising long-term delivery system for the posterior eye, and systematically discovered 
a route to ester prodrugs, defining a predictable and useful range of half-lives. We 
developed a method of quantitatively imaging Cy7-tagged carriers inside the vitreous, 
using commonly available IVIS instruments. In next steps we hope to collaborate with 
pharmaceutical partners in the ocular field, in an attempt to improve their current drug 
delivery by IVT injection. 
We also identified a small neutral PEDF peptide (10 peptide) which shows promise in 
treating anterior neovascular eye disease/corneal disease bi simple eye drop administration. 
Many such conditions (eg; keratitis) cause significant blindness. 
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S.1 Boc-N-R-O-ahx-DNP compounds 
S.1.1 Synthesis of intermediates and final products 
Synthesis of Methyl 5-oxo-5-[(tert-butoxycarbonylmethyl)amino]valerate (1). Amide 
of sarcosine-t-butyl ester with glutaric acid monomethyl ester. 
0.1 mEq of sarcosine tert-butyl ester hydrochloride was dissolved in DCM with 0.2 mEq 
of TEA under stirring at RT. Then 0.1 mEq of glutaric acid monomethyl ester chloride was 
dissolved in DCM and this solution was added dropwise on the first solution. After 30 min 
the reaction was complete. It was followed by TLC (DCM:MeOH; 9:1). The crude product 
was purified by ColCh with a mixture of DCM:MeOH. Final product: meO-glt-Sar-O-tbut. 
Synthesis of Potassium 5-Oxo-5-(tert-butoxycarbonylamino)valerate (2). Potassium 
salt of glutaric acid half amide with sarcosine-t-butyl ester. 
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0.1 mEq of cmpd 1 was dissolved in a mixture of MeOH:water, 9:1. To this solution, 0.1 
mEq of KOH was added. The reaction was stirred at RT. After 1 h the reaction was 
complete. It was followed (Boc UV absorbance) by TLC (DCM:MeOH; 9:1). The solution 
was dried under vacuum, product in water was extracted in a separation funnel 
(ether/water), and aqueous phase freeze-dried to give the potassium salt. Final product: KO-
glt-Sar-O-tbut. 
Synthesis of Methyl 6-oxo-6-[(tert-butoxycarbonylmethyl)amino]hexanoate (3). 
Amide of sarcosine-t-butyl ester with adipic acid monomethyl ester. 
0.1 mEq of glycine tert-butyl ester hydrochloride was dissolved in DCM with 0.2 mEq of 
TEA under stirring at RT. Then 0.1 mEq of methyl adipoyl acid monomethyl ester chloride 
was dissolved in DCM and this solution was added dropwise to the first solution. After 30 
min the reaction was done. It was followed by TLC (DCM:MeOH; 9:1). The crude product 
methyl ester was purified by ColCh with a mixture of DCM:MeOH. Final product: meO-
adp-Gly-O-tbut. 
Synthesis of Potassium 6-Oxo-6-(tert-butoxycarbonylamino)hexanoate (4). Potassium 
salt of adipic acid half amide with sarcosine-t-butyl ester. 
0.1 mEq of cmpd 3 was dissolved in a mixture of MeOH:water 9:1. To this solution, 0.1 
mEq of KOH was added. The reaction was stirred at RT. After 1 h the reaction was 
complete. It was followed (Boc UV absorbance) by TLC (DCM:MeOH; 9:1). The solution 
was dried under vacuum, product in water was extracted in a separation funnel 
(ether/water), and aqueous phase freeze-dried to give the potassium salt. Final product: KO-
adp-Gly-O-tbut. 
Synthesis of Tert-butyl {2-[(4-hydroxypentanoyl)amino]ethyl}carbamate (8). 3-
hydroxypentanoic acid amide with mono-Boc-ethylenediamine (a secondary alcohol to 
which a chromophoric acid can later be attached). 
To synthesize a secondary amino alcohol, we have followed the method described by 
Chalid et al (2011) with some modifications. 0.1 mEq of N-Boc-ethylenediamine was 
dissolved in 5 mL of methanol in a round bottom flask. Then 0.1 mEq of γ-Valerolactone 
(Figure S-1) was added to the reaction. The reaction was stirred at RT, and followed by 
TLC (DCM:MeOH; 9:1). After 16 h the reaction was complete. The mixture was dried 
under vacuum and purify it by CC (DCM:MeOH). Final produc: Boc-NetN-val-secOH. 
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Figure S-1. Chemical structure of γ-Valerolactone. 
There were three compounds (below) for which we used the above alternative synthetic 
route to attach chromophoric carboxamides to aid in kinetic monitoring of ester hydrolysis, 
by HPLC. 
For example, cmpd 12 is a chromophoric sarcosine amide which can be amide bound to 
adipic or glutaric esters (left side) of N-blocked amino alcohols to enable facile observation 
of chromophore detachment following ester hydrolysis (Figure S-11). 
The synthesis pathway to achieve the chromophore-sarcosine compound (12) are the 
following: 
Synthesis of Tert butyl (2-[[(3-nitrophenyl)carbonyl]amino]ethyl)carbamate (9). 
Amide between 3-nitrobenzoic acid and mono-Boc-ethylenediamine. 
0.1 mEq of N-Boc-ethylenediamine was dissolved in DCM with 0.1 mEq of TEA under 
stirring at RT. Then 0.1 mEq of 3-Nitrobenzoyl chloride was dissolved in DCM and this 
solution was added dropwise on the first solution. After 30 min the reaction was complete. 
It was followed (nitrophenyl UV absorbance) by TLC (DCM:MeOH; 9:1). The crude 
product was purified by ColCh with a mixture of DCM:MeOH. Final product: Boc-NetN-
ph-NO2. 
Synthesis of N-(2-Aminoethyl)-3-nitrobenzamide (10). Removal of Boc group from (9). 
0.1 mEq of cmpd 9 was deblocked by dissolution in a mixture of TFA 20 % v/v in DCM at 
RT. After 17 h the reaction was complete. 20 volumes of toluene were added to the mixture 
and the sample was dried by rotary evaporation. The reaction was followed by TLC 
(DCM:MeOH; 9:1). Final product: NetN-ph-NO2. 
Synthesis of 2-[N-Methyl(1-tert-butoxyethenyl)amino]-1-[2-(m-nitrobenzoyl-amino) 
ethylamino]-1-ethanone (11). A chromophoric amide of Boc-Sarcosine. 
0.1 mEq of Boc-sarcosine was mixed with 0.2 mEq of TEA and an excess of isobutyl 
chloroformate in ACN under stirring at RT. On the other hand, after 15 min, 0.1 mEq of 
cmpd 10 was dissolved in ACN and add it dropwise to the reaction. After 30 min the 
reaction was complete. It was followed by TLC (DCM:MeOH; 9:1). The crude product was 
purified by ColCh with a mixture of DCM:MeOH. Final product: Boc-Sar-NetN-ph-NO2. 
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Synthesis of 2-(Methylamino)-1-[2-(m-nitrobenzoylamino)ethylamino]-1-ethanone 
(12). Removal of Boc group from (11). The chromophore-Sarcosine compound. 
0.1 mEq of cmpd 11 was dissolved in a mixture of TFA 20% v/v in DCM at RT. After 17 
h the reaction was complete. 20 volumes of toluene were added to the mixture and the 
sample was dried by rotary evaporation. The reaction was followed by TLC (DCM:MeOH; 
9:1). Final product: Sar-NetN-ph-NO2. (a chromophoric amide of sarcosine) 
Synthesis of Methyl 5-(N-methyl{2-[2-(p-nitrobenzoylamino)ethylamino]-2-
oxoethyl}amino)-5-oxovalerate (13). Amide of the cmpd 12 with glutaric acid 
monomethyl ester. 
0.1 mEq of cmpd 12 was mixed with 0.2 mEq of TEA in ACN under stirring at RT. Then, 
0.1 mEq of glutaric acid monomethyl ester chloride was dissolved in ACN and this solution 
was added dropwise on the first solution. After 30 min the reaction was complete. The 
reaction was followed by TLC (DCM: MeOH; 9:1). When the reaction was complete, the 
mixture was dried under vacuum and extracted with a mixture of water: DCM. The organic 
phase was collected and dried under vacuum. Final product: meO-glt-Sar-NetN-ph-NO2. 
S.1.2 Characterization of intermediates and final products 
Methyl 5-oxo-5-[(tert-butoxycarbonylmethyl)amino]valerate (1). 
Appearance: transparent oil. The molecular weight of the compound was 273.33 g/mol. 
The yield of the reaction was 100 % (Figure S-2). 
1H NMR (500 MHz, Chloroform-d) δ 4.16 (s, 1H), 3.64 (s, 2H), 3.12 (s, 2H), 2.90 (t, J = 
5.4 Hz, 1H), 2.35 (t, J = 5.5 Hz, 1H), 1.96 (p, J = 5.5 Hz, 1H), 1.43 (s, 5H). 
CH3
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Figure S-2. Chemical structure of methyl 5-[(2-tert-butoxy-2-oxoethyl)(methyl)amino]-5-
oxopentanoate (meO-glt-Sar-O-tbut). 
Potassium 5-Oxo-5-(tert-butoxycarbonylamino)valerate (2). 
Appearance: transparent-yellowish oil. The molecular weight of the compound was 297.39 
g/mol. The yield of the reaction was 96.9 % (Figure S-3). 
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1H NMR (500 MHz, DMSO-d6) δ 4.11 (s, 1H), 2.97 (s, 2H), 2.32 (t, J = 7.1 Hz, 1H), 2.27 
(t, J = 7.1 Hz, 1H), 2.02 (p, J = 7.1 Hz, 1H), 1.42 (s, 5H). 
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Figure S-3. Chemical structure of Potassium 5-Oxo-5-(tert-butoxycarbonylamino)valerate (KO-glt-Sar-
O-tbut). 
Methyl 6-oxo-6-[(tert-butoxycarbonylmethyl)amino]hexanoate (3). 
Appearance: transparent oil. The molecular weight of the compound was 273.33 g/mol. 
The yield of the reaction was 100 % (Figure S-4). 
1H NMR (500 MHz, Chloroform-d) δ 6.73 (s, 1H), 4.17 (s, 1H), 3.64 (s, 2H), 2.52 (t, J = 
8.0 Hz, 1H), 2.35 (t, J = 8.1 Hz, 1H), 1.77-1.67 (m, 1H), 1.61 (pd, J = 7.9, 1.1 Hz, 1H), 
1.43 (s, 5H). 
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Figure S-4. Chemical structure of methyl 6-[(2-tert-butoxy-2-oxoethyl)amino]-6-oxohexanoate (meO-
adp-Gly-O-tbut). 
Potassium 6-Oxo-6-(tert-butoxycarbonylamino)hexanoate (4). 
Appearance: transparent-yellowish oil. The molecular weight of the compound was 297.39 
g/mol. The yield of the reaction was 97 % (Figure S-5). 
1H NMR (500 MHz, DMSO-d6) δ 8.49 (s, 1H), 4.17 (s, 2H), 2.30-2.24 (m, 2H), 2.16-2.10 
(m, 1H), 2.13 (s, 1H), 1.56-1.45 (m, 4H), 1.42 (s, 9H). 
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Figure S-5: Chemical structure of potassium 6-Oxo-6-(tert-butoxycarbonylamino)hexanoate (KO-adp-
Gly-O-tbut). 
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tert-butyl {2-[(4-hydroxypentanoyl)amino]ethyl}carbamate (8). 
Appearance: transparent oil. The molecular weight of the compound was 260.33 g/mol. 
The yield of the reaction was 100 %. (Figure S-6). 
1H NMR (500 MHz, Chloroform-d) δ 6.16 (s, 1H), 5.05 (s, 1H), 4.13 (ddd, J = 12.3, 3.1, 
1.3 Hz, 1H), 3.92 (ddd, J = 12.3, 3.1, 1.3 Hz, 1H), 3.74 (dqd, J = 11.4, 6.8, 2.4 Hz, 1H), 
3.20 (td, J = 12.1, 3.1 Hz, 1H), 3.06 (td, J = 12.1, 3.1 Hz, 1H), 2.70 (td, J = 12.4, 4.0 Hz, 
1H), 2.15 (td, J = 12.5, 1.5 Hz, 1H), 1.97 (s, 1H), 1.88 (tdd, J = 12.6, 11.4, 4.1 Hz, 1H), 
1.70 (tdd, J = 12.5, 2.4, 1.4 Hz, 1H), 1.44 (s, 9H), 1.16 (d, J = 6.9 Hz, 3H). 
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Figure S-6. Chemical structure of tert-butyl {2-[(4-hydroxypentanoyl)amino]ethyl}carbamate (Boc-
NetN-val-secOH). 
tert-butyl (2-{[(3-nitrophenyl)carbonyl]amino}ethyl)carbamate (9). 
Appearance: yellow oil. The molecular weight of the compound was 309.32 g/mol. The 
yield of the reaction was 100 %. (Figure S-7). 
1H NMR (500 MHz, Chloroform-d) δ 8.60 (t, J = 2.0 Hz, 1H), 8.48 (ddt, J = 20.7, 7.5, 1.9 
Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 6.75 (s, 1H), 5.12 (s, 1H), 3.74 (t, J = 4.3 Hz, 2H), 3.58 
(t, J = 4.3 Hz, 2H), 1.44 (s, 9H). 
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Figure S-7. Chemical structure of tert-butyl (2-{[(3-nitrophenyl)carbonyl]amino}ethyl)carbamate 
(Boc-NetN-ph-NO2). 
N-(2-aminoethyl)-3-nitrobenzamide (10). 
Appearance: yellow oil. The molecular weight of the compound was 209.2 g/mol. The yield 
of the reaction was 100 %. (Figure S-8). 
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1H NMR (500 MHz, Deuterium Oxide) δ 8.46 (dp, J = 3.8, 2.0 Hz, 2H), 8.30 (dt, J = 7.5, 
2.0 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 6.75 (s, 1H), 4.70 (s, 2H), 3.94 (t, J = 5.0 Hz, 2H), 
3.26 (t, J = 5.0 Hz, 2H). 
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Figure S-8. Chemical structure of N-(2-aminoethyl)-3-nitrobenzamide (NetN-ph-NO2). 
2-[N-Methyl(1-tert-butoxyethenyl)amino]-1-[2-(m-nitrobenzoylamino)ethylamino]-1-
ethanone (11). 
Appearance: yellow powder. The molecular weight of the compound was 378.43 g/mol. 
The yield of the reaction was 100 %. (Figure S-9). 
1H NMR (500 MHz, Chloroform-d) δ 8.59 (t, J = 2.0 Hz, 1H), 8.46 (dt, J = 7.3, 1.9 Hz, 
1H), 8.12 (dt, J = 7.5, 2.0 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.34 (s, 1H), 6.75 (s, 1H), 4.04-
3.95 (m, 4H), 3.58 (t, J = 7.5 Hz, 2H), 3.05 (s, 3H), 2.71 (d, J = 2.2 Hz, 1H), 2.42 (d, J = 
2.2 Hz, 1H), 1.36 (s, 9H). 
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Figure S-9. Chemical structure of 2-[N-Methyl(1-tert-butoxyethenyl)amino]-1-[2-(m-
nitrobenzoylamino) ethylamino]-1-ethanone (Boc-Sar-NetN-CO-ph-NO2). 
2-(Methylamino)-1-[2-(m-nitrobenzoylamino)ethylamino]-1-ethanone (12). 
Appearance: yellow powder. The molecular weight of the compound was 378.43 g/mol. 
The yield of the reaction was 100 %. (Figure S-10). 
1H NMR (500 MHz, Deuterium Oxide) δ 8.53-8.43 (m, 2H), 8.04 (dt, J = 7.5, 2.0 Hz, 1H), 
7.63 (t, J = 7.5 Hz, 1H), 6.75 (s, 1H), 4.70 (s, 2H), 3.98 (t, J = 4.9 Hz, 2H), 3.58 (t, J = 4.9 
Hz, 2H), 3.44 (s, 2H), 3.32 (s, 3H). 
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Figure S-10. Chemical structure of 2-(Methylamino)-1-[2-(m-nitrobenzoylamino)ethylamino]-1-
ethanone (Sar-NetN-CO-ph-NO2). 
Methyl 5-(N-methyl{2-[2-(p-nitrobenzoylamino)ethylamino]-2-oxoethyl}amino)-5-
oxovalerate (13). 
Name of the structure: Methyl 5-(N-methyl{2-[2-(p-nitrobenzoylamino)ethylamino]-2-
oxoethyl}amino)-5-oxovalerate. 
Appearance: yellow powder. The molecular weight of the compound was 408.41 g/mol. 
The yield of the reaction was 68.41% (Figure S-11). 
1H NMR (500 MHz, Chloroform-d) δ 9.69 (s, 1H), 8.33-8.27 (m, 2H), 7.99-7.93 (m, 2H), 
6.75 (s, 1H), 4.09 (s, 2H), 3.98 (t, J = 4.5 Hz, 2H), 3.64 (s, 3H), 3.58 (t, J = 4.5 Hz, 2H), 
3.00 (s, 3H), 2.90 (t, J = 8.0 Hz, 2H), 2.35 (t, J = 5.3 Hz, 2H), 1.96 (tt, J = 8.1, 5.3 Hz, 2H). 
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Figure S-11. Chemical structure of Methyl 5-(N-methyl{2-[2-(p-nitrobenzoylamino)ethylamino]-2-
oxoethyl}amino)-5-oxovalerate (meO-glt-Sar-NetN-CO-ph-NO2). 
 
 
